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the Larynx
In the anterior neck at the level of vertebrae C3 through C6 lies the larynx, 
part of the airway connecting the inferior part of the pharynx with the trachea 
and  involved in  voice production (vocalization) and swallowing.1 The larynx 
serves as the organ of phonation (vocal cords closed = phonation position) 
and as an airway (vocal cords open = respiratory position). It protects the airway 
from aspiration during the act of  swallowing. The larynx is bordered cranially by 
the free margins of the epiglottis, the aryepiglottic fold, and the interarytenoid 
eminence. Caudally, the inferior border of the cricoid cartilage marks the 
junction of the larynx with the trachea. The larynx forms the narrowest point 
in the respiratory tract between the nasopharynx and trachea. The laryngeal 
cavity is divided into three parts in relation to the glottis:
•		Supraglottis:	laryngeal	inlet	to	the	sinus	of	Morgagni;
•	 	Glottis:	plane	of	the	vocal	cords	plus	approximately	1	cm	of	their	subglottic	
flank;
•	 	Subglottis:	extending	to	the	lower	border	of	the	cricoid	cartilage.
The vocal cord consists of the vocal ligament, vocal muscle, and associated 
mucosal covering. The glottis (rima glottidis) is the opening between the vocal 
cords. It has a membranous part backed by the vocal ligament and a cartilagi-
nous part formed by the vocal process of the arytenoid cartilages.2 Figure 1 
shows a sagittal view of the larynx. 
Figure 1. sagittal view of the larynx.
FunCtIonaL hIstoLogy
The epiglottis, which protrudes from the front edge of the larynx upwards, 
extends into the pharynx and therefore has a lingual (anterior) and a laryngeal 
(posterior) side. The entire lingual side and the top of the laryngeal side are 
covered with a multilayered non-keratinized squamous epithelium. Towards 
the base of the epiglottis at the laryngeal side the epithelium transforms into 
a pseudostratified ciliated cylindrical epithelium admixed with goblet cells 
(respiratory epithelium). At this site the lamina propria contains seromucous 
glands. The epiglottis acts as a valve that prevents food entering the trachea 
during swallowing. 
Below the epiglottis, the mucous membrane of the larynx forms two pairs of 
sagittal folds that protrude from the side into the lumen of the larynx. The upper 
pair, the plicae ventriculares (‘false vocal cords’), is lined with respiratory 
epithelium. The loose lamina propria contains many seromucous glands. In 
contrast with the subjacent vocal cords (plicae vocales, ‘true vocal cords’) that 
form the glottis, the false vocal folds can only narrow but not completely 
close the laryngeal lumen. The true vocal cords are coated with a multilayered 
non-keratinized squamous epithelium. Underneath this epithelium there are 
tightly packed bundles of parallel arranged elastic fibers, which together form 
the vocal ligament (left and right). Bundles of striated muscle run parallel to 
these	fibers;	they	form	the	two	musculi	vocales,	whose	variable	tonus	can	vary	
the voice pitch.3 Figure 2 shows a normal endoscopic view of the vocal cords 
during phonation.4
Figure 2. a normal endoscopic view of the vocal cords during phonation.
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LaryngeaL muCosaL premaLIgnant
LesIons
Laryngeal squamous cell carcinoma (LSCC) is the second most common type of 
head and neck squamous cell carcinoma (HNSCC), accounting for approximately 
700 cases each year reported in the database of the Netherlands Cancer Registry.5 
Despite major advances in the treatment of cancer, the long-term survival rate 
of LSCC patients has not changed much in the Netherlands during the last five 
decades (Figure 3).6 Most reports agree that cigarette smoking and alcohol 
abuse, and especially a combination of these two detrimental factors, are major 
risk factors. The etiological role of smoking has been proven both clinically 
and experimentally. There is also mounting evidence that gastroesophageal 
reflux is a potential aetiological factor. Human papillomavirus infection seems 
to play little if any role in laryngeal carcinogenesis.7
LSCC is supposed to be preceded by intraepithelial laryngeal lesions. Clinically, 
these lesions may present themselves by hoarseness and on laryngoscopy, red 
or white patches of the mucosa are seen, also known as erythro- or leukoplakia 
respectively (Figure 4). Other terms to describe them include keratosis, dys-
plasia, squamous intraepithelial neoplasia, laryngeal intraepithelial neoplasia, 
squamous intraepithelial lesions, to list only a few of the most commonly used 
terms.7 They are collectively considered to represent an altered epithelium 
with a possibly increased likelihood of progression to LSCC for which we will 
employ the term laryngeal mucosal premalignant lesions (LMPLs). This altered 
epithelium shows a variety of cytological and architectural changes that 
have traditionally been taken together under the common denominator of 
dysplasia.8,9  
Laryngeal precancer has been reported as a condition with between 2 and 10 
cases per 100000 of the population in the United States.10 Unfortunately, there 
is currently no universally accepted histopathological classification system for 
LMPLs nor is there consensus on diagnostic criteria for the various entities, 
notably on criteria for different grades of dysplasia. This results in poor repro-
ducibility between pathologists that have to evaluate biopsies from LMPLs.11,12 
In its first guideline on laryngeal carcinoma The Dutch Head and Neck Society 
reported also about the need for a nationwide uniformity concerning the 
terminology in LMPLs.13 
The rate of malignant transformation varies, depending on the grade of dys-
plasia. However, there are no means to predict which of these lesions will 
progress into LSCC and which will not. This illustrates the imperfect ability to 
relate morphological changes to biologic potential.14 In an effort to fill this gap, 
histopathological analysis has been extended by the assessment of molecular 
biological markers. The genetic changes and the sequence of genetic events 
underlying the progression of normal mucosa to LSCC are still not entirely 
recognized.7 In spite of this lack of knowledge,  various biomarkers have never-
theless been demonstrated to have potential prognostic value which could 
be clinically relevant.15 However, currently, there is no good evidence for the use 
of biomarkers in predicting the future behavior of laryngeal dysplastic lesions 
in clinical practice.16
Besides histopathological classification and molecular biological changes, 
other important factors that may affect the chance of malignant transforma-
tion are surgical management and/or follow-up of LMPLs, and continuation 
of smoking.12,17-21 The challenge has always been to diagnose and treat 
potentially malignant or precursor lesions as early as possible with the aim to 
prevent their progression to invasive disease while simultaneously leaving 
lesions that will not progress untouched.
Figure 3. Mortality due to laryngeal cancer in the netherlands, 1950-2005.
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Figure 4. Leukoplakia of the right true vocal cord.
hIstopathoLogy
Dysplastic areas in the epithelium of the upper aerodigestive tract are believed 
to be a potential source for development of cancer. There is evidence that in 
an individual lesion, the more severe the dysplasia, the greater the likelihood 
is of progression to malignancy. Rarely however, non-dysplastic lesions may 
also show malignant development.8,22-25 Therefore, presence and severity of 
dysplasia cannot be used as a reliable guide for the treatment of individual 
cases. Nevertheless, the crude relationship between grading dysplasia and 
risk of progression to malignancy makes dysplasia grading necessary. 
Grading of dysplasia continues to be a hotly debated subject. It is subjective 
and lacks intra- and inter-observer reproducibility due to the insufficiency of 
validated morphological criteria and the biological nature of dysplasia.25-28 
Moreover, due to the absence of a consensus,  several systems are currently 
employed.29 In the current literature and clinical practice, the 2005 World 
Health Organization (WHO), Squamous Intraepithelial Neoplasia (SIN), and 
the Ljubljana Classification of Squamous Intraepithelial Lesions (SIL) systems 
are the most widely used and are considered the most relevant.7,8
In spite of the above mentioned shortcomings, conventional histopathological 
evaluation based on light microscopic examination of hematoxylin & eosin-
stained slides is still the most valid method for assessing the malignant potential 
of preneoplastic head and neck lesions.22 Moreover, it is important to  realize 
that having a diagnosis is a prerequisite for selecting the most effective and 
efficient treatment. Therefore, a disease classification system is also a predictive 
system.25,30 The aim should be to adapt treatment to the likelihood of disease 
progression thus decreasing the incidence of invasive disease, reducing the 
need for radical treatment and improving survival while avoiding unnecessary 
treatment and follow-up in cases which lack significant potential to malignant 
transformation.27
treatment
The current practice is to perform a microlaryngoscopy with biopsy or excision 
of these lesions. A nationwide survey by Paleri et al. demonstrated the lack of 
consensus in managing laryngeal dysplasia in the UK, and acknowledged that 
there is a considerable lack of evidence regarding the natural history, the 
optimum management and best follow-up strategies.31,32 So far, a wide range 
of therapeutic strategies for different grades of dysplasia have been suggested 
by various authors.17 The revised guideline on laryngeal carcinoma by The 
Dutch Head and Neck Society reported about the management of severe 
dysplasia/carcinoma in situ. However no attention is paid to other LMPLs.6  
CLInICaL Case
To illustrate the clinical course of a typical case of a patient with a LMPL we 
describe patient A. In 2005 this 51-year old male and smoker (30 pack years) 
visited the outpatient clinic of the department of Otorhinolaryngology because 
of hoarseness since two months. Direct laryngoscopy revealed a bilateral leuko-
plakic lesion of the vocal cord. Histopathological investigation of the biopsies, 
obtained by microlaryngoscopy, revealed mild dysplasia. The patient subse-
quently quitted smoking.  
During follow-up the patient underwent microlaryngoscopies with the taking of 
biopsies for four times (one, two, four, and seven years after initial presentation 
respectively). Histopathological investigation repeatedly revealed moderate 
dysplasia and infection. Seven years after initial presentation in 2005, the 
pathologist concluded that the biopsy material taken at microlaryngoscopy 
contained laryngeal squamous cell carcinoma, which illustrates that even mod-
erate dysplasia may develop into invasive cancer, the theoretically assumed 
intermediate stages of severe dysplasia or in situ cancer either being skipped 
in progressing to malignancy or missed between or in previous biopsies.   
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aIms and sCope oF thIs thesIs
This thesis aims to investigate the current clinical practice of laryngeal 
mucosal premalignant lesions and to develop a translational method in order 
to find additional tools to predict more accurately the risk of malignant trans-
formation in these lesions.
In chapter 2 the current clinical management of LMPLs as commonly done by 
otorhinolaryngologists, working in university hospitals (tertiary referral centers) 
or in general hospitals (secondary referral centers) in The Netherlands, is de-
scribed and discussed. In chapter 3.1 the significance of dysplasia and the 
importance of a valid method for assessing precursor lesions of the head and 
neck is highlighted. Also, the different histopathological classification sys-
tems for grading intraepithelial lesions of the head and neck are reviewed. 
chapter 3.2 analyzes the interobserver variability in the classification of LMPLs 
by reassessing the histopathology of previously diagnosed cases when using 
the several classification systems currently used and to determine the possible 
therapeutic consequences of disagreement among observers. Next, chapter 
3.3 describes the observer study in which histopathological assessment of glass 
slides is compared with virtual slide microscopy. The same study population 
was used and the same pathologists reviewed the cases as in Chapter 3.2.
In the intermezzo the literature on the potential value of the use of biomarkers 
in improving the identification of LMPLs that may progress into malignancy is 
reviewed.   
In chapter 4 a method is described that allows simultaneous assessment of DNA 
content and biomarker expression in paraffin-embedded tissue sections. This 
method is used in chapter 5 to investigate the predictive value of simultaneous 
assessment of multiple biomarkers for malignant progression in LMPLs on a 
cellular level. For comparison, the predictive value of chromosome instability 
(CI) with detection of chromosome 1 and 7 alterations by fluorescence in situ 
hybridization (FISH) is also tested in these cases. 
The thesis concludes with a general discussion.
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abstraCt
objeCtIves/hypothesIs: To investigate the current clinical management of 
laryngeal mucosal premalignant lesions (LMPLs) among otorhinolaryngologists 
working in university hospitals (tertiary referral centers) and nonuniversity 
hospitals (secondary referral centers) in The Netherlands. Then to compare 
the investigated practice with the results published in the literature.
study desIgn: Cross-sectional study.
methods: A survey was conducted to assess the management of LMPLs. The 
questionnaire consisted of a systematic series of figures representing the 
initial presentation of a patient with a leukoplakic lesion at 12 different 
anatomical locations. The study group consisted of otorhinolaryngologists at 
all eight tertiary referral centers in The Netherlands (n=22) and a random 
selection of otorhinolaryngologists (n=25) from secondary referral centers 
throughout the country.
resuLts: Comparing the initial management (surgical excision versus biopsy) 
preferred by otorhinolaryngologists at tertiary referral centers with that 
preferred by those at secondary referral centers, significant differences were 
found for seven anatomical locations. Notable differences were observed 
concerning the treatment of glottic lesions and the management of mild to 
moderate dysplasia after biopsy. Among the different tertiary referral centers, 
no uniform preference in management was noticed.
ConCLusIons: There are significant differences in the management of LPMLs 
between otorhinolaryngologists at tertiary and secondary referral centers, 
depending on the location and histopathology of the lesions. Consensus on 
and development of guidelines concerning the management of LMPLs could 
be useful to optimize the diagnosis, treatment, and followup of these lesions.
IntroduCtIon
Laryngeal squamous cell carcinoma (LSCC) is the most common type of 
head and neck squamous cell carcinoma (HNSCC), accounting for 1% to 2% 
of all malignancies worldwide.1–3 Despite major advances in the treatment of 
cancer, the long-term survival rate of LSCC patients has remained essentially 
unchanged during the last two decades.4,5
The possibility of progression of an intraepithelial lesion to invasive cancer is 
a common clinical concern. These laryngeal mucosal premalignant lesions 
(LMPLs), which include varying grades of dysplasia as well as carcinoma in situ 
(CIS), are frequently encountered in clinical practice. They display a wide 
spectrum of mucosal changes and are potentially premalignant. Unfortunately, 
there is no universally accepted histopathological classification system for 
LMPLs, nor is there consensus on diagnostic criteria for the various entities, 
notably on criteria for different grades of dysplasia. This results in poor repro-
ducibility of the pathologists’ interpretation of LMPLs, which may have signif-
icant therapeutic implications.6,7 The chance of malignant progression varies, 
depending on the grade of dysplasia. However, there are no means to predict 
which of these lesions will progress into LSCC and which will not. In an effort 
to fill this gap, histopathological and molecular biological markers have been 
studied, mostly retrospectively. Besides histopathological classification and 
molecular biological changes, other important factors that may affect the 
chance of malignant development are surgical management and follow-up 
of LMPLs.5,7 The challenge has always been to diagnose early and then treat 
potentially malignant or precursor lesions, thereby preventing their progression 
to invasive disease. The current practice of performing microlaryngoscopy 
with biopsy or excision of these lesions is often inadequate and unsatisfying, 
as demonstrated by the continued progression to invasive carcinoma, even with 
diligent surveillance.7 So far, a wide range of therapeutic strategies for different 
grades of dysplasia has been suggested by various authors. However, despite 
the growing interest in and use of evidence-based guidelines in medicine, 
there is a lack of outcome reviews on this matter.5
The objective of this study was to investigate the current clinical management 
of LMPLs among otorhinolaryngologists in The Netherlands in the absence of 
evidence-based guidelines. We then compared the practices investigated in 
The Netherlands with the results published in the literature.
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materIaLs and methods
In The Netherlands, a patient’s initial step is to visit the general practitioner. If 
necessary, the patient can be referred to a nonuniversity hospital (secondary 
referral center) or a university hospital (tertiary referral center). The physician 
at a nonuniversity hospital may then refer the patient to a university hospital, 
depending on the need for particular expertise or facilities. Patients with 
head and neck malignancies in particular are treated in the country’s eight 
tertiary referral centers (seven university hospitals and one cancer institute).
In the present study, a questionnaire was sent to all tertiary referral centers in 
The Netherlands and to a random selection of secondary referral centers 
throughout the country. The secondary referral centers were asked to have 
the form filled in by the otorhinolaryngologist with particular interest and 
expertise in laryngology. All forms were sent by mail along with a covering 
letter providing information about the survey. The form could be returned by 
regular mail or e-mail. The questionnaire was developed by the authors. It 
contains a systematic series of figures representing the initial presentation of 
a patient with a leukoplakic lesion at 12 different anatomical locations (Table 
1). The first question concerns the initial management and offers the following 
choices: 1) surgical excision, which could be either carbon dioxide (CO2) micro-
scopic laser surgery (henceforth called laser microsurgery) or conventional 
microsurgery;	2)	biopsy	of	 the	 lesion;	3)	watchful	observation;	or	4)	 referral	 
to a tertiary hospital. The next question should only be answered if the option 
of an initial biopsy of the lesion was chosen. That question concerns the 
continuation of management when the histopathological diagnosis, made 
according to World Health Organization (WHO) criteria, reveals 1) hyperplasia, 
2) mild to moderate dysplasia, or 3) severe dysplasia/CIS.8 The options given 
for management are 1) a second procedure with surgical excision (laser 
microsurgery or conventional microsurgery), 2) watchful observation, 3) referral 
to a tertiary hospital, or 4) radiotherapy. Figure 1 shows an example of a case 
as presented in the questionnaire.
statIstICaL anaLysIs
Statistics	 were	 performed	 using	 SPSS	 software	 (version	 16.0.01;	 SPSS	 Inc.,	
Chicago, IL). The Fisher exact test was used for 2 x 2 tables.
table 1. different Locations of Leukoplakic Lesions presented in the Questionnaire.
uni- and/or bilateral Location
uni- and bilateral  Vocal cord with no involvement of the anterior commissure
uni- and bilateral  Vocal cord with involvement of the anterior commissure
uni- and bilateral  Vocal cord with supraglottic expansion and no involvement of the anterior commissure
uni- and bilateral  Vestibular cord with no involvement of the anterior commissure
unilateral  Arytenoid with no involvement of the posterior commissure
NA   Arytenoids with involvement of the posterior commissure
NA   Free edge of epiglottis
NA   >50% of laryngeal side of epiglottis
NA = not applicable.
resuLts
The questionnaire was returned by a total of 47 otorhinolaryngologists, 22 
from tertiary referral centers and 25 from secondary referral centers. Table 2 
gives an overview of the results.
tertIary reFerraL Centers
Initial management. Twenty-two otorhinolaryngologists returned the question-
naire containing 12 examples of different locations, yielding 264 cases that were 
judged. Regarding glottic lesions without involvement of the anterior com-
missure, almost all otorhinolaryngologists (95%) in this group chose to initially 
resect the lesion completely by either laser or conventional microsurgery.
Management after biopsy. If an initial biopsy of the lesion was preferred, the 
management after histopathological classification of hyperplasia was a second 
procedure with surgical excision in 3 of 97 cases (3%), and watchful observation 
in 94 of 97 cases (97%). In the event of mild to moderate dysplasia, in 15 of 97 
cases	(15%)	a	second	procedure	with	surgical	excision	was	planned;	in	82	of	
97 cases (85%) watchful observation was preferred. Clearly, watchful observation 
was chosen in the majority of cases with hyperplasia or mild to moderate dys-
plasia. In contrast, in the event of CIS, all patients would be treated: in 42 of 
97 cases (43%) by surgical excision, and in 55 of 97 cases (57%) by radiotherapy.
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Aim at:
  Surgical excision
   With the use of:     CO2 laser
               Conventional
  Biopsy
  Periodic observation
  Referral to tertiary hospital
If chosen for an initial biopsy of the lesion what is the continuation of management when the histopathological 
investigation reveals:
•	 	Hyperplasia
  Second procedure with surgical excision
   With the use of:     CO2 laser
               Conventional
  Periodic observation
  Referral to tertiary hospital
  Radiotherapy
•	 	Mild	/	Moderate	dysplasia
  Second procedure with surgical excision
   With the use of:     CO2 laser
               Conventional
  Periodic observation
  Referral to tertiary hospital
  Radiotherapy
•	 	Severe	dysplasia	(=	CIS)
  Second procedure with surgical excision
   With the use of:     CO2 laser
               Conventional
  Periodic observation
  Referral to tertiary hospital
  Radiotherapy
Fig. 1. example of a case presented in the questionnaire: unilateral vocal cord lesion with no involvement of 
the anterior commissure. co2 = carbon dioxide; cis = carcinoma in situ.
Table	2.	Overview	of	the	Results.
Vocal	cord	with	no	involvement	of	the	anterior	commissure
        unilateral***             Bilateral***
Surgery      tertiary      secondary     tertiary      secondary
Laser      16        -         17        -
Conventional   -        11         0        8
Laser/Conven.   5        -         4        -
Biopsy      1        13         1        16
        Sur WO RT   Sur WO Ref RT  Sur WO RT   Sur WO Ref RT
Hyperpl     1  -  -    2  11  -  -   1  -  -    2  14  -  -
Mild/mod dyspl   1  -  -    1  10  2  -   1  -  -    2  9  5  -
CIS       1  -  -    -  -  13  -   1  -  -    -  -  16  -
Watchful obs.   -        1         -        1
Vocal	cord	with	involvement	of	the	anterior	commissure
        unilateral***             Bilateral
Surgery      tertiary      secondary     tertiary      secondary
Laser      9        -         7        -
Conventional   -        4         -        6
Laser/Conven.   5        -         4        -
Biopsy      8        21         11        19
        Sur WO RT   Sur WO Ref RT  Sur WO RT   Sur WO Ref RT
Hyperpl     1  7  -    2  19  -  -   -  11  -    1  17  1  -
Mild/mod dyspl   1  7  -    2  13  6  -   1  10  -    1  9  9  -
CIS       4  -  4    -  -  19  2   1  -  10    -  -  17  2
Watchful obs.   -        -         -        -
Vocal	cord	with	supraglottic	expansion	and	no	involvement	of	the	anterior	commissure
        unilateral*             Bilateral***
Surgery      tertiary      secondary     tertiary      secondary
Laser      11        -         11        -
Conventional   -        4         -        2
Laser/Conven.   1        -         1        -
Biopsy      10        21         10        23
        Sur WO RT   Sur WO Ref RT  Sur WO RT   Sur WO Ref RT
Hyperpl     -  10  -    2  19  -  -   -  10  -    2  19  2  -
Mild/mod dyspl   3  7  -    1  12  8  -   3  7  -    2  13  8  -
CIS       5  -  5    -  -  18  3   4  -  6    -  -  20  3
Watchful obs.   -        -         -        -
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Table	2.	Overview	of	the	Results	(Continued).
Vestibular	cord	with	no	involvement	of	the	anterior	commissure
        unilateral***             Bilateral**
Surgery      tertiary      secondary     tertiary      secondary
Laser      18        -         16        -
Conventional   -        9         -        8
Laser/Conven.   1        -         1        -
Biopsy      3        16         5        17
        Sur WO RT   Sur WO Ref RT  Sur WO RT   Sur WO Ref RT
Hyperpl     -  3  -    1  15  -  -   -  5  -    1  15  1  -
Mild/mod dyspl   -  3  -    1  10  5  -   1  4  -    1  9  7  -
CIS       -  -  3    -  -  16  -   2  -  3    -  -  17  -
Watchful obs.   -        -         -        -
Arytenoid	with	no	involvement	and	arytenoids	with	involvement	of	the	posterior	commissure
        unilateral              Bilateral
Surgery      tertiary      secondary     tertiary      secondary
Laser      12        -         7        -
Conventional   -        9         -        5
Laser/Conven.   1        -         -        -
Biopsy      9        14         15        18
        Sur WO RT   Sur WO Ref RT  Sur WO RT   Sur WO Ref RT
Hyperpl     -  9  -    1  13  -  -   -  15  -    1  17  -  -
Mild/mod dyspl   -  9  -    1  9  4  -   1  14  -    2  8  8  -
CIS       6  -  3    -  1  13  -   5  -  10    -  -  16  2
Watchful obs.   -        2         -        2
Epiglottis:	free	edge	and	>50%	of	laryngeal	side
        Free edge              >50% of laryngeal side
Surgery      tertiary      secondary     tertiary      secondary
Laser      14        -         4        -
Conventional   -        9         -        2
Laser/Conven.   1        -         1        -
Biopsy      7        14         17        23
        Sur WO RT   Sur WO Ref RT  Sur WO RT   Sur WO Ref RT
Hyperpl     -  7  -    1  13  -  -   -  17  -    2  20  1  -
Mild/mod dyspl   3  4  -    1  8  5  -   -  17  -    2  12  9  -
CIS       7  -  -    -  -  14  -   6  -  11    -  -  20  3
Watchful obs.   -        2         -        -
Comparison of secondary and tertiary referral centers (surgery versus biopsy) using Fisher’s exact test, 
*=p<0.05, **=p<0.01, ***=p<0.001 
Sur = surgery | WO = watchful observation | RT = radiotherapy | Ref = referral to a tertiary center
Differences among otorhinolaryngologists in tertiary referral centers. Regarding 
a vocal cord lesion with no involvement of the anterior commissure, initial 
surgery was chosen in 21 of 22 cases (95%) for both uniand bilateral lesions. 
No significant differences were seen in this category between uni- and bilateral 
cases. Regarding vocal cord lesions with involvement of the anterior commissure, 
initial surgery was chosen in 14 of 22 (64%) cases with unilateral lesions and in 
11 of 22 (50%) cases with bilateral lesions. The remaining otorhinolaryngologists 
preferred to take an initial biopsy first regarding a vocal cord lesion with involve-
ment of the anterior commissure. Apparently, different approaches exist for 
these locations. After taking a biopsy containing histopathologically proven 
CIS, radiotherapy was given in 4 of 8 (50%) and 10 of 11 (91%) of these vocal 
cord lesions with involvement of the anterior commissure, respectively, also 
indicating differences of opinion.
seCondary reFerraL Centers
Initial management. Of the 25 otorhinolaryngologists who returned the 
questionnaire, the following distribution (integrated over all 12 anatomical 
locations)	was	seen:	surgical	incision	in	77	of	300	cases	(25.7%);	biopsy	of	the	
lesion	 in	215	of	300	cases	 (71.7%);	watchful	observation	 in	8	of	300	cases	
(2.6%);	and,	in	0	of	300	cases	(0%),	referral	to	a	tertiary	hospital.
Management after biopsy. When the choice was made to take a biopsy of the 
lesion first, the preferred management after histopathological classification 
of hyperplasia was as follows: in 18 of 215 cases (8.4%), a second procedure 
with	surgical	excision;	in	192	of	215	cases	(89.3%),	watchful	observation;	and	
in 5 of 215 cases (2.3%), referral to a tertiary center. In the event of mild to 
moderate dysplasia, the following steps were preferred: in 17 of 215 cases (8%), 
a	second	procedure	with	surgical	excision	was	planned;	in	122	of	215	cases	
(57%),	watchful	observation	took	place;	and	in	76	of	215	cases	(35%),	the	patients	
were referred to a tertiary center. In the event of CIS, the responses were as 
follows:	in	1	of	215	cases	(0.5%),	watchful	observation	was	chosen;	in	199	of	215	
cases	(92.5%),	they	chose	referral	to	a	tertiary	hospital;	and	in	15	of	215	cases	
(7.0%), radiotherapy was preferred. Referral to a tertiary center was chosen 
significantly more frequently in the event of mild to moderate dysplasia versus 
hyperplasia: in 76 of 215 cases (35%), versus 5 of 215 cases (2.3%), respectively 
(P<.001).
Differences among otorhinolaryngologists at secondary referral centers. One 
of the main differences noted among otorhinolaryngologists at secondary 
referral centers is in patient management after a biopsy showing mild to 
moderate dysplasia: 35% would refer to a tertiary center and 57% would 
prefer watchful observation.
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Comparison between otorhinolaryngologists in tertiary and secondary referral 
centers. To compare the initial management (surgical excision versus biopsy 
of the lesion) by otorhinolaryngologists at tertiary and secondary referral 
centers, the Fisher exact test (2-sided) was used. The results of this test, as shown 
in Table II, describe significant differences: in five locations with P< .001, and 
in one location with P<.01 and P<.05.
dIsCussIon
In this report, we use the results of a questionnaire to make an inventory of the 
current practice of management of LMPLs in The Netherlands. The question-
naire focused on the initial management of leukoplakic lesions and management 
after a biopsy has been taken – once the histopathological diagnosis is known. 
The first follow-up studies of precancerous conditions of the larynx were pub-
lished in the early 1950s and concerned CIS and keratosis, respectively.9,10 
Since then, several follow-up studies on the long-term risk of malignant progres-
sion in LMPLs have been reported. These studies usually do not distinguish 
between natural evolution without treatment (prognostic value) and response 
to treatment (predictive value). Moreover, many histopathological classification 
systems have been used over the past decades. That diversity, along with the 
inconsistencies in treatment and period of follow- up, have made it difficult to 
compare the results.11,12 Table 3 summarizes an overview of the literature on 
the long-term risk of subsequent malignancy.
Table	3.	Literature	review	of	the	long-term	risk	of	subsequent	malignancy.
studies / 
references
n Histopathological	
classification
Initial	Intervention	/	
Treatment
Malignant	
progression
Putney et al. 
1953
62 Keratosis (excision) biopsy and 
WO
21/62 (34%)
Mcgavran et 
al. 1960
84 Keratosis (84) Biopsy, WO 3/84 (4%)
Gabriel et 
al. 1962
30 Hyperkeratosis (30) Biopsy and WO (24)
RT (6)
1/30 (3%)
Norris et al. 
1963
116 Keratosis without atypia (30)
Keratosis with atypia (86)
Excision and WO (29) 
RT (1)
Excision and WO (83)
RT (3)
1/30 (3%)
11/86 (13%)
CIS (4), invasive carci-
noma (5), equivocal (2)
studies / 
references
n Histopathological	
classification
Initial	Intervention	/	
Treatment
Malignant	
progression
Crissman et 
al. 1979
92 Mild keratosis (50)
Moderate keratosis (26)
Severe keratosis (16)
Biopsy and WO 0/50 (0%)
0/26 (0%)
3/16 (19%)
Henry et al. 
1979
43 Keratosis Biopsy and WO 5/43 (12%)
Hellquist et 
al. 1981
20 Severe dysplasia (15)
CIS (5)
Excision (3)
Stripping (6)
RT (6)
Stripping (3)
RT (2)
5/15 (33%) (n=2 
excision, n=1 stripping, 
n=2 RT)
0/5 (0%)
Hintz et al. 
1981
45 CIS (45) Biopsy/Stripping and 
RT (18)
Biopsy/Stripping and 
WO (27)
5/18 (28%)
17/27 (63%)
Hellquist et 
al. 1982
193 Hyperplasia and/or keratosis 
(with or without mild dysplasia) 
(98)
Moderate dysplasia (24)
Severe dysplasia and CIS (39)
Excision (98)
Excision (24)
Excision/Stripping 
(23)
RT (16)
5/98 (5%) (n=2 
severe dysplasia, n=3 
invasive carcinoma)
6/24 (25%) (n=3 severe 
dysplasia, n=3 invasive 
carcinoma)
5/23 (22%)
4/16 (25%)
Gillis et al. 
1983
32 Keratosis (7)
Keratosis with atypia (12)
Atypia (5)
CIS (8)
Excision (7)
Excision (12)
Excision (5)
Excision and RT (8)
3/7 (43%) (n=1 CIS, 
n=2 invasive carcinoma)
5/12 (42%) (n=2 CIS, 
n=3 invasive carcinoma)
4/5(80%) (n=2 CIS, n=2 
invasive carcinoma)
3/8 (38%)
Hirade et al. 
1983
52 Hyperplasia (34)
Low grade dysplasia (6)
High grade dysplasia (4)
CIS (5)
Invasive carcinoma (3) 
Excision (44)*
Excision and RT (9)*
1/34 (3%)
1/6 (17%)
2/4 (50%)
4/5 (80%)
Moesgaard 
Nielsen et 
al. 1986
31 Mild dysplasia (30)
Moderate dysplasia (1)
Stripping (31) 1/30 (3%)
0/1 (0%)
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studies / 
references
n Histopathological	
classification
Initial	Intervention	/	
Treatment
Malignant	
progression
Olde Kalter 
et al. 1987
106 Simple hyperplasia (38)
Hyperplasia with atypia (62)
CIS (6)
Excision and WO 
(106)
2/38 (5%)
17/62 (27%)
1/6 (17%)
Riera Velasco 
et al. 1987
87 Hyperkeratosis (46)
Slight-moderate dysplasia (31)
Severe dysplasia (5)
CIS (5)
Stripping and WO 
(87)
1/46 (2%)
6/31 (19%)
1/5 (20%)
1/50 (20%)
Stenersen et 
al. 1988
57 Severe dysplasia or CIS (57) Biopsy, stripping and 
WO (41)
RT (16)
19/41 (46%)
3/16 (19%)
Højslet et al. 
1989
147 Hyperplasia and/or keratosis 
with or without mild dysplasia 
(128)
Moderate dysplasia (9)
CIS (10)
Biopsy and WO (128)
Biopsy and WO (9)
Biopsy and WO (3)
RT (7)
6/128 (5%)
4/9 (44%)
4/10 (40%) (n=2 biopsy 
and WO, n=2 RT) 
Sllamniku et 
al. 1989
921 Keratosis without atypia (604)
Keratosis with mild atypia (204)
Keratosis with moderate atypia (23)
Keratosis with severe atypia (90)
Biopsy and WO (804)
Stripping (117)
18/604 (3%)
15/204 (7%)
4/23 (17%)
25/90 (28%)
Stenersen et 
al. 1991
57 Severe dysplasia or CIS Biopsy and WO (41)
RT (16)
19/41 (46%)
Not reported
Cuchi et al. 
1994
241 Keratosis without dysplasia (104)
Keratosis with dysplasia (55)
Chronic inflammations without 
dysplasia (34)
Chronic inflammations with dys-
plasia (7)
Papillomas without dysplasia 
(22)
Papillomas with dysplasia (12)
CIS (7)
Biopsy (241)
8/104 (8%)
15/55 (27%)
1/34 (3%)
4/7 (57%)
5/22 (23%)
4/12 (33%)
7/7 (100%)
studies / 
references
n Histopathological	
classification
Initial	Intervention	/	
Treatment
Malignant	
progression
Blackwell et 
al. 1995
62 No dyplasia (6)
Mild dysplasia (26)
Moderate dysplasia (15)
Severe dysplasia (9)
CIS (6)
Biopsy and WO (62) 0/6 (0%)
3/26 (12%)
5/15 (33%)
4/9 (44%)
1/6 (17%)
Blackwell et 
al. 1995
65 Hyperkeratosis without 
dysplasia (6)
Mild dysplasia (26)
Moderate dysplasia (15)
Severe dysplasia (9)
CIS (9)
Biopsy and WO (6)
Biopsy and WO (26)
Biopsy and WO (13)
RT (2)
Biopsy and WO (5)
Partial laryngectomy 
(3)
RT (1)
Biopsy and WO (1)
Partial laryngectomy 
(2)
RT (2)
CO2 laser (2)
Partial laryngectomy 
+ RT (1)
TLE (1)
0/6 (0%)
3/26 (12%)
5/15 (33%) (n=5 biopsy 
and WO)
4/9 (44%) (n=4 biopsy 
and WO)
1/9 (11%) (n=1 biopsy 
and WO)
Cardesa et 
al. 1997
Data are equal to Cuchi et al. 
1994
Uno et al. 
1997
40 Hyperkeratosis (1)
Parakeratosis (1)
Dyskeratosis (12)
Mild dysplasia (10)
Moderate dysplasia (9)
Severe dysplasia (7)
Biopsy and WO (40) 0/1 (0%)
0/1 (0%)
2/12 (17%) (n=1 CIS, 
n=1 invasive carcinoma)
3/10 (30%) (n=1 CIS, 
n=2 invasive carcinoma)
1/9 (11%) (n=1 CIS)
3/7 (43%) (n=1 CIS, 
n=2 invasive carcinoma)
Chapter 2
32
Management of Laryngeal Premalignant Lesions in the Netherlands
33
studies / 
references
n Histopathological	
classification
Initial	Intervention	/	
Treatment
Malignant	
progression
Plch et al. 
1998
123 Hyperplasia (24)
Mild dysplasia (63)
Moderate dysplasia (25)
Severe dysplasia (7)
CIS (4)
Biopsy and WO (24)
Biopsy and WO (63)
Biopsy and WO (25)
Biopsy and WO (7)
RT (4)
0/24 (0%)
0/63 (0%)
1/25 (4%) (n=1 CIS)
4/7 (57%) (n=1 CIS, 
n=3 invasive carcinoma)
3/4 (75%) 
Crissman et 
al. 1993
367 Keratosis without atypia (362)
Keratosis with atypia (230)
CIS/severe dysplasia (367)
Not reported 5/362 (1.4%)
31/230 (13.5%)
42/367 (11.4%)
Gallo et al. 
2001
259 Keratosis without dysplasia (143)
“  with mild dysplasia (56)
“  with moderate dysplasia(28)
“  with severe dysplasia/CIS (32)
Type I cordectomy 
(143)**
Type I cordectomy (56)
Type I (16) and Type 
III (12)
Type III cordectomy 
(32) 
6/143 (4%)
4/56 (7%)
6/28 (21%)
3/32 (9%)
Ricci et al. 
2003
185 Keratosis without dysplasia (86)
“  with mild dysplasia (42)
“  with moderate dysplasia(36)
“  with severe dysplasia/CIS (21)
Biopsy and excision 
(86)
Biopsy and excision 
(42)
Biopsy and excision 
(36)
Biopsy and surgery 
(21)***
2/86 (2%)
2/42 (5%)
5/36 (14%)
3/21 (14%)
Gale et al. 
2009
1268 squamous hyperplasia/basal-
parabasal hyperplasia (1089)
atypical hyperplasia (179)
Not reported 12/1089 (1%)                       
17/179 (9.5%) 
*  not specified for histopathological classification and 1 case not histologically re-examined.
**  29, 30
*** cordectomies in laryngeal fissure and laser excisions
n = number of patients 
rt = radiotherapy
Wo = watchful observation
cis = carcinoma in situ
In this study we found a significant difference between the initial management 
preferred by an otorhinolaryngologist at a tertiary center and that of an otorhi-
nolaryngologist working at a secondary center. In general, the former tends 
to excise a lesion more frequently than the latter, who tends to be more 
conservative and more frequently just takes a biopsy. This difference in initial 
management may be influenced by the fact that the latter group usually has 
limited access to laser microsurgery. After a biopsy, the otorhinolaryngologists 
at secondary referral centers referred a patient to a tertiary center significantly 
more frequently in the event of mild to moderate dysplasia compared with 
hyperplasia (P<.001). Watchful observation took place in 57% of these cases. 
In contrast, in tertiary centers such lesions were significantly more frequently 
initially completely removed. This may very well affect the chance of malignant 
progression. These divergent approaches probably contribute to the differences 
found in the literature with respect to the probability of malignant progression 
in mild and moderate dysplasia. That probability is reported to vary from 0% 
to 30%13–16 and 0% to 44%13–19 of the cases, respectively. For hyperplasia, severe 
dysplasia, and CIS, the probability of progression is respectively 0% to 3%,13,15,20 
20% to 57%,13,15,16,19,21 and 0% to 80%.13,15,18–23 However, genetic abnormalities 
may be present in the macroscopically normal surrounding mucosa. Therefore, 
complete removal may have little impact on the chance of progression.24,25 
Furthermore, the treatment preferred by otorhinolaryngologists at secondary 
referral centers in the event of mild to moderate dysplasia – surgery (8%), watch-
ful observation (57%), and referral (35%) – appears to be independent of the 
location of the lesion. It seems that the decision on treatment is predominantly 
based on the histopathological diagnosis. If so, it is striking that otorhinolaryn-
gologists at tertiary referral centers preferred watchful observation for mild to 
moderate dysplasia in 85% of the cases. Of the patients with these lesions 
seen in the secondary centers, a significant share was referred to tertiary 
centers. In light of the conservative approach taken by the tertiary hospitals 
in these cases, the rationale behind this referral is questionable. The unknown 
risk of further malignant progression of these lesions may contribute to these 
frequent referrals. Generally, in deciding whether or not to operate nonmalig-
nant lesions, much will also depend on the complaints (e.g., hoarseness) of 
the patient and the preoperative estimate of induced morbidity due to the 
operation. According to Table III, mild to moderate dysplasia is mainly treated 
by biopsy and watchful observation. This impression is particularly compelling 
when concentrating on more recent studies. In the literature there is still no 
consensus on the treatment of glottic LMPLs with severe dysplasia or CIS. 
Treatment modalities are widespread and mainly concern radiotherapy versus 
(laser) surgery. The recommendation made in the Dutch national guidelines is 
to treat glottic CIS with endoscopic de-epithelization, unless the lesion can 
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be removed completely. Radiotherapy is a good alternative if complete removal 
is not possible.22,26–28 In our study, after taking a biopsy showing CIS on histo-
pathological examination, otorhinolaryngologists at tertiary referral centers 
favor radiotherapy (57% of cases) over surgical excision (43% of cases), mainly 
depending on localization. For example, in the event of bilateral vocal cord 
involvement and involvement of the anterior commissure, radiotherapy was 
chosen in as much as 91% of the cases. This is most likely due to the difficulty of 
removing this lesion completely with surgery and to the functional consequences 
of performing radical surgery in the anterior commissure. On the other hand, 
a different management among otorhinolaryngologists at tertiary referral 
centers was noticed in the event of unilateral lesions of the vocal cord with 
involvement of the anterior commissure and also in the event of unilateral 
lesions of the vocal cord with supraglottic expansion and no involvement of 
the anterior commissure. So, for glottic lesions without involvement of the 
anterior commissure, most tertiary centers preferred to excise the lesion 
immediately without first taking a biopsy. If the anterior commissure is involved, 
a significant proportion of the respondents would shift to a policy of first taking 
a biopsy and waiting in cases with less than CIS on histopathological exami-
nation. Adding to the uncertainty about the initial management of LMPLs, 
there are to our knowledge no guidelines or consensus on the follow-up of 
these lesions. In The Netherlands and probably many other countries, there 
is no official nationwide guidance. If any guidelines or recommendations are 
available, they are probably based on consensus rather than on a high level 
of evidence from the literature. Questions on whether and how frequently 
follow-up checks are necessary remain unanswered. Yet, besides initial treat-
ment, follow-up may very well also influence outcome. Again the varying and 
uncertain reported chance of malignant progression does not facilitate 
making strong recommendations about follow-up. Future studies identifying 
robust prognostic markers might steer the development of rational guidelines 
for follow-up and treatment.
Based on the data of this study and the literature, our opinion is that if a 
leukoplakic lesion can be removed completely without expecting morbidity 
(e.g., without involvement of the anterior commissure), it may be recommended 
to initially excise the lesion completely without knowing the histology, so as 
to perform an operation which is both diagnostic and therapeutic. If treatment 
of the lesion may be expected to have a risk of functional impairment, it may 
be recommended to take a biopsy first to decide whether or not the lesion 
should be treated radically. Depending on the histology, it may be considered 
to treat the patient additionally or observe the patient. Which cut-off point 
should be chosen to treat is a matter of debate. No discussion will be on the 
necessity to treat severe dysplasia or CIS. On the other hand, there will neither 
be much discussion on the fact that hyperplasia may safely be observed (without 
strict follow-up) and could be treated depending on (voice) complaints of the 
patient. The main question is whether or not to treat mild, and, more particular, 
moderate dysplasia. It could be considered to treat these lesions anyway if no 
functional impairment is expected or to observe them according to a follow-up 
regimen.
ConCLusIon
The present study provides an inventory of current practice in the management 
of LMPLs in The Netherlands. Several treatment modalities are available but 
evidence-based guidelines are lacking, with the exception of those for treating 
CIS. This lack of consensus and guidelines may be explained by the absence 
of evidence in the literature. Moreover, the lack of prognostic parameters for 
malignant progression may add to the uncertainty about the best way to treat 
these lesions. In the current study, it was not possible to establish the exact 
prognostic significance of management. On the other hand, it is evident that 
in the absence of clear guidelines differences in management exist and may 
very well influence the clinical course. Building consensus and developing 
guidelines for the management of LMPLs could be useful to optimize the 
diagnosis, treatment, and follow-up of these lesions.
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abstraCt
baCkground: Grading of dysplasia, including head and neck lesions, continues 
to be a hotly debated subject. It is subjective and lacks intra- and inter-observer 
reproducibility due to the insufficiency of validated morphological criteria 
and the biological nature of dysplasia. Moreover, due to the absence of a 
consensus,  several systems are currently employed. 
objeCtIves: The aims of this review are to:
1) Highlight the significance of dysplasia and the importance of a valid method 
for assessing precursor lesions of the head and neck.
2) Review the different histopathological classification systems for grading 
intraepithelial lesions of the head and neck.
3) Discuss and review quality requirements for these grading systems.
ConCLusIon: Regarding the different classification systems, data concerning 
the WHO classification system are the most available in current literature. There 
is no simple relationship or overlapping between the classification systems. 
Further studies should be done to see whether other systems have advantages 
above the current WHO system and to discover indications that could lead to an 
universal classification system for intraepithelial lesions of the head and neck.
IntroduCtIon
Head and neck squamous cell carcinoma (HNSCC) is one of the most often 
encountered	malignancies;	it	carries	a	bad	prognosis.1,2 To improve survival, 
adequate diagnosis and treatment of precursor lesions is urgently needed. 
These precursor lesions are defined as an altered epithelium with an increased 
likelihood for progression to squamous cell carcinoma (SCC). The altered 
epithelium shows a variety of cytological and architectural changes that have 
traditionally brought under the common denominator dysplasia.3 
The presence of dysplastic areas in the epithelium of the upper aerodigestive 
tract (UADT) is believed to be associated with a likely progression to cancer. 
There is evidence that in an individual lesion, the more severe the dysplasia 
the greater the likelihood is of progression to malignancy. Rarely however, 
non-dysplastic lesions may also show malignant development.3-8 Therefore, 
presence and severity of dysplasia cannot be used as a reliable guide for the 
treatment of individual cases. Nevertheless, the crude relationship between 
grading dysplasia and risk of progression to malignancy makes dysplasia 
grading necessary. 
Grading of dysplasia, including head and neck lesions, continues to be a hotly 
debated subject. It is subjective and lacks intra- and inter-observer reproducibil-
ity due to the insufficiency of validated morphological criteria and the biological 
nature of dysplasia.8-10 Moreover, due to the absence of a consensus,  several 
systems are currently employed.11 
Nevertheless conventional histopathological evaluation based on light micro-
scopic examination of hematoxylin & eosin-stained slides is, in spite of the 
above mentioned shortcomings, still the most valid method for assessing the 
malignant potential of preneoplastic head and neck lesions.4 Moreover, it is 
important to notice that making a diagnosis is a prerequisite for selecting the 
treatment which ensures the best prognosis, making the disease classification 
system a predictive system.8,12 The aim should be to tailor forms of therapy to 
the likelihood of disease progression thus reducing the incidence of invasive 
disease, limiting the need for radical surgery and improving survival while 
avoiding unnecessary follow-up in cases which lack significant premalignant 
potential.10
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gradIng systems: overvIew
During the last decades many classifications of intraepithelial head and neck 
lesions have been proposed as illustrated by the fact that for intraepithelial 
laryngeal lesions, more than 20 classification systems have been described.13-18 
This seriously hampers the assessment of the long-term risk of subsequent 
malignancy, because different histopathological classifications and initial 
interventions make comparison of reported data difficult or even impossible 
because of inconsistencies in the criteria used for evaluation of the histological 
features.8,19,20 The need for uniformity in reporting these lesions is obvious. 
The majority of the classifications in the current literature have followed criteria 
similar to those in common use for the grading of epithelial lesions of the 
uterine cervix.21,22 Whether this is justified, is debatable. In cervical epithelium, 
there is clear distinction between normal and abnormal layers of the epithelium 
and consequently the degree of dysplasia can be assessed by determining the 
horizontal level of this border in the epithelium, resulting in substantial intra- 
and inter-observer consistency. Such a sharp distinction between normal and 
abnormal layers in the epithelium of the UADT is less obvious and consequently 
the definition of the degree of dysplasia is much more susceptible for discussion, 
this resulting in substantial intra- and inter-observer variability.8,10,23
When looking at the current classification systems as mentioned in the WHO-
IARC blue book series the following ones are proposed. The WHO classification 
is similar to the classification for the uterine cervix, and is widely used in spite 
of the shortcomings as mentioned. It recognizes low, moderate and severe 
dysplasia and carcinoma in situ (CIS), defined in the same way as for cervical 
lesions. The SIN classification (squamous intraepithelial neoplasia) can be 
considered synonymously, excepted that severe dysplasia and CIS are com-
bined as SIN 3 (Table 1). Besides the WHO and SIN classification system, the 
Ljubljana classification is mentioned (Table 1).3,11 
Table	1.	Classification	systems	that	categorize	intraepithelial	head	and	neck	lesions.3,11
2005 WHO Classification Squamous Intraepithelial Ljubljana Classification Squamous  
     Neoplasia (SIN)  Intraepithelial Lesions (SIL)
squamous cell hyperplasia    squamous cell (simple) hyperplasia
mild dysplasia   SIN 1   basal/parabasal cell hyperplasia*
moderate dysplasia  SIN 2   atypical hyperplasia**
severe dysplasia   SIN 3***   atypical hyperplasia**
carcinoma in-situ   SIN 3***   carcinoma in-situ
* basal/parabasal cell hyperplasia may histologically resemble mild dyplasia, but the former is conceptually
benign lesion and the latter the lower grade of precursor lesions.
** ‘risky epithelium’. The analogy to moderate and severe dysplasia is approximate.
*** the advocates of SIN combine severe dysplasia and carcinoma in-situ.
The Ljubljana classification, developed by laryngeal pathologists and used since 
1971, focuses on the clinical decision points which involve the identification of: 
1) purely hyperplastic lesions that do not require close follow-up (simple or 
abnormal hyperplasia), 2) mild degrees of atypia who require close follow-up 
to recognize any progression to severe atypia (atypical or ‘risky’ hyperplasia), 
3) severe atypia (carcinoma in situ) who require treatment (surgery or 
radiotherapy).4,16,19,24,25 
Apart from these taxonomic problems, the need to differentiate between 
severe dysplasia and carcinoma in situ is debatable. Several authors have 
commented on the difficulty in separating these categories in conventional 
classification systems.4,5,13 To reduce categories still further, occasionally a 
binary classifying system has been proposed.10,26
QuaLIty reQuIrements For 
gradIng systems
A grading system can be devised in two ways: an arbitrary system can be 
composed with no detailed knowledge of the domain, or data about the domain 
can be used in statistical methods of analysis. Since most grading and scoring 
systems in histopathology are imposed on domains without prior data analysis, 
the psychological factors that affect the creation of these systems becomes 
important. There is often an interaction between histopathological grading 
systems and clinical therapies especially if trials of treatment for a particular 
condition are widespread. Some authors suggest that the pathologist is 
required only to divide cases into the number of different treatment options 
available. Others, including Morris, argue that the pathologist should trans-
mit the maximum amount of information possible from their interpretations 
without the addition of extraneous ‘noise’.27,28 Furthermore, reproducibility 
and prognostic value (use of results) are important conditions.
reproduCIbILIty
Reproducibility refers to the degree to which observer measurement or diag-
nosis remains the same on repeated independent observations of an unchanged 
characteristic.29 This consistency can be assessed between different observers 
(interobserver) or within a single observer (intraobserver). When studying the 
accuracy in grading dysplasia of the UADT there is no test available, which is 
thought	 to	be	better	 than	 the	pathologist’s	observation;	an	accepted	gold	
standard is not available for assessing the validity obtained when grading 
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these lesions. Therefore, reproducibility, normally used to assess precision, 
is used to provide an indication of validity. When combined for this goal, 
inter- and intraobserver agreement levels give an estimate of the degree of 
bias and validity in situations (like grading dysplasia of the UADT), where an 
appropriate gold standard is not available.30
If a scoring system is to be clinically useful then it should be reproducible 
both between pathologists and for the same pathologist at different times: inter- 
and intra-observer reproducibility.27 In histopathology, results of the diagnostic 
evaluation are discrete diagnostic categories (for example, moderate dysplasia 
in a laryngeal lesion) rather than variable parameters and for this reason kappa 
statistics are often used as indicators of performance.31-33 Kappa statistics 
measure levels of agreement between observers and make allowance for the 
degree of agreement that would occur by chance alone.34 Since most grading 
systems in squamous lesions produce an ordinal categorical result then kappa 
statistics are a relevant means of assessing reproducibility.8,27,32,34,35 A kappa 
statistic of 1 represents perfect agreement and 0 represents the level of 
agreement expected by chance alone.27 Landis et al. described guidelines to 
interpret the quantitative significance of kappa.31 
Concerning the head and neck region, data of oral lesions outnumber laryngeal 
lesions. Pindborg et al. for the first time indicated the need for an internationally 
accepted set of criteria for oral epithelial dysplasia in 1975.36 Since then, several 
studies have shown large intra- and interobserver variability in the assessment 
of intraepithelial head and neck lesions (Table 2).10,26,30,36-41
There are also additional features that negatively influence reproducibility. 
Fischer et al. suggested that inflammation, lesion site, and biopsy technique 
(punch and wedge) modifies the reliability of oral histological lesions.38 Clinical 
information submitted with biopsy specimens did not increase accuracy and 
consistency.41
With these considerations in mind, reproducibility for the larynx gave an overall 
kappa value of 0.32 for the WHO classification, whereas the use of a two grade 
system (low and high grade) gave a kappa figure of 0.52.10 Data concerning 
the SIN classification and Ljubljana classification in relation to reproducibility 
of laryngeal lesions are not available in current literature. Agreement for lesions 
of the oral cavity and oropharynx varies from 35.8 to 92.8% for the WHO classi-
fication, kappa values varying from 0.15 to 0.59.26,30,37-41 A binary system (high/
low risk), evaluated by Kujan et al., resulted in 74.3% agreement and a kappa 
value of 0.50. Particularly for the cases of moderate dysplasia the binary grading 
system may have merit in helping clinicians to make critical decisions.26 Fischer 
et al. also reduced the number of pathologic diagnoses to three categories (‘no 
abnormality/hyperkeratosis’, ‘mild, moderate, or severe dysplasia’, ‘carcinoma 
in situ/carcinoma’) which resulted in a kappa value of 0.70 (compared with 
0.59 using the various pathologic diagnoses separately).38 Data concerning 
the SIN classification and Ljubljana classification in relation to reproducibility of 
oropharyngeal lesions and lesions of the oral cavity are not available in current 
literature. Table 2 shows an overview of observer variability in head and neck 
lesions. 
Table	2.	Observer	variability	in	head	and	neck	lesions.
studies / 
referenc-
es
Localisation Number	
of slides
histo-
pathological	 
classification
Number	of	
examinators
Agreement Kappa	value
Abbey et 
al. 1995
oral cavity / 
oropharynx 
120 WHOº 6 35.8-57.5% 0.15-0.41
Fischer et 
al. 20041
oral cavity / 
oropharynx
87 WHOº 24 0.59 (95% CI: 
0.45-0.72)
0.70 (95% CI: 
0.56-0.84)2
Karabulut 
et al. 1995
oral cavity / 
oropharynx
100 WHOº 4 49-69% 27-45%3
Tabor et al. 
2003
oral cavity / 
oropharynx
43 WHO 3 53% 0.58
Abbey et 
al. 1998
oral cavity / 
oropharynx
120 WHOº 6 38.5% 0.174
Brothwell 
et al. 2003
oral cavity / 
oropharynx
64 WHOº 3 51% 0.37
Kujan et al. 
20061
oral cavity / 
oropharynx
68 WHO and  
binary system 
(”low-risk” or 
“high-risk”)
4 WHO:
37.7%  
(unweighted)
92.8% 
(weighted)
Binary sys-
tem: 74.3%
WHO:
0.22 (95% CI: 
0.11-0.35  
unweighted)
0.63 (95% CI: 
0.42-0.78 
weighted)
Binary system: 
0.50
Mclaren et 
al. 2000
larynx 100 WHO and 
two-grade 
(low and high 
grade)
13 WHO: 0.32
Two-grade: 
0.52
º = WHO is not explicitely stated, but terms are in agreement with this system.
1 = The unweighted kappa considers all disagreements to be equally important, while the weighted kappa 
(Kw) yields a higher reliability when disagreements between raters are small compared with when they are 
large.
2 = the pathologic diagnoses are restricted to three categories (‘no abnormality/hyperkeratosis’, ‘mild, 
moderate, or severe dysplasia’, ‘carcinoma in situ/carcinoma’).
3 = when comparing the kappa values between the two pairs of pathologists with the same education, 
these values did not diverge from the general level of kappa values, indicating that the interobserver  
variability was due to individual differences rather than to educational background.
4 = Clinical information submitted with biopsy. Same population as37.
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prognostIC and predICtIve vaLue
Altmann et al. and Putney et al. reported the first follow-up studies of precancer-
ous	conditions	of	the	larynx;	carcinoma	in	situ	and	keratosis,	respectively.42,43 
Since then several follow-up studies concerning the natural evolution and long-
term risk of malignant progression in intraepithelial lesions have been reported. 
In these studies, usually no distinction between natural evolution without 
treatment (prognostic value) and predictive value (response to treatment) 
is made. Therefore, data on malignant progression as summarized below 
concern both treated and untreated cases. 
Malignant progression of intraepithelial laryngeal lesions diagnosed with the 
WHO classification is, according to current literature, as follows: hyperplasia 
0-3%13,44,45, mild dysplasia 0-30%13,45-47, moderate dysplasia 0-44% 5,13,45-49, severe 
dysplasia 20-57%13,45,47,49,50, CIS 0-80%13,44,45,48-52. 
Regarding the SIN classification, relevant figures are as follows: SIN I 5%, SIN 
II 25%, and SIN III 11-25%.5,53 Clinical data concerning follow-up on laryngeal 
lesions graded with the Ljubljana classification showed a marked increase in 
the incidence of malignant progression from simple, abnormal, and atypical 
hyperplasia (resp. 0.7%, 1.0%, and 9.5%).25 Recently, a study by Gale et al. 
showed 1.1% (12/1089) progression to carcinoma of squamous hyperplasia/
basal-parabasal hyperplasia and 9.5% (17/179) of atypical hyperplasia (CIS is 
not included).20
Few studies have examined the cancer risk related to different grades of oral 
dysplasias.54-57 Silverman et al. reported malignant transformation in 36% of 
cases with oral dysplasia. The degree of dysplasia is not specified.56 Schepman 
et al. reported 12% malignant transformation in oral lesions histopathological 
classified with the WHO classification. Leukoplakias consisting of moderate 
or severe epithelial dysplasia, had a significantly higher risk of developing 
a carcinoma than leukoplakias of a lower stage (p<0.01).55 In another study 
26% of cases with hyperplasia/mild dysplasia and 67% of cases with moderate/
severe dysplasia developed into carcinoma.54 Lumerman et al. studied malignant 
transformation in hyperplasia with dysplasia, mild dysplasia, moderate dys-
plasia,	 severe	dysplasia,	and	CIS;	 respectively	29%,	8%,	17%,	17%,	0%.57 Data 
concerning the SIN classification in relation to predictive value of oral lesions 
are not available in current literature. The only study in current literature 
which studied the application of the Ljubljana classification to grading oral 
intraepithelial lesions has been published by Zerdoner et al. No cases of simple 
(0/79) or abnormal (0/42) hyperplasia showed progression to carcinoma, 
18.2% (2/11) of atypical hyperplasia progressed to invasive cancer.58  
Interpretation of these reported data of oral intraepithelial lesions are hampered 
by small sample sizes, surgical intervention carried out for high-risk dysplasias 
and variability in reporting dysplasia grades. The greater part of published 
data only considered macroscopical features (i.e. leukoplakia) and no histology.59,60 
It should also be noted that the predictive value of dysplasia is dependent on 
the prevalence of leukoplakia in a given population.8 Size, and not histology 
seems to be the most important in predicting malignant transformation.61  
So, it appears that regarding reproducibility as well as in terms of prognosis, 
still a lot of progress has to be made. 
Molecular markers are subject of investigation: in spite of many studies, the 
molecular events that induce the development of premalignancies to carcinoma 
are still unknown, and we are still forced to conclude that over (or under)-
expression of biomarkers itself adds little predictive value over standard 
histology.62-66 Therefore, until now they are not applicable in clinical practice.67 
Finally, some remarks have to be made on the relationship between clinical 
aspects and risk of malignant progression. In general, homogeneous leukoplakic 
lesions are thought to have a low risk of malignant transformation, mixed 
white and red lesions (or speckled leukoplakia) an intermediate risk, and pure 
erythroplakia (red lesions) the highest risk of cancer development. However, 
none of these macroscopic features is reliably diagnostic of any histological 
grade of precursor lesion, and histological analysis of these lesions is mandatory 
to determine their biological potential. Occasionally precursor lesions may 
appear clinically normal.3,11,20,68 Furthermore, nomenclature or terminology 
concerning the macroscopic features is still a subject of discussion.69 
evaLuatIon
As outlined before, a histological dysplasia system ideally should meet two 
basic requirements. At first, it should be easily applicable in daily routine 
practice with low inter- and intra-observer variability. Secondly, it should allow a 
clear separation between patients who need treatment to prevent progression 
towards malignancy and those for whom no treatment is needed.
Regarding inter- and intraobserver variability, evaluation of the WHO classi-
fication shows for laryngeal lesions an overall kappa value of 0.32, whereas 
the use of a two grade system (low and high grade) gave a kappa figure of 
0.52.[10] Its prognostic significance is as follows: hyperplasia 0-3%13,44,45, mild 
dysplasia 0-30%13,45-47, moderate dysplasia 0-44%5,13,45-49, severe dysplasia 
20-57%13,45,47,49,50, CIS 0-80%13,44,45,48-52. For oral lesions, inter- and intraobserver 
figures of the WHO classification vary between kappa scores of 0.15 and 
0.59.26,30,37-41 Its prognostic significance is 12-67%, as can be inferred from the 
data mentioned before.
When looking at the SIN classification it has to be noted, that with respect 
to reproducibility, no data of head and neck lesions are available in current 
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literature. Concerning prognostic significance of laryngeal lesions the following 
data are available: SIN I 5%, SIN II 25%, SIN III 11-25%.5,53 Data concerning the 
SIN classification in relation to predictive value of oral lesions are not available 
in current literature.
Figure 1. Photomicrograph showing area of increased epithelial thickness together with hyperkeratosis: mild 
dysplasia (WHo) or parabasal hyperplasia (Ljubljana)
Regarding the Ljubljana classification, its use for the larynx has been documented 
extensively. Its relevance for prognosis has been amply demonstrated by the 
pathologists and clinicians who developed the system. However, its usefulness 
has not yet resulted in widespread acceptance. For the oral cavity, there is 
only one study that reports its use in this anatomic location.58 In that study a 
prognostic significance, similar to the larynx was noted. However, data on 
reproducibility are also lacking for this anatomic area. Further studies should be 
done to see whether it has an advantage above the current WHO dysplasia 
system.
Figure 2. Photomicrograph showing blunt and elongated epithelial ridges and cytonuclear atypia confined to 
the lower epithelial half: moderate dysplasia (WHo) or atypical hyperplasia (Ljubljana).
Although the histological assessment of the WHO dysplasia system and the 
Ljubljana system are based on the same architectural and cytological changes, 
there is no simple relationship or overlapping between the classification 
systems.3,11,19,20 Figure 1, figure 2, and figure 3 illustrate the areas of similarity 
in the classification systems but also the problems arising when matching the 
WHO categories moderate and severe dysplasia with the Ljubljana category 
atypical hyperplasia. According to Gale et al., comparing the three discussed 
classification systems, it is unlikely that they will come together in the very 
near future. On the other hand, future discoveries mainly in molecular biology 
could be the basis for a single, universal classification system for intraepithelial 
lesions of the UADT.20
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Figure 3. Photomicrograph showing epithelial alterations involving the entire epithelial thickness: severe 
dysplasia (WHo) or atypical hyperplasia (Ljubljana).
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abstraCt
The objective of this study is to measure interobserver variability in the 
classification of laryngeal mucosal premalignant lesions by reassessing the 
histopathology of previously diagnosed cases and to determine the possible 
therapeutic consequences of disagreement among observers. Histopatho-
logical assessment of 110 laryngeal mucosal premalignant lesions was done 
by three pathologists. Each slide had to be classified according to the World 
Health Organization, Squamous Intraepithelial Neoplasia, and the Ljubljana 
Squamous Intraepithelial Lesions systems. After the independent assessment, 
a joint meeting took place. To assess the relation between histopathological 
grading and subsequent clinical management, we created a two- and a three-
grade system besides one comprising all options. For all analyses, the SAS/
STAT statistical software was used. The highest unweighted К-values concerning 
the all-options system are observed for the Squamous Intraepithelial Neoplasia 
classification (0.28, 95% confidence interval 0.23–0.33), followed by the World 
Health Organization and Ljubljana classifications. For the two-grade system the 
Ljubljana classification shows the highest unweighted К-values (0.50, 95%, 0.39–
0.61), followed by the World Health Organization and Squamous Intraepithelial 
Neoplasia classifications. For the three-grade system, the unweighted К-values 
are similar. The implementation of weighted К-values led to higher scores within 
all three classification systems, although these did not exceed 0.55 (moderate 
agreement). Given the high level of consensus, simultaneous pathological 
assessment may be said to provide added value in comparison with indepen-
dent assessment. In the current study, no clear tendency is observed in favor 
of any one classification system. The proposed three-grade system could be 
an improved histopathological tool because it is easier to correlate with clinical 
decision making and because it yields better unweighted К-values and 
proportions of concordance than the all options system. Furthermore, clinical 
management could benefit from assessment by more than one pathologist in 
suspected cases of dysplasia or carcinoma.
IntroduCtIon
Laryngeal mucosal premalignant lesions are seen frequently in clinical practice. 
They are defined as an altered epithelium with an increased likelihood of 
progression to laryngeal squamous cell carcinoma. The altered epithelium 
shows a variety of cytological and architectural changes that have traditionally 
been brought under the common denominator of dysplasia.1,2 Grading of dys-
plasia, including that of laryngeal lesions, continues to be a topic of debate. 
It is subjective and has been shown to lack intra- and inter-observer reproduc-
ibility, which may have significant therapeutic implications.3–7 To minimize both 
morbidity and mortality, it is highly important to detect the lesions at risk for 
malignancy in its earliest stage.8–10 Unfortunately, there is no universally accepted 
histopathological classification system. Moreover, there is no consensus on the 
diagnostic criteria for the various entities, particularly on criteria to differentiate 
severe dysplasia from carcinoma in situ. This is illustrated by the fact that during 
the last decades, more than 20 classification systems have been described for 
laryngeal mucosal premalignant lesions.3,11–15 In the current literature and 
clinical practice, the 2005 World Health Organization, Squamous Intraepithelial 
Neoplasia, and the Ljubljana Classification of Squamous Intraepithelial Lesions 
systems are the most widely used and are considered the most relevant. So 
far, the reproducibility of one of these systems, the World Health Organization 
classification, has been evaluated for laryngeal lesions in just one published 
study.6 Thus, for the Squamous Intraepithelial Neoplasia and Ljubljana systems, 
no data are available on reproducibility for laryngeal lesions. 
The objective of the present study is to reassess the histopathology of previously 
diagnosed laryngeal mucosal premalignant lesions in order to measure the inter-
observer variability of the World Health Organization, Squamous Intraepithelial 
Neoplasia, and Ljubljana classification systems and to determine the possible 
therapeutic consequences of disagreement among observers. Moreover, a pro-
posal to compensate for this variability is made to facilitate the use for clinical 
purposes.
materIaLs and methods
To set up an interobserver study on the histopathological assessment of 
laryngeal mucosal premalignant lesions, three pathologists with head and 
neck pathology as a field of interest (Marie-Louise van Velthuysen, Freek Bot, 
and Piet Slootweg) reviewed laryngeal mucosal premalignant lesions cases. 
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Sections stained with hematoxylin and eosin (H&E) were obtained from the 
files of the Departments of Pathology at the Radboud University Nijmegen 
Medical Center (n¼60) and the Maastricht University Medical Center (n¼50). 
The sections represented a range of diagnoses along the spectrum of laryngeal 
mucosal premalignant lesions. Table 1 gives an overview of the original histo-
pathological diagnoses made according to the World Health Organization 
classification system.1 The 110 slides were selected by two investigators (Stijn 
Fleskens and Ewa Bergshoeff) who did not participate as one of the reviewing 
pathologists. Each pathologist independently reviewed the anonymized 110 
microscopic slides without any previous discussion and was completely blinded 
to the initial diagnosis and grade. No clinical information was provided with 
the cases. Each slide had to be classified according to the 2005 World Health 
Organization classification, the Squamous Intraepithelial Neoplasia classification, 
and the Ljubljana classification. The criteria they used were derived from the 
WHO-IARC blue book.1
Table	1.	An	overview	of	the	cases	according	to	the	original	histopathological	diagnosis.	
	 	 	 	 	 	 Study	population
Original	histopathological	diagnosis	 Number	of	cases
Hyperkeratosis    3
Inflammation    6
Squamous cell hyperplasia  17
Mild dysplasia    23
Moderate dysplasia   32
Severe dysplasia    16
Carcinoma in situ    13
Total     110
The World Health Organization classification provides the following options: 
normal	histopathology	(hyperkeratosis);	inflammation;	hyperplasia;	mild	dyspla-
sia;	moderate	dysplasia;	severe	dysplasia;	carcinoma	 in	situ;	and	squamous	
cell carcinoma. The Squamous Intraepithelial Neoplasia classification is slightly 
different:	normal	histopathology	(hyperkeratosis);	inflammation;	SIN	1;	SIN	2;	
SIN	3;	and	squamous	cell	carcinoma.	The	options	in	the	Ljubljana	classification	
are	different	again:	normal	histopathology;	inflammation;	squamous	cell	(simple)	
hyperplasia;	basal/parabasal	cell	hyperplasia;	atypical	hyperplasia;	carcinoma	
in	situ;	and	squamous	cell	carcinoma.
To calibrate the categories across the three systems and thus be able to compare 
the classification systems (Table 2), we used the proposal made in the WHO-
IARC blue book and by Gale et al.1,16 All three pathologists were familiar with 
the different classification systems. The microscopic slides examined by the 
reviewers were those on which the initial diagnoses had been made. After the 
independent assessment, cases with different independent diagnoses were 
randomly selected on the basis of the all-options system. At a joint meeting, 
this random selection was assessed by the three pathologists together in 
order to determine the degree of consensus, which serves as an indicator of 
the implications of having lesions reviewed by more than one pathologist 
simultaneously.
Besides comparing all separate options of each system, we designed a 
two- and a three-grade system (see Table 2) to include clinical management 
in the histopathological grading.1,17 The two- and three-grade systems are 
based on the risk of malignant progression and its consequences for clinical 
practice: a ‘low-risk’ group, not needing treatment based on grading, and a 
‘high-risk’ group, requiring treatment, usually consisting of (laser) surgery or 
radiotherapy.4,18,19 In the ‘high-risk’ group, the three-grade system additionally 
distinguishes mild and moderate dysplasia from severe dysplasia, carcinoma 
in	 situ,	 and	 squamous	 cell	 carcinoma	 (World	 Health	 Organization);	 it	 also	 
distinguishes SIN 1 and 2 from SIN 3 and squamous cell carcinoma (Squamous 
Intraepithelial Neoplasia), and it differentiates (atypical hyperplasia) dysplasia 
from carcinoma in situ and squamous cell carcinoma (Ljubljana). This further 
differentiation was made because in daily practice normal histology, inflam-
mation, and hyperplasia (green segment in Table 2) are generally considered 
to require no periodic observation. In contrast, the other histopathological 
diagnoses do require at least periodic observation (yellow segment in Table 
2) and treatment (pink segment in Table 2), respectively.
statIstICaL anaLysIs
The К-statistics were calculated to assess the degree of interobserver agreement 
in the reporting of all options for each of the three classification systems and 
the derived two- and three-grade systems. The statistics describe the extent 
to which observers concur on a diagnosis, adjusted for levels of agreement 
that are expected to occur by chance alone. The interpretation of К-values could 
not rely on any absolute definitions. According to Altman (slightly adapted 
from Landis and Koch20,21), К-values	o0.20	indicate	poor	agreement;	0.21–0.4	
fair	agreement;	0.41–0.6	moderate	agreement;	0.61–0.8	good	agreement;	and	
values 0.81–1.00 very good agreement. Standard weighted and unweighted 
К-values and their 95% confidence intervals were calculated for each pair-wise 
comparison of the three pathologists. Weighted К-values take into account the 
amount of disagreement between two raters when a scoring system has three 
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or more categories, which means that more weight is given to a difference 
of more than one category than to a difference between raters of only one 
category.22
All analyses were performed with SAS/STAT statistical software (SAS system 
8.2, SAS Institute, Cary, NC, USA). Generalized, unweighted К-values for the 
three raters and their 95% confidence intervals were calculated using the SAS 
macro MAGREE. Finally, the proportion of total concordance among the three 
raters was calculated for each of the three scoring systems and the derived 
two and three-grade systems.
Table	2.	Overview	of	the	scoring	form	and	definition	of	a	two-	and	three-grade	system. 
WHO SIN SIL
normal normal normal
inflammation inflammation inflammation
hyperplasia squamous cell (simple) hyperplasia
basal/parabasal cell hyperplasia
mild dysplasia sin 1
moderate dyplasia sin 2 atypical hyperplasia (dysplasia)
severe dysplasia
sin 3
carcinoma in situ
carcinoma in situ
squamous cell carcinoma squamous cell carcinoma squamous cell carcinoma
Two-grade system: 1) light grey 2) white + dark grey
Three-grade system: 1) light grey 2) white 3) dark grey
resuLts
Two cases were excluded from analysis because of insufficient quality of the 
H&E-stained sections. Two other cases were excluded because of insufficient 
laryngeal tissue in the H&E-stained sections.
unweIghted and weIghted К-vaLues
Table 3 gives an overview of the unweighted and weighted К-values with 95% 
confidence intervals.
Table	3.	Overview	of	the	unweighted	and	weighted	К-values	with	95%	confidence	intervals.
all options all options Two-grade* Three-grade Three-grade
who unweighted weighted unweighted unweighted weighted
observer 1 vs. 2 0.25  
(0.14-0.36)
0.50  
(0.39-0.60)
0.47  
(0.29-0.64)
0.37  
(0.22-0.51)
0.50  
(0.37-0.62) 
observer 1 vs. 3 0.20  
(0.10-0.30)
0.49  
(0.39-0.59)
0.40  
(0.23-0.58)
0.38  
(0.23-0.52)
0.47  
(0.33-0.60)
observer 2 vs. 3 0.21  
(0.11-0.31)
0.48  
(0.37-0.58)
0.45  
(0.28-0.63)
0.42  
(0.28-0.57)
0.53  
(0.40-0.66)
overall 0.21  
(0.17-0.26)
0.44  
(0.33-0.55)
0.39  
(0.31-0.47)
sIn
observer 1 vs. 2 0.24  
(0.13-0.35)
0.45  
(0.34-0.57)
0.41  
(0.23-0.59)
0.35  
(0.20-0.50)
0.48  
(0.35-0.61)
observer 1 vs. 3 0.29  
(0.17-0.40)
0.51  
(0.40-0.62)
0.42  
(0.24-0.59)
0.39  
(0.24-0.54)
0.48  
(0.34-0.61)
observer 2 vs. 3 0.33  
(0.21-0.44)
0.52  
(0.41-0.63)
0.46  
(0.29-0.63)
0.45  
(0.31-0.59)
0.55  
(0.42-0.68)
overall 0.28  
(0.23-0.33)
0.43  
(0.32-0.54)
0.40  
(0.32-0.48)
Ljubljana
observer 1 vs. 2 0.19  
(0.07-0.30)
0.41  
(0.29-0.52)
0.43  
(0.26-0.61)
0.32  
(0.17-0.47)
0.43  
(0.29-0.57)
observer 1 vs. 3 0.23  
(0.12-0.34)
0.43  
(0.32-0.55)
0.49  
(0.32-0.66)
0.46  
(0.32-0.61)
0.54  
(0.40-0.68)
observer 2 vs. 3 0.18  
(0.08-0.28)
0.40  
(0.30-0.50)
0.56  
(0.41-0.72)
0.40  
(0.26-0.54) 
0.50  
(0.37-0.63)
overall 0.19  
(0.14-0.24)
0.50  
(0.39-0.61)
0.39  
(0.31-0.47)
* only unweighted К-values are applicable for the two-grade system
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All options
Comparison of the results using all grading options of the World Health 
Organization, Squamous Intraepithelial Neoplasia, and Ljubljana classification 
systems yielded the following overall unweighted К-values: 0.21 (95% confi-
dence	interval	0.17–0.26);	0.28	(95%	confidence	interval	0.23–0.33);	and	0.19	
(95% confidence interval 0.14–0.24), respectively. Weighted and unweighted 
К-values for the pair-wise comparisons of the three are presented in Table 3.
Two-grade system
Comparison of the results for the two-grade system for the World Health 
Organization, Squamous Intraepithelial Neoplasia, and Ljubljana classification 
systems gave the following overall unweighted К-values: 0.44 (95% confidence 
interval	0.33–0.	55);	0.43	 (95%	confidence	 interval	0.32–0.54);	and	0.50	 (95%	
confidence interval 0.39–0.61), respectively. Weighted К-values for the pair-wise 
comparisons of the three observers are presented in Table 3.
Three-grade system
Comparison of the results using the three-grade system for the World Health 
Organization, Squamous Intraepithelial Neoplasia, and Ljubljana classification 
systems gave overall unweighted К-values of: 0.39 (95% confidence interval 
0.31–0.	47);	0.40	(95%	confidence	interval	0.32–0.48);	and	0.39	(95%	confidence	
interval 0.31–0.47), respectively. Weighted and unweighted К-values of the 
pair-wise comparisons of the three observers are presented in Table 3.
proportIon oF ConCordanCe
Table 4 shows the proportion of concordance among the pathologists for the 
three classification systems. The proportions using all grading options of the 
World Health Organization, Squamous Intraepithelial Neoplasia, and Ljubljana 
classification systems were 13% (95% confidence interval 7–20), 24% (95% confi-
dence interval 16–32), and 17% (95% confidence interval 10–24), respectively. 
Using the two-grade version of the World Health Organization, Squamous 
Intraepithelial Neoplasia, and Ljubljana classification systems, the proportions 
of concordance were 60% (95% confidence interval 51–70), 60% (95% confidence 
interval 51–70), and 62% (95% confidence interval 53–72), respectively. The 
proportions for the three-grade version of the World Health Organization, 
Squamous Intraepithelial Neoplasia, and Ljubljana classification systems were 
42% (95% confidence interval 33–52), 43% (95% confidence interval 34–53), 
and 47% (95% confidence interval 38–57), respectively.
Table	4.	Proportion	of	concordance	among	the	three	pathologists	and	95%	confidence	intervals.
all options Two-grade Three-grade
who 13% (7-20) 60% (51-70) 42% (33-52)
sIn 24% (16-32) 60% (51-70) 43% (34-53)
Ljubljana 17% (10-24) 62% (53-72) 47% (38-57)
sImuLtaneous pathoLogICaL assessment at the joInt
meetIng
World Health Organization
A total of 45 cases with different independent diagnoses that had been made 
on the basis of the all-options system were selected randomly. Consensus 
could be achieved in 37/45 (82%) of the cases.
Squamous Intraepithelial Neoplasia
A total of 47 cases with different independent diagnoses based on the all-
options system were selected randomly. Consensus could be achieved in 
37/47 (79%) of the cases.
Ljubljana
A total of 40 cases with different independent diagnoses made on the basis of 
the all-options system were selected randomly. Consensus could be achieved 
in 28/40 (70%) of the cases. Regarding the World Health Organization and 
Squamous Intraepithelial Neoplasia classifications, the clinically relevant 
differentiation between moderate and severe dysplasia (SIN 2 or 3) was the 
main source of disagreement. Consensus could not always be reached in these 
cases, as illustrated in Figure 1. For the Ljubljana classification, the clinically 
relevant differentiation between (para)basal and atypical hyperplasia turned 
out to be the most difficult for the raters, as illustrated in Figure 2.
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Figure 1. Photomicrograph showing a mucosal lesion for which no consensus could be reached, opinions 
differing between moderate or severe dysplasia/sin 2 or 3 (World Health organization and squamous  
intraepithelial neoplasia classifications).
Figure 2. Photomicrograph showing a mucosal lesion for which no consensus could be reached, opinions 
differing between atypical versus basal cell hyperplasia (Ljubljana classification).
dIsCussIon
In this report, the histopathology of previously diagnosed laryngeal mucosal 
premalignant lesions was reassessed by three experienced head and neck 
pathologists. The purpose was to measure the interobserver variability of the 
three most frequently used classification systems. In this study, these systems 
have been assessed using all their original categories. Alternatively, a two- or 
three-grade system has been used, clustering the categories according to 
the clinical consequences each one would have. When comparing the results 
of the current study with the literature, we noted that the only available similar 
study – by McLaren et al,6 based on 100 laryngeal biopsies – published a 
К-value of 0.32 using all grading options and 0.52 for a two-grade system using 
the World Health Organization classification. No 95% confidence intervals 
were given in that study. In comparison, when we used the World Health 
Organization classification, we found an overall unweighted К-value for all 
options of 0.21 (95% confidence interval 0.17–0.26). Our weighted К-values 
ranged from 0.48 (95% confidence interval 0.37–0.58) to 0.50 (0.39–0.60). 
Using the two- or three-grade system gave an overall К-value of 0.44 (95% 
confidence interval 0.33–0.55) and 0.39 (95% confidence interval 0.31–0.47), 
respectively. The implementation of weighted К-values led to higher values for all 
three classification systems. However, they did not exceed 0.55, corresponding 
with moderate agreement by Altman’s criteria.20,21
Concerning the proportion of concordance for the two- and three-grade system, 
it should be noted that in 38–40% and 53–58% of the cases, respectively, the 
three pathologists disagreed. The proposed two or three-grade system is 
based on the presumed chance of malignant progression and its implications 
for clinical practice: ‘low risk’ with mainly periodic observation in comparison 
with ‘high risk’ requiring (laser) surgery or radiotherapy. By extension, the clinical 
consequences would be either overtreatment (ie, surgery or radiotherapy 
instead of periodic observation) or undertreatment (ie, periodic observation 
instead of surgery or radiotherapy). Either way, the therapeutic implications 
would be significant. In that light, there is a need for additional tools to identify 
which lesions would and which would not become malignant if left untreated.
In our review of the literature, we noted that other authors have also proposed 
or investigated a binary or two-grade system to classify head and neck mucosal 
premalignant lesions.4,6,16,23 Gale et al16 concluded that the results of a long-
term follow-up study of 1268 patients once again justify the proposal of the 
Ljubljana classification. It entails dividing the morphological criteria into two 
basic groups: benign (squamous hyperplasia and basal/ parabasal hyperplasia) 
and potentially malignant (atypical hyperplasia). It has been customary to use 
relatively few categories (three or two) and to assess accuracy by measuring 
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interobserver agreement with К-statistics. The extent of interobserver agreement 
is often less than anticipated when carefully controlled studies are undertaken, 
and there has been a tendency to recommend the use of fewer categories.6,23–26 
However, according to Deolekar and Morris,24 the policy to lower the degree 
of inter- and intra-observer disagreement by reducing the number of subjective 
categories is misleading. Although acknowledging the importance of grading 
pathological continua, they concluded that information is lost when too few 
categories are used. The judgment should be cited along with a confidence 
interval so
as not to imply a degree of accuracy that cannot be achieved. Some have 
argued that it would be logical to use more categories and to give the clinician 
a range of values within which the true value will lie (a 90, 95, or 99% confidence 
interval).24,27 Shannon28 measured information on a binary system. One bit of 
information reduces uncertainty by one-half, two bits reduce it to one-quarter 
of the initial level, and three bits reduce uncertainty to one-eighth.
We prefer a three-grade system because of the correlation with daily clinical 
practice (no periodic observation, periodic observation, and treatment ((laser) 
surgery or radiotherapy). We would rather avoid the use of only two categories. 
Furthermore, our current study shows higher unweighted К-values and propor-
tions of concordance than found with the all-options system.
Comparison of the categories within the different systems has prompted 
discussion on the position of atypical hyperplasia in the Ljubljana classification. 
This category showed an overlap with moderate as well as severe dysplasia. 
Therefore, no optimal discrimination is possible between grades 2 and 3 (yellow 
and pink segment in Table 2).
In the current study, the highest К-values for the all-options system are found for 
the Squamous Intraepithelial Neoplasia classification, followed by the World 
Health Organization and Ljubljana classifications. For the two-grade system, 
the Ljubljana classification has the highest К-values, followed by the World 
Health Organization and Squamous Intraepithelial Neoplasia classifications. 
The К-values are similar for the three-grade system. As the 95% confidence 
intervals show some overlap, as seen in Table 3, no statistically significant 
(P<0.05) differences are found among the three classification systems. In the 
future, a similar study based on more cases might demonstrate statistically 
significant differences.
Furthermore, because of a high level of consensus, the simultaneous patholog-
ical assessment had added value in comparison with independent assessment. 
A consequence could be to advise assessment by more than one pathologist 
for suspected cases of dysplasia or carcinoma. Similar proposals are found in 
current guidelines for esophageal and colonic premalignant lesions.29–31
Montgomery32 suggested that we should look beyond the problem of inter-
observer variability in the diagnosis of esophageal dysplasia. He thinks that 
sampling error on the part of endoscopists is probably more serious a problem 
than observer variation among the pathologists who are reviewing patient 
samples. However, this possibility would only make the diagnosis of premalig-
nant lesions even less reliable and offers no excuse for the observer variation. 
In our opinion, the identification of patients with intermediate-level laryngeal 
dysplasia and high risk of malignancy is a multidisciplinary challenge for both 
clinician and pathologist, a claim that has been made before.6 The necessity 
or urgency to treat a laryngeal mucosal premalignant lesion is dependent on 
several factors: the (voice) complaints of the patient and the risk of progression 
to invasive cancer or the risk that the sample is not representative for the entire 
lesion. In the absence of reliable biological markers, the grade of dysplasia is 
still the most often used parameter to guide the treatment decision. Realizing 
that clinicians should be aware of the fact that sampling errors may occur and 
that the determination of the grade of dysplasia is variable. In case of suspicion 
of a sampling error, a re-biopsy or more extensive surgery should be considered.
ConCLusIon
In the current study, we have observed no clear tendency in favor of one 
particular system for classifying laryngeal mucosal premalignant lesions. The 
weighted К-values did not exceed 0.55, indicating only moderate agreement 
and underscoring the assertion that current clinical management is in need 
of additional tools to identify lesions that would or would not become ma-
lignant if left untreated. The proposed three-grade system could be useful 
because of its correlation with daily clinical practice (no periodic observation, 
periodic observation, and treatment). Another advantage is that it yields better 
unweighted К-values and a higher proportion of concordance in comparison 
with the all-options system. Moreover, because of a high level of consensus, 
simultaneous pathological assessment provides added value in comparison 
with independent assessment. Therefore, assessment by more than one 
pathologist might be advisable for suspected cases of dysplasia or carcinoma.
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abstraCt
aIm: Whole Slide Imaging  (WSI) is a technology in which histopathological 
slides are optically scanned to produce digital images. Aim of the present 
study is validation of WSI for tissue samples of pathologic lesions in which 
subtle differences could have major clinical implications. 
methods: Larynx biopsies were used containing preneoplastic lesions. Glass 
slides were scanned using an Olympus dotSlide system with 40x objective. 
WSI were displayed at a calibrated monitor and were reviewed according to 
the 2005 WHO classification system by three pathologists with head and neck 
pathology as a field of interest. Diagnoses were converted into a three grade 
system relevant for clinical management. WSI diagnosis concordance rates 
were calculated. Kappa statistics were calculated to assess the degree of inter- 
and intra-observer agreement.
resuLts: The overall interobserver agreement was comparable for both WSI 
and glass slide diagnoses (unweighted kappa 0.38 and 0.39, respectively). The 
intraobserver (glass vs WSI) agreement ranges from 0.41 – 0.48 and 0.52 – 0.57 
for unweighted and weighted К-values respectively. WSI showed overall slightly 
less (although not statistically significant) concordance with the consensus 
diagnosis compared to glass slides.
ConCLusIon: This study shows that difficult diagnostic cases could be diag-
nosed using WSI, without compromising diagnostic quality.
IntroduCtIon
Whole Slide Imaging (WSI) is a technology in which histopathological slides 
are optically scanned to produce digital images. These so-called ‘virtual slides’ 
can be viewed locally or remotely (using internet technology) on a computer 
screen. It is the result of an evolution that started over 40 years ago by making 
static digital images of diagnostically relevant areas on a glass slide. Subse-
quently, these images could remotely be diagnosed by a (second opinion) 
pathologist (i.e. telepathology)1. Today, we have reached the point where 
whole slides can be digitized in minutes at high magnification. So far, virtual 
microscopy (VM) has mainly been used for educational and research purposes. 
In surgical pathology, VM was found to be useful for frozen section diagnostics 
in remotely situated hospitals without a practicing pathologist on location2-5. 
Main advantages of VM in surgical pathology practice are:
•		Digital	archiving;	slides	do	not	get	lost	and	keep	constant	quality	over	time.	
Slides are retrieved within seconds. 
•	 	Virtual	slides	can	be	demonstrated	during	multi-disciplinary	clinical	meetings	
at high resolution, possibly with annotations.
•			Slide	conferences/panels	and	(real-time)	consultation	of	expert	pathologist(s)	
worldwide by means of a secure internet connection which may prevent 
patient delay or save travelling time.
•			Remote	working	(e.g.	from	home)	is	possible,	evading	traffic.	
As with most technological advancements, training (of pathologists) and assess-
ment of the validity of VM are required before this technology can safely be 
implemented in the daily diagnostic practice6. Published validation studies 
have addressed the fields of dermatopathology7, uropathology8 and (general) 
surgical pathology5 in a primary diagnostic setting. Application of VM in a 
second opinion setting (as part of an in house quality assurance protocol) was 
studied in the fields of breast pathology9 and (general) surgical pathology10. 
In these studies, the use of VM resulted in significant discrepancies (discordant 
result possibly influencing choice of treatment) in 0 – 2.3% of cases.  
We expect a major future role for VM in consultation of specialized pathologists 
for difficult diagnostic cases. Specimens offered for consultation are generally 
more complicated, often requiring careful analysis of fine details. These speci-
mens therefore pose higher demands on image quality, which is especially 
challenging when using VM. Aim of the present study is validation of VM for 
tissue samples of pathologic lesions in which subtle differences could have 
major clinical implications. We used a set of 106 larynx biopsies containing pre-
neoplastic lesions, of which glass slide interobserver variability was previously 
studied11. In the present study, slides were independently assessed by three 
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expert pathologists using VM according to the WHO classification system12. 
Comparing results obtained with glass slides and VM, we analyze the hypothesis 
that the accuracy and interobserver variability of laryngeal biopsy diagnosis 
by means of VM is comparable to using glass slides. 
materIaLs and methods
Case seLeCtIon
Pre-malignant laryngeal H&E stained biopsy specimens (n=110) were used which 
were described previously11. Specimens were obtained from the departments 
of pathology of Radboud University Nijmegen Medical Center (n=60) and 
Maastricht University Medical Center (n=46), The Netherlands. Each case is 
represented by one slide. Table 1 gives an overview of the original histo-
pathological diagnoses according to the WHO classification system12. In our 
previous study, three classification systems were used simultaneously (WHO, 
Squamous Intraepithelial Neoplasia system and the Ljubljana Squamous 
Intraepithelial Lesions system). No clear tendency in favor of any one of the 
classification systems was found. We proposed a three grade system which 
could be useful because of its better reproducibility and correlation with 
clinical management. In the present study, we will only use the WHO system 
and derived a three grade system because of its wide acceptance. Inclusion 
of patient materials was in accordance with regulations of the local ethical 
committee.
vIrtuaL mICrosCopy
Glass slides were scanned using a commercially available digital slide scanner 
(Olympus	dotSlide	system,	software	version	2.3;	build	8521,	Olympus	Corp,	
Japan). The system is based on a conventional research microscope (Olympus 
BX51) with attached RGB CCD camera (Olympus XC10).  The camera contains 
a 1.4 megapixel Peltier cooled CCD with pixels of size 6.45x6.45 μm. Entire 
slides	were	scanned	using	a	40x	objective	(N.A.	0.95;	Plan	SAPO,	Olympus).	
The specimen level pixel size for this set up is 0.16 μm/pixel, coinciding with 
the Nyquist limit at λ = 500nm. The area occupied with tissue to be scanned 
was automatically detected (if required interactively adjusted) by the scanner 
software. Focusing of the sample was performed fully automatically.
Virtual slides were assessed using a high resolution, color calibrated LED 
monitor (HP LP2480zx, Hewlett-Packard Company, Palo Alto, CA) attached to 
a notebook computer (HP ProBook containing an Intel Core i3 @ 2.13 GHz, 
3Gb RAM) on which the virtual slides were stored on a hard drive. The OlyVIA 
virtual slide viewing software (version 2.0, build 5720, Olympus running under 
Windows 7) was used with a regular wired computer mouse for navigation. 
Calibration of the monitor was performed using a colorimeter (Datacolor 
Spyder 3 Elite, Lawrenceville, USA). 
experImentaL set up
Virtual slides were reviewed according to the 2005 WHO classification system 
by three pathologists, experienced in head and neck pathology (Table 1). All 
three pathologists also participated in our previously published study, in 
which the same set of laryngeal specimens was used for assessing reproduc-
ibility of glass slide diagnoses. The WHO classification system distinguishes: 
normal	histopathology	(including	hyperkeratosis);	inflammation;	hyperplasia;	
mild	dysplasia;	moderate	dysplasia;	severe	dysplasia;	carcinoma	in	situ	and	
squamous cell carcinoma12. In the present study, the additional option ‘no 
confident diagnosis possible’ was allowed. 
All cases were assessed using WSI by all three pathologists. The time between 
the glass slide assessment and the WSI assessment (wash-out period) was at 
least 15 months (since the consensus meeting, see below). Prior to the assess-
ment a short training course was given, containing in total 13 general pathology 
cases, i.e. dermato, colon, prostate and parotispathology, to get familiar with 
the usage of virtual slides. To allow the level of intraobserver agreement for 
glass slide diagnoses, one pathologist reassessed the original glass slides 2.5 
months after seeing the WSI. 
In concordance with Fleskens et al observer agreement was studied applying 
all 8 grades of the WHO system as well as using two reduced systems existing 
of three and two grades, respectively11. These reduced systems were devised 
approximating the clinical management of laryngeal premalignancies, having 
one grade ‘within normal limits’, one grade of patients prompted for immediate 
treatment and (in the three grade system) an intermediate ‘closely monitor’ 
grade (for details see Table 1). 
In our previous study a glass slide consensus diagnosis was reached for 83 cases. 
Consensus was reached for a specimen if the initial diagnosis was concordant 
for all three pathologists, or if during a consensus meeting all three pathologists 
came to an agreement. Because of the low number of cases for which consensus 
was reached when applying the 8 grade WHO system, consensus was only 
defined for the three and two grade systems. 
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Table	1.	2005	WHO	classification	system,	definition	of	a	two-	and	three-grade	system	and	overview	
of	the	original	histopathological	diagnosis	(n=110).
WHO
normal (incl. hyperkeratosis)
n = 3
inflammation
n = 6
Hyperplasia
n = 17
Mild dysplasia
n = 23
Moderate dysplasia
n = 32
severe dysplasia
n = 16
carcinoma in situ
n = 13
squamous cell carcinoma
n = 0
Two-grade	system:	1)	light	grey	2)	white	+	dark	grey
Three-grade	system:	1)	light	grey	2)	white	3)	dark	grey
statIstICs
Kappa statistics with 95% confidence intervals were calculated to study the 
level of concordance between different (glass slide and WSI) readings. When 
appropriate, linearly weighted kappa values were also calculated, taking into 
account the extend of disagreement. Kappa statistics were calculated for 
comparison of individual observers as well as overall, applying the multiple 
kappa procedure where appropriate. If the multiple kappa statistic could not be 
calculated (e.g. for weighted kappa), an average kappa value over all individual 
kappa values was used as a surrogate. 
To study a possible bias in diagnoses (i.e. structural over- or underdiagnosing), 
the non-parametric Signs-tests was used (applying Sidak correction for multiple 
comparisons). Accuracy of WSI diagnoses was studied by calculating the pro-
portions of agreement with the consensus diagnosis. Fisher’s exact test was 
used to study differences between WSI and glass slides diagnoses compared 
to the consensus. 
resuLts
Of 110 available cases, four cases were excluded prior to pathologist’s assess-
ment due to insufficient quality or insufficient laryngeal tissue. Observer 1 and 
3 classified an additional 5 cases as inadequate, because of insufficient amount 
of material (both observers twice, of which one case corresponding), insufficient 
specimen quality (three cases for observer 1 of which one was also rejected 
by observer 3) and insufficient WSI image quality (two cases by observer 3).
gLass sLIde observer agreement
Interobserver results for glass slide diagnoses were reproduced from Fleskens 
et al (top part of Table 2)11. Allowing the full WHO classification system, a 
discouragingly low overall unweighted kappa value of 0.21 was found. The 
weighted kappa, which puts more penalty on larger disagreements, was on 
average 0.49, indicating that disagreements are generally small (1 or 2 grades 
difference). Focusing closer on clinically relevant information, the two grade 
(unweighted) and three grade (weighted) kappa values ranged from 0.40 
to 0.53 (average 0.44 and 0.50, respectively). To estimate the intraobserver 
variability for glass slide diagnoses of laryngeal premalignancies, one observer 
reassessed the glass slides (Table 2 bottom row). Kappa values slightly exceeded 
those for the interobserver agreement, however this increase never reached 
statistical significance.
Comparing individual pathologist’s assessments with the (two and three 
grade) consensus diagnoses, concordances up to 92% were found. However, 
one pathologist only agreed with the consensus diagnosis in 73% of cases 
when applying the three grade system.
wsI assessment
In general WSI assessment of laryngeal premalignancies showed interobserv-
er agreement comparable to glass slides diagnoses (Table 2). The kappa val-
ue for the two-grade system showed the largest difference between the two 
modalities (0.44 versus 0.38). Concordance for different pathologists with the 
consensus diagnoses was in general somewhat lower for WSI compared to 
glass slide diagnoses (Table 3). These differences where most markedly when 
applying the three grade system, exceeding 10% for all three pathologists. 
None of these differences reached statistical significance (Fisher’s exact test). 
The intraobserver glass slide versus WSI agreement was in general somewhat 
better than the interobserver agreements for WSI and glass slide diagnoses 
(Table 2). Averaged over the three pathologists, the intraobserver agreement 
coincided remarkably well with the glass slide intraobserver agreement. 
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For each pathologist, the full WHO grading was compared between WSI and 
glass slides to detect possible over- or underdiagnosing. No systematic biases 
could be shown from data in the present study (applying the Signs test). 
Table	2.	Overview	of	the	unweighted	and	weighted	К-values	with	95%	confidence	intervals.
all options all options Two-grade Three-grade Three-grade
Obs. Unweighted Weighted Unweighted Unweighted Weighted
glass slide  
inter-observer	
(a)
1 vs 2 0.25 
(0.14-0.36) 
0.50 
(0.39-0.60)
0.47 
(0.29-0.64)
0.37 
(0.22-0.51) 
0.50 
(0.37-0.62)
1 vs 3 0.20 
(0.10-0.30) 
0.49 
(0.39-0.59)
0.40 
(0.23-0.58)
0.38 
(0.23-0.52) 
0.47 
(0.33-0.60)
2 vs 3 0.21 
(0.11-0.31) 
0.48 
(0.37-0.58)
0.45 
(0.28-0.63)
0.42 
(0.28-0.57) 
0.53 
(0.40-0.66)
Overall 0.21 
(0.17-0.26)
0.49 (b) 0.44 
(0.33-0.55)
0.39 
(0.31-0.47)
0.50 (b)
virtual slide  
inter-observer
1 vs 2 0.24 
(0.13-0.35) 
0.45 
(0.34-0.56)
0.35 
(0.15-0.54)
0.34 
(0.19-0.48) 
0.43 
(0.29-0.57)
1 vs 3 0.38 
(0.26-0.49) 
0.54 
(0.42-0.66)
0.36 
(0.17-0.54)
0.39 
(0.24-0.54) 
0.51 
(0.37-0.64)
2 vs 3 0.33 
(0.21-0.44) 
0.48 
(0.37-0.60)
0.43 
(0.25-0.60)
0.39 
(0.25-0.53) 
0.47 
(0.34-0.61)
Overall 0.25 
(0.20-0.30)
0.49 (b) 0.38 
(0.31-0.45)
0.38 
(0.30-0.46)
0.47 (b)
Glass	versus	
virtual	slide
1 0.26 
(0.15-0.37)
0.53 
(0.43-0.62)
0.53 
(0.36-0.71)
0.48 
(0.34-0.63)
0.57 
(0.45-0.70)
2 0.30 
(0.19-0.41)
0.54 
(0.44-0.65)
0.49 
(0.32-0.66)
0.41 
(0.27-0.55)
0.52 
(0.40-0.64)
3 0.37 
(0.26-0.48)
0.57 
(0.46-0.67)
0.56 
(0.39-0.72)
0.45 
(0.31-0.59)
0.57 
(0.44-0.69)
Average 0.31 0.55 0.53 0.45 0.55
glass slide  
intra-observer
2 0.29 
(0.17-0.40)
0.55 
(0.45-0.65)
0.52 
(0.35-0.69)
0.41 
(0.27-0.55)
0.53 
(0.41-0.65)
(a) Taken from Fleskens et al. (b)	Average Kappa calculated because Overall Kappa could not be used.
Table	3.	Concordance	of	individual	pathologist	diagnosis	with	consensus	diagnosis.
Pathologist	1 Pathologist	2 Pathologist	3
Concordance	three	grade	system
glass slides 70 / 83 (84%) 61 / 83 (73%) 67 / 83 (81%)
virtual slides 56 / 78 (72%) 52 / 83 (63%) 53 / 78 (68%)
Concordance	two	grade	system	(severe	dysplasia	and	worse	versus	others)
glass slides 76 / 83 (92%) 73 / 83 (88%) 73 / 83 (88%)
virtual slides 66 / 78 (85%) 67 / 83 (81%) 67 / 78 (86%)
Included in this analysis are cases for which initial glass slide diagnosis (two/three grade system) was concordant 
between three pathologists and cases for which consensus was reached in an independent consensus session.
None of the pathologists scored significantly different between glass and virtual slides (Fisher’s exact test p>.05)
dIsCussIon
The present study aimed to assess validity of using WSI for larynx biopsy 
diagnosis, which we consider exemplary for demanding diagnostic applications 
requiring study of very fine detail. Cases were taken from a previously published 
study on observer variability of traditional glass slide diagnoses11. It was found 
that the intraobserver agreement (comparing WSI and glass slide diagnoses 
for individual pathologists) exceeded the interobserver agreement for WSI 
and glass slide diagnoses. Thus it may be concluded that the effect of using 
WSI remains within the variability inherent to the diagnostic process. 
In our previous study, it was concluded that grading of laryngeal premalig-
nancies is intrinsically difficult, which is reflected in the relatively low kappa 
values for glass slide diagnoses11. Roughly, a kappa value ranging from 0.2 – 0.4 
represents fair agreement, ranging from 0.4 – 0.6 indicating moderate agree-
ment13. The use of the Kappa statistic and its interpretation are not undisputed14. 
Note that the value of kappa depends, among other factors, on the number of 
distinguished classes, making comparison of kappa-values sometimes difficult. 
In the present study the intra observer (glass slide) kappa values only slightly 
exceeded the previously found interobserver kappa values, showing that the 
limited reproducibility is not caused by differences in interpretation of diagnostic 
criteria by different pathologists. Similar results were found for grading dysplasia 
in ulcerative colitis, with overall (unweighted) interobserver kappa values not 
exceeding 0.3515. Also, intraobserver kappa values were smaller than 0.6 for 
5 of 7 participating pathologists15. In cervix premalignant lesions overall kappa 
interobserver values ranged from 0.30 – 0.33 (unweighted) and 0.36 – 0.42 
(weighted) using a three grade system16. Intraobserver overall kappa values 
were 0.47 (unweighted) and 0.51 (weighted). Apparently, observer variability 
is not caused by the imaging modality, but rather by the lack of objective and 
reproducible criteria presently in use for grading laryngeal dysplasia15. In the 
present study, grading into three clinically relevant classes was discordant 
with the consensus diagnosis in 16 to 27% of cases for different pathologists. 
In other words, approximately 1 in 5 patients gets a histopathological grade 
different from the consensus (gold) standard. It was concluded previously that 
this problem may be alleviated by having multiple pathologists assess difficult 
slides11,15. However, feasibility of such consultation will be hampered by the 
unavailability of specialized pathologists. Results of the present study show 
that alternative WSI based assessment of laryngeal premalignancies will not 
compromise diagnostic accuracy. Consulting colleagues may accordingly be 
performed using WSI, without being impeded by geographical limits. 
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The precision of WSI and glass slide diagnoses (expressed in the kappa value) 
were comparable in this study. In contrast, the accuracy (comparing with the 
consensus diagnoses) appeared to be higher using glass slides. Assessment 
of accuracy requires the availability of an accepted gold standard. In most 
published studies a consensus diagnosis based on glass slides is used for this 
purpose, assuming that traditional microscopy is at least as accurate as using 
WSI. Nielsen et al stated that the ‘validity of the criterion standard is considered 
of great importance and the criterion standard should have been verified, for 
example, using conference microscopy’17. However, it is conceivable that for 
certain applications the use of WSI exceeds glass slides in diagnostic accuracy. 
In a study on dermatopathology cases, pathologists rated WSI image quality 
superior to light microscopy18. Next to the fact that generally WSI are produced 
under optimal microscope settings, additional software features (e.g. easy 
switching between magnifications, availability of an overview of the specimen at 
all times) may increase accuracy. Also, it should be noted that using a consensus 
diagnosis based on glass slides yields a considerable bias in favor of glass 
slide diagnoses.
The equipment used in the present study was selected to render an optimal 
digital image, to rule out discrepancies caused by factors other than the mere 
use of WSI. Images were produced by an Olympus dotSlide system using 40x 
optical objective, which was described to produce superior image quality19. 
Images were assessed by the pathologists using a high quality, calibrated display 
as advised in a review by Pantanowitz20. All pathologists in the present study 
used exactly the same computer and display, which were calibrated before 
use. The importance of this was illustrated by Ho, describing an adenocarcino-
ma which was missed due to a color fidelity issue in a pilot validation study8. 
Better color fidelity probably could have been achieved by using the method 
proposed by Yagi21. Because the color displayed can be affected by variation 
in capture parameters (for example, illumination and filters), image processing 
and display factors in the digital systems themselves, Yagi developed two cali-
bration (glass) slides. One is a color chart slide, the other an H&E stained slide 
of a mouse embryo. By means of these slides and a calibration website color 
fidelity can be monitored in an effective but low cost manner. 
In conclusion, data of the present study show that WSI is a valid alternative to 
glass slide assessment of diagnostically challenging tissue sections. Using 
laryngeal premalignancies, it was shown that in general observer variability 
was comparable for the two modalities. These results indicate that WSI may 
facilitate consultation of specialized pathologists for difficult cases.
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In Chapter 2 we have demonstrated that there is no consensus regarding the 
management of laryngeal mucosal premalignant lesions (LMPLs), and in Chapter 
3 the limitations of the histopathological evaluation have been discussed as 
one of the stumbleblocks in harmonizing diagnostic and therapeutic approach. 
Moreover, the value of histological diagnosis in terms of prediction of malig-
nant progression is far from adequate. To obtain additional tools in order to 
improve prediction of malignant progression, the value of molecular markers 
in LMPLs has been the subject of extensive investigations. Nankivell et al. and 
Rodrigo et al. recently published reviews concerning biomarkers in laryngeal 
dysplasia and laryngeal epithelial precursor lesions respectively.1,2 They 
concluded that the quality of reporting of the studies was very variable. As 
there are no universally accepted scoring systems, most immunohistochemical 
studies differ in the methods that were used to quantify biomarker staining 
which precludes a pooling of the results published for each biomarker. In this 
intermezzo we will discuss the current status of some biomarkers in the diagnosis 
and management of LMPLs as obtained until now.
bIomarkers In LmpLs
DNA content. As malignancy usually implies abnormal DNA content, analysis 
of this feature has been supposed to be of value in predicting malignant 
progression. Munck-Wikland et al. investigated carcinoma in situ (CIS) lesions 
and concluded that the lesions which progressed to invasive cancer showed 
a clear tendency towards more pronounced DNA aberration.3 Bergshoeff et 
al. found that chromosome instability (CI) is a reliable marker for malignant 
progression. CI was indicated by the presence of imbalances and/or poly-
ploidization for chromosomes 1 and 7 by fluorescence in situ hybridization 
(FISH) (unpublished data). 
Overall, very limited data are available about DNA content in LMPLs. Although 
there are some indications for a predictive value in case of CIS, the evidence 
is too meagre for application in the diagnostic management of LMPLs. 
Proliferation markers. As progression to malignancy implies disturbed prolif-
eration, Ki67 (a cell cycle-associated protein and a marker of cell proliferation)4 
and proliferating cell nuclear antigen (PCNA: a nuclear protein whose expression 
is associated with the late G1 and S phases of the cell cycle)3 are intensively 
investigated markers within the context of malignant progression.1,2 Three stud-
ies reported on Ki67, however with contradictory results.5-7 One retrospective 
study reported a higher rate of malignant progression in cases with elevated 
Ki67 expression2,6, whereas another reported no prognostic significance for this 
marker.2,5 Furthermore, a case-control study showed a higher Ki67 expression 
in non-progressing controls.2,7 These contradictory outcomes prevent the 
application of Ki-67 expression in diagnostic practice.
The studies that analyzed the prognostic significance of PCNA expression 
showed consistently higher levels PCNA positivity in the lesions that progressed 
to invasive cancer.2,3,8,9 In one study this did not reach statistical significance.9 
So, as a single marker PCNA positivity showed consistent findings in literature, 
in contrast to Ki67, and is therefore the most promising proliferation marker. 
However, the publications on PCNA originate from the 1990’s and there have 
not been any additional studies that demonstrated sufficient sensitivity and 
specificity for this marker to be employed in clinical practice.     
Cell cycle regulators. Abnormal proliferation implies abnormal regulation of 
proliferation. Hence, the proteins that control the cell cycle have been inves-
tigated as markers of malignant progression in several studies.2 P53 is the 
most frequently studied cell cycle-related protein. When functioning properly, 
p53 is activated by hypoxia or DNA damage, leading to cell-cycle arrest, 
attempted DNA repair, and, if DNA repair is ineffective, to apoptosis.2,10 Of 
the seven studies concerning p53 (a well-established tumor suppressor gene) 
analyzed by Rodrigo et al.2,3,6,7,9,11-14, two demonstrated an association of p53 
expression with progression to malignancy.3,12 Nankivell et al. reported that 
p53 was the only biomarker with sufficient data to attempt a meta-analysis. 
The overall pooled relative risk (RR) was 1.42 (95% Confidence Interval (ConfInt) 
0.20-10.12).1 Pignatoro et al. also assessed the expression of MDM-2 (a protein 
which	 is	 capable	 of	 binding	 and	 inactivating	 p53);	 the	 expression	was	 not	 
associated with progression to malignancy. On the other hand, cases with 
negative MDM-2 expression exhibited a higher progression rate.2,6 
Cyclin D1 is the second most frequently studied cell cycle-related protein.2 
Its function is to inactivate Rb binding capacity for E2F via phosphorylation, 
together with cyclin-dependent kinase 4 and 6 and facilitating progression 
from the G1 phase to the S phase.2,15 Elevated expression has been associated 
with malignant progression in two studies.12,16 However, other studies failed 
to show this association or overexpression was not found at all.6,17 So, data 
concerning cyclin D1 are contradictory.
The CCND1 gene amplification was also evaluated in one study, and was 
significantly associated with malignant progression. In this study, all cases 
with	CCND1	amplification	showed	cyclin	D1	overexpression;	however,	only	
CCND1 gene amplification and not protein overexpression was significantly 
correlated with progression to malignancy.2,17 
Of the cyclin-dependent kinase inhibitors (CDKI), p16, p21 and p27 are impor-
tant in mediating the stepwise progression from the resting G0 phase into G1 
and they have been analyzed as well.1,2,11,13,15 The comparative analysis of p16 
expression in biopsy samples from patients with premalignant lesions whose 
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disease did and did not progress to cancer did not show any significant 
statistical difference.13 p21 and p27 expression showed no association with 
malignant progression.11 
So, in conclusion, p53 is the most frequently studied cell-cycle related bio-
marker as a single marker. In most studies however, this biomarker did not 
show a predictive significance in LMPLs. Therefore p53 currently is not useful 
as a single predictive marker in daily practice. The same is the case for cyclin 
D1 (contradictory data) and CDKIs (no association with malignant progression). 
Transmembrane receptors. The epidermal growth factor receptor (EGFR) is a 
transmembrane receptor tyrosine-kinase, which influences cell division, migra-
tion, adhesion, differentiation and apoptosis. EGFR is overexpressed in many 
cases of head and neck squamous cell carcinoma (HNSCC).2,14 The expression 
of the EGFR has been reported to be significantly higher in cases that 
progressed to malignancy. Although it is clearly associated with malignant 
progression, its specificity is low, and it probably adds little clinical predictive 
value over routine histology.12 
Another important, but inhibitory, growth factor pathway associated with 
head and neck squamous cell carcinoma (HNSCC) is the transforming growth 
factor-β (TGF-β) pathway.2,14 Franchi et al. reported that the loss of TGF-β type 
II receptor expression was significantly more frequent in cases that progressed 
to cancer,18 suggesting that the loss of TGF-β mediated growth inhibition 
could facilitate the progression of laryngeal precancerous lesions to invasive 
carcinoma.2 So, this study concerning TGF-β in LMPLs suggest a potential 
role of TGF-β immunostaining in the assessment of the risk for evolution of 
LMPLs. Franchi et al. concluded that this has to be confirmed in prospective 
studies.18  
Cell adhesion molecules. Both cell-cell interactions and cell-stroma interactions 
play an important role during carcinogenesis. Alterations in proteins implicated 
in the regulation of these interactions are frequent in HNSCC and have also been 
explored as markers of cancer risk in LMPLs.2 Osteopontin (OPN) can function 
both as a cell adhesion molecule and as a cytokine. It binds to the integrin cell 
surface receptors αv or β1-containing integrins as well as exon v6-containing 
CD44 isoforms (CD44v6), thereby supporting proliferation, chemotaxis, attach-
ment, and migration of many cell types.2,19 CD44 is a cell surface glycoprotein 
that is involved in regulating cell-cell and cell-matrix interactions, migration, 
and tumor growth and progression. It is considered a marker of stemness.2,20 
the OPN/CD44v6 axis has been assessed by Staibano et al.. This study showed 
that the disease-free survival rate in patients affected by laryngeal dysplasia 
negatively correlated with intense OPN staining and full-thickness CD44v6 
positivity.2,21 These results suggest that the up-regulation of the OPN/CD44v6 
axis is an early event during the progression of laryngeal dysplasia.2   
Overexpression of focal adhesion kinase (FAK) has been observed in both 
HNSCC and laryngeal dysplasias.2,22 FAK overexpression correlated significantly 
with increased cancer risk and was an independent predictor of laryngeal 
cancer development in multivariate analysis. FAK gene amplification, however, 
did not exhibit any prognostic significance. Furthermore, it was also shown 
that both CTTN gene amplification (cortactin is encoded by the CTTN gene) 
and protein expression correlated significantly with progression to malignancy. 
The combination of cortactin and FAK evaluation was statistically significantly 
superior in terms of prognostic value and also sensitivity, therefore their use 
as complementary markers was recommended.2,17 Sugár et al. reported that 
all 51 cases that stained positive for cortactin progressed to cancer, whereas 
the 46 that showed no staining did not progress.1,23 
So, limited studies suggest that OPN/CD44v6, FAK, and cortactin are potentially 
reliable predictors of malignant progression. The predictive value, however, 
has yet to be confirmed in large-scale prospective studies.2
Other biomarkers. Podoplanin is a mucin-type transmembrane glycoprotein 
whose physiological function is still unknown. Despite this, podoplanin ex-
pression has been widely used as marker of lymphatic endothelial cells and 
lymphangiogenesis due to its specific expression by lymphatic but not by 
blood vessel endothelium.2,24 In addition, podoplanin expression has been 
found to be upregulated in a number of human cancers, including HNSCC.2,25,26 
And it has also been described as a marker of malignant progression and 
poor prognosis in oral cancer.2,26,27 Elevated podoplanin expression showed a 
higher risk of malignant progression in laryngeal dysplasias according to data 
published by Rodrigo et al., although the differences did not reach statistical 
significance.2,25 The expression of a Kv3.4 (an A-typ potassium (K+)) channel 
subunit was determined in a set of 67 laryngeal dysplasias. In this retrospective 
study by Menéndez et al. patients with Kv3.4-positive lesions had a significantly 
higher laryngeal cancer incidence than those with negative lesions.2,28 Menéndez 
et al. also reported recently that the human ether à-go-go-related gene 1 
(HERG1) potassium channel expression is a biologically and clinically relevant 
feature in HNSCC progression and also during malignant transformation.29  
So, a few recently published studies suggest that podoplanin, Kv3.4, and HERG1 
are potentially reliable predictors of malignant progression. Their predictive 
value, however, has yet to be confirmed in large-scale prospective studies.2
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ConCLusIon
Despite many efforts, the molecular events that are associated with the devel-
opment of premalignancies to carcinoma are still not completely elucidated 
and we have to conclude that the analysis of over (or under)-expression of single 
biomarkers currently adds little predictive value to standard histology. There-
fore, until now they  have not been applied in clinical practice.1,2,21,30 Whether 
the value of biomarkers may be improved if some of them are combined has not 
yet been studied as no studies which have analyzed different biomarkers 
simultaneously at the single-cell level in LMPLs were published so far. To 
determine the value of this approach for a better prediction of malignant 
progression we developed a method to simultaneously assess the DNA ploidy 
status and presence of other biomarkers in paraffin-embedded tissue 
sections at the level of the individual cell which is described in Chapter 4. 
Thereafter, we applied this method on LMPLs retrospectively to evaluate the 
predictive value of multiple biomarkers simultaneously (Chapter 5).
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abstraCt
aIms: Aneuploidy is a potential biomarker for predicting progression of 
premalignancies. Ploidy assessment is mostly performed on nuclei isolated 
from tissue sections. Ploidy assessment in situ in tissue sections may be a 
large improvement, enabling selective sampling of nuclei, thus allowing the 
correlation between ploidy and histology. Existing ploidy analysis methods in 
sections suffer from limited sensitivity. The aim was to reliably assess ploidy in 
sections, combined with simultaneous assessment of other markers at the 
individual cell level. 
methods and resuLts: Ploidy was measured in 22 paraffin-embedded oral 
premalignancies. The DNA stoichiometric Feulgen procedure was used on 
isolated nuclei, as well as fluoresence in situ hybridization analysis. In tissue 
sections, Feulgen was combined with immunohistochemistry for Ki67 prolifer-
ation marker, enabling distinction between cycling euploid and aneuploid cells. 
Aneuploidy was reliably detected in tissue sections (sensitivity 100%, specificity 
92%). One section in which aneuploidy was detected was misclassified in 
isolated nuclei analysis. Sections were also successfully analysed using our 
model combined with DNA double strand break marker γ-H2AX in fluorescence 
microscopy, underlining the power of biomarker evaluation on single cells in 
tissue sections.
ConCLusIons: The analysis model proposed in this study enables the 
combined analysis of histology, genotypic and phenotypic information.
IntroduCtIon
Chromosomal instability or microsatellite instability may be important causes 
of genomic alterations leading to carcinoma. DNA aneuploidy, an aberrant 
chromosome number, has been suggested as a useful marker for neoplastic 
progression of premalignant lesions at different localizations, including oesopha-
gus, skin, head and neck, and colon.1–9 DNA ploidy status may prove especially 
informative when combined with phenotypic information describing expression 
levels of proteins related to, for example, cell cycle progression or DNA damage 
response. For instance, the combined analysis of DNA ploidy and expression 
of different biomarkers is capable of estimating the malignant potential of 
Barrett’s oesophagus10 and colonic cancer.11 
Ploidy and protein expression may be assessed simultaneously at the individual 
cell level using flow cytometry. Alternatively, image cytometry enables DNA 
ploidy assessment by microscopy, allowing for subsequent visual inspection 
of nuclei of interest.12 Cytometric ploidy analysis of (pre)malignancies is mostly 
performed on intact nuclei, extracted from thick (50 μm) tissue sections (Hedley 
procedure13). Both techniques mentioned above suffer from the fact that 
the original tissue context is lost, rendering correlation with histopathology 
impossible.14 This may, for example, result in overlooking small aneuploid cell 
populations, because of dilution of the data by the abundant presence of 
normal euploid cells.15 Also, when dealing with small tissue fragments from 
biopsy specimens, insufficient material may be available for isolation of nuclei.16 
In contrast, image cytometric measurement enables analysis of protein expres-
sion in situ in immunohistochemically stained tissue sections. Although possible, 
ploidy analysis in such relatively thin sections is cumbersome. On one hand, 
measurement in thin tissue sections (i.e. 2–5 μm) is hampered by reduced 
precision because of truncation of nuclei (Figure 1).17 As a result, sensitivity 
for detecting aneuploid cells is compromised.18,19 On the other hand, use of 
thick sections (i.e. >10 μm) may lead to biased sampling with preference for 
smaller nuclei and nuclei in less densely populated areas of the tissue because 
of nuclear overlap.20,21 Mathematical correction models, described to overcome 
the effect of nuclear truncation,18,20 have only limited applicability in practical 
situations.22 It has been shown that ploidy analysis of 7-μm sections without 
integrated optical density (IOD) correction is more sensitive in detecting 
aneuploid subpopulations compared with analysis of 5-μm sections with IOD 
correction.23 Other studies have shown that IOD correction may even be 
harmful to the data.22,24 Sections of thickness ≥7 μm do not require IOD 
correction.18,20 
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The present paper aims to describe an analysis model that offers improved 
sensitivity for detecting aneuploid cells in tissue sections, based on image 
cytometric DNA ploidy measurement. This improvement is realized by com-
bining a stoichiometric DNA dye with MIB-1 (a monoclonal antibody directed 
against the nuclear Ki67 antigen) proliferation marker,25 making the distinction 
possible between euploid cells that have entered the cell cycle (i.e. MIB-1+) and 
resting (G0) aneuploid cells (i.e. MIB-1)). This analysis may be combined with 
other relevant markers at the individual cell level. Because of such multiplexing, 
highly specific prognostic information can be derived from selectively sampled 
parts of a (pre)malignancy, probably facilitating tailored treatment in the near 
future. Also, the study of basic development and progression of malignancies 
is facilitated using this new approach. The method also allows assessment of 
the spatial distribution of aneuploid cells.
Figure 1. schematic representation of the effect of nuclear truncation caused by sectioning. shown is an example 
nucleus (height in the section 7 μm) at three different section thicknesses (2, 7 and 12 μm). the top of the figure 
gives an impression of the amount of nuclear overlap. the effect of truncation increases with decreasing section 
thickness, whereas the amount of nuclear overlap decreases with decreasing section thickness. sections below 
approximately 7 μm require correction of the measured integrated optical density values. Biased sampling 
because of larger amounts of nuclear overlap will occur when section thickness exceeds a certain value.
materIaLs and methods
patIent seLeCtIon
Twenty-two specimens from oral biopsies were retrospectively obtained from the 
archives of the Department of Pathology at the Radboud University Nijmegen 
Medical Centre (Nijmegen, the Netherlands). All specimens were routinely 
fixed in 4% buffered formalin and paraffin embedded. Standard 4 μm-thick 
haematoxylin and eosin-stained sections were used for classification of the 
lesions.
The 22 tissue specimens in this study consisted of one specimen without 
abnormalities, five specimens showing hyperkeratosis, one mild dysplasia, six 
moderate dysplasias, six severe dysplasias, one carcinoma in situ (CIS) and 
two squamous cell carcinomas, according to World Health Organization 
criteria.26 From each tissue block, one 50-μm section was cut for isolation 
of nuclei and subsequent cytospin preparation. Additionally, sections were 
cut for DNA ploidy assessment (thickness 6–7 μm) and fluorescence in situ 
hybridization (FISH) analysis (4 μm), as described below.
experImentaL set-up
To compare results of DNA ploidy analysis in tissue sections with accepted 
standards, material from the same patients was analysed using DNA ploidy 
measurement of isolated nuclei as well as using double target FISH on tissue 
sections. Because of its in situ multiplexing potential, fluorescence microscopy 
will eventually be the measurement modality of choice. As a ‘proof of principle’, 
immunofluorescence staining of double strand break (DSB) marker γ-H2AX was 
combined with simultaneous DNA ploidy assessment. DNA ploidy assessment 
using stoichiometric dyes is not straightforward in fluorescence microscopy, 
mainly because of fading of fluorochromes. Therefore, experiments in tissue 
sections using the commonly used Feulgen staining were also performed.
dna pLoIdy measurement oF IsoLated nuCLeI From
thICk seCtIons
Feulgen–Schiff-stained cytospins containing nuclei isolated from 50 μm thick 
sections were prepared essentially as described in the consensus criteria of the 
European Society for Analytical Cellular Pathology (ESACP12). Briefly, nuclei were 
isolated using digestion with 2 ml 0.5% (w ⁄ v), pH 1.5 pepsin (Sigma Aldrich, 
St Louis, MO, USA) for 60 min at 37°C. Hydrolysis was performed using 5 N 
HCl at 25°C for 60 min. Next, specimens were stained with Schiff’s reagent 
(Merck, Darmstadt, Germany) at room temperature for 60 min.
DNA ploidy status was assessed according to the ESACP criteria,12 using a 
QPath image cytometry station (Leica Microsystems GmbH, Wetzlar, Germany). 
The system acquires digital images using a monochromatic charge-coupled 
device (CCD) camera attached to a Leica DM LB2 microscope using a 40x 
objective	 [Leica	HCX	 PL	 Fluotar,	 numerical	 aperture	 (NA)	 =	 0.75;	 resulting	
specimen level pixel size 0.326 x 0.326 μm2]. Cytospins were measured fully 
automatically. The system allows definition of criteria that objects have to 
meet before being included in the final dataset. Criteria applied in this study 
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were: area between 50 and 850 pixels and roundness [defined as perimeter2 ⁄ 
(13.3 x area)] <1.25. Based on previous experience, these criteria minimize the 
amount of debris entering the analysis without rejecting true nuclear objects. 
Ploidy index (DI) histograms were manually classified by two independent 
observers (J.v.d.L., I.O-H.). Histograms were classified as tetraploid histogram: 
>10% of cells in the tetraploid region, or >5% and <10% of cells in the tetraploid 
region	and	presence	of	cells	 in	 the	octaploid	region;	aneuploid	histogram:	
presence of a peak outside the diploid and tetraploid regions, or >1% of cells 
with	DNA	index	exceeding	5c;	diploid	histogram:	all	others.	
doubLe-target FLuoresCenCe In sItu hybrIdIzatIon on
tIssue seCtIons
FISH was performed on 4 lm thick tissue sections as described previously.27,28 
Briefly, sections were deparaffinized, pretreated with 85% formic acid ⁄ 0.3% 
H2O2, 1 m NaSCN and 4 mg ⁄ ml pepsin, post-fixed in 1% formaldehyde in 
phosphate-buffered saline (PBS), dehydrated in an ethanol series and hybrid-
ized with a mixture of digoxigenin-labelled human centromere 1-specific and 
biotin-labelled centromere 7-specific DNA probes [1 ng ⁄ μl 60% formamide, 
2x sodium-saline citrate (SSC), 10% dextran sulphate and 50x excess salmon 
sperm carrier DNA]. After hybridization the preparations were washed strin-
gently in 2 x SSC at 42°C (two times for 5 min) and 0.1x SSC at 60°C (two times 
for 5 min). The probes were detected by application of (i) mouse anti-digoxin 
(Sigma) ⁄ avidin fluorescein (Vector Laboratories, Burlingame, CA, USA), (ii) 
rabbit antimouse rhodamin (Dako, Glostrup, Denmark) ⁄ biotinylated goat anti-
avidin (Vector), and (iii) swine antirabbit rhodamin (Dako) ⁄ avidin fluorescein. 
Preparations were mounted in Vectashield (Vector Laboratories) containing 
4,6-diamidino-2-phenyl	indole	(Sigma;	0.2	g	⁄	ml).
Evaluation of the FISH results was carried out according to the criteria previously 
described.9,27 FISH signals were scored per colour and nucleus for the presence 
of aberrant copy numbers. The highest copy number per nucleus was deter-
mined and set if ≥20% of the nuclei (50–200 nuclei were counted, depending 
on the size of the lesion) showed this number of FISH signals. Based on this 
evaluation, areas were categorized as either monosomic, disomic, trisomic, 
tetrasomic or polysomic (more than four signals per nucleus) for the respective 
probe targets. Next, the lesions were divided into a group of lesions without 
evidence of chromosomal alterations (diploid), showing altered but balanced 
chromosome copy numbers (trisomy or tetrasomy, possibly indicating tri- or 
tetraploidization), and a group of lesions showing characteristics of chromosome 
instability, i.e. containing chromosome copy number imbalances and ⁄ or 
chromosome polysomy (indicative for aneuploidy).
seQuentIaL assessment oF kI67 expressIon and dna 
pLoIdy In tIssue seCtIons
MIB-1 immunostaining of Ki67
Paraffin-embedded tissue sections (7 μm thick) were deparaffinized and pre-
treated by 0.01 M citrate buffer (pH 6.0) and heated in a microwave oven for 
3 min at 850 W until boiling, followed by 10 min at 180 W. For immunohistochem-
ical analysis in transmitted light microscopy, the slides were preincubated 
with 20% normal horse serum for 30 min and incubated overnight at 4°C with 
the	primary	 antibody	directed	 against	 Ki67	 (clone	MIB-1;	Dakocytomation,	
Glostrup, Denmark) diluted 1:100 in PBS with 1% bovine serum albumin (BSA). 
Biotin-labelled horse antimouse (Vector Laboratories) was used as secondary 
antibody followed by incubation with avidinbiotinylated peroxidase complex 
(Vectastain	 ABC	 Kit;	 Vector)	 according	 to	 the	manufacturer’s	 description.	 
Subsequently, visualization was done using 3-amino-9-ethylcarbazole (AEC 
1:50;	ScyTek	Laboratories,	Logan,	UT,	USA).
For immunofluorescence analysis, after microwave antigen retrieval treatment 
similar to that described above, the slides were preincubated with 20% normal 
goat serum for 30 min and incubated overnight at 4°C with the primary antibody 
as described above. Next, incubation with the secondary antibody goat anti-
mouse IgG (H+L) Dylight 488 conjugated (Pierce, Thermo Fisher Scientific Inc., 
Rockford, IL, USA) diluted 1:200 in PBS with 1% BSA was performed. Nuclear 
DNA was stoichiometrically stained with DRAQ5 1:200 in PBS (Biostatus Ltd, 
Shepshed, UK).
Digital image acquisition
Representative areas were selected in each specimen by an experienced head 
and neck pathologist (P.J.S.) and consisted of: (i) areas classified histopatho-
logically as within normal limits and (ii) areas containing the most severe lesion. 
Images taken from the basal as well as from more superficial epithelial layers 
of these areas in MIB-1-stained sections were digitized and stored. Images of 
MIB-1-stained sections were stored in 24-bit RGB using a 3CCD camera (Sony 
950P;	 Sony,	 Tokyo,	 Japan)	 attached	 to	 a	 Zeiss	 AxioPhot	 microscope	 (Carl	
Zeiss,	Oberkochen,	Germany)	with	40x	objective	(Plan	Neofluar,	NA	=	0.75;	
specimen level pixel size 0.32 x 0.32 μm2). Images were corrected for unequal 
illumination using a stored image of an empty microscope field. Similar images 
were acquired from specimens stained with fluorescent dyes, using a CoolSNAP 
HQ high-resolution cooled CCD camera (Photometrics, Tucson, AZ, USA) 
connected to an AxioSkop 2plus (Carl Zeiss), equipped with appropriate 
bandpass filters.
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DNA ploidy assessment in tissue sections
After the acquisition of the MIB-1 images in transmitted light microscopy, the 
AEC immunohistochemical staining was removed and slides were restained 
for DNA. For this purpose, slides were placed in demineralized water at 37°C 
for 4 h, and were placed overnight
in demineralized water to remove the Imsol. Thereafter, the AEC precipitation 
product was removed by washing twice in alcohol 100% for 5 min and for 5 min 
in methanol. Post-fixation of the slides was done in Böhm at room temperature 
for 60 min. Subsequently, the slides were stained with Feulgen as described 
above (section ‘DNA ploidy measurement of isolated nuclei’). Contours of 
nuclei in stored images of MIB-1-stained slides were extracted and shown as 
an overlay in the live camera image, to facilitate acquisition of exactly the same 
locations in the Feulgen-stained sections. Images of the Feulgen-stained 
sections were acquired using the same camera and microscope set-up as 
described above, using a bandpass filter (565.5 ± 20 nm).
In fluorescence microscopy, nuclear DNA was stoichiometrically stained with 
DRAQ5 1:200 in PBS (Biostatus Ltd, Shepshed, UK). Images of DRAQ-5 were 
acquired simultaneously with acquisition of the MIB-1 fluorescence signal. 
Therefore, no restaining was required, facilitating the accuracy and ease of use 
of this procedure. To evaluate the applicability of multiparameter fluorescence, 
γ-H2AX immunofluorescence signal was acquired simultaneously in the same 
sections (see below).
Application of digital image analysis
For both transmitted light and fluorescence microscopy, automated recogni-
tion of nuclei was performed using Canny29 edge detection combined with 
morphological processing to separate touching nuclei. If required, results of 
automatic segmentation were interactively corrected. To obtain an internal 
reference for diploid Feulgen IOD, in each specimen a number of nuclei in 
the non-epithelial stroma were measured. IOD of both Feulgen and MIB-1 
staining were calculated. Feulgen IOD was converted to DI using the internal 
diploid reference.
Combined assessment of MIB-1 immunohistochemistry and DNA content in 
individual nuclei within tissue sections allows for multivariate analysis of these 
parameters. Figure 2A shows an example of a scatterplot of DI versus MIB-1 
positivity. In the scatterplot, two important regions may be defined. The blue 
region contains cells which are MIB-1) and possess a DNA content exceeding 
that of diploid cells (DI >1.25). Because in a normal diploid population all 
cells with DI >1.25 are either in the S or G2 phase of the cell cycle, such cells 
are expected to be MIB-1+. Therefore, cells within the blue coloured region 
are suspect for aneuploidy. The second region of importance is coloured red, 
and contains nuclei that are MIB-1+ and show DI values considerably exceeding 
tetraploidy (DI >2.25). Such cells by definition have an abnormal DNA content as 
hypertetraploidy exceeds the DNA content of cells in the G2 phase. Calculation 
of the percentages of cells in the red and blue regions enables a comparison 
with the QPath data from the cytospins (see Results).
Figure 2. Data from a tissue section containing moderate dysplasia. a, scatterplot of Dna ploidy and MiB-1 
expression: dark grey region contains MiB-1- [integrated optical density (ioD)MiB1 ≤1] with Dna content 
exceeding diploid cells [ploidy index (Di) >1.25]; white region contains MiB-1+ cells with Di value exceeding 
those expected in the tetraploid histogram peak (Di >2.25). B, Di histogram of the same specimen, extracted from 
the same data.
γ-h2ax ImmunoFLuoresCenCe staInIng
Paraffin-embedded tissue sections (7 μm thick) were deparaffinized and 
pretreated using 0.01 M citrate buffer (pH 6.0) and heated in a microwave 
oven for 3 min at 850 W until boiling, followed by 10 min at 180 W. Next, slides 
were preincubated with 20% normal goat serum for 30 min and incubated 
overnight at 4°C with the primary antibody γ-H2AX, 1:500 diluted in Tris-buffered 
saline (TBS) with 1% BSA. Incubation with the secondary antibody goat anti-
rabbit IgG (H+L) Dylight 549 conjugated (Pierce, Thermo Fisher Scientific Inc.) 
diluted 1:200 in TBS with 1% BSA was done for 60 min at room temperature.
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statIstICs
All data analysis was performed using SPSS software version 16.0 (SPSS Inc., 
Chicago, IL, USA).
resuLts
dna pLoIdy measurement oF IsoLated nuCLeI 
(QPATH	ANALySIS)
DNA ploidy measurement of cytospins from each of the 22 cases containing 
nuclei isolated from 50-μm sections resulted on average in analysis of 1776 
cells (range 1452–3715). The coefficient of vatiation of the diploid population 
was on average 3.6% (range 2.5–5.2%). Manual classification of histograms by 
two observers independently was concordant for all cases. Thirteen cases were 
classified as diploid, four cases as tetraploid and five as aneuploid. Table 1 
shows the results of ploidy analysis compared with histopathological diagnosis. 
Figure 3A shows an example case containing moderate dysplasia, which 
contained a small aneuploid subpopulation (6.3% of cells, DI of aneuploid 
population is 1.29).
Table	1.	DNA	ploidy	results	on	nuclei	isolated	from	different	histopathologically	classified	oral	lesions	(n=22).
Pathology
DNA	ploidy
diploid tetraploid aneuploid
None 1
Hyperkeratosis 4 1
Mild dysplasia 1
Moderate dysplasia 2 2 2
Severe dysplasia 3 1 2
Carcinoma in situ 1
Sq. cell carcinoma 1 1
doubLe target FIsh on tIssue seCtIons
FISH analysis was performed in 16 cases. Eight cases that were diploid by QPath 
analysis also showed only diploid nuclei by FISH analysis (Table 2). All cases 
that were non-diploid (tetraploid or aneuploid) in the QPath analysis showed 
either unbalanced FISH results or increased numbers (>2) of balanced spots 
in larger numbers of cells. In one of three cases that were tetraploid by QPath 
analysis the FISH analysis revealed two signals for chromosome 1 versus 3 signals 
for chromosome 7 in the majority of cells, deviating from the normal 2 versus 
2 distribution. The example case from Figure 3A showed nuclei in a 2 versus 
3 (chromosome 1 versus 7) imbalance in FISH analysis (FISH image in Figure 3B).
Table	2	Comparison	of	results	from	DNA	ploidy	analysis,	assessed	in	cytospins	of	isolated	nuclei,	and	
double	target	FISH	analysis	for	chromosomes	1	and	7	centromeres		in	tissue	sections	(n=17).	Aneusomy	
isdefined	as	an	imbalance,	with	at	least	one	chromosome	containing	>2	signals	per	nucleus.
DNA	ploidy	in
isolated nuclei
Chromosome	1	and	7	copy	numbers	in	FISH	analysis
Disomy Tetrasomy Trisomy Aneusomy
diploid 8
tetraploid 2 1
aneuploid 1 1 3
dna pLoIdy and mIb-1 assessment In tIssue seCtIons
In transmitted light microscopy (i.e. with Feulgen restaining after MIB-1 assess-
ment), on average eight microscopic fields were measured for each patient 
(range 3–12), containing on average a total of 959 nuclei (range 141–2838). 
Per patient an average of 71 nuclei in the stroma was used as internal diploid 
reference (range 21–204). Results of simultaneous assessment of DNA ploidy 
and MIB-1 may be visualized using scatterplots. Figure 2A shows these data for 
the case shown in Figure 3, which was found to be aneuploid by both FISH and 
QPath analysis. Clearly, a strong relationship exists between MIB-1 expression 
and DNA content, with the majority of cells with DI >1.25 (i.e. outside the diploid 
region) being MIB-1+. This fits normal cycling cells with a DNA content inter-
mediate between diploidy and tetraploidy. The presence of cells in both the 
red and blue regions in the scatterplot indicates aneuploidy, and is therefore 
concordant with the other analysis modalities (QPath and FISH). The majority of 
cells in the blue region possessed DI values just exceeding the 1.25 threshold, 
coinciding with the aneuploid DI value of 1.29 found by QPath analysis. The DI 
histogram in Figure 2B shows that the cells within the blue-coloured region (with 
DI between 1.25 and 2.25) could not be discriminated from the MIB-1+ nuclei 
with identical DNA content based only on DNA ploidy analysis without the 
combination with MIB-1.
One case, which showed trisomy in FISH analysis (indicative for triploidy) showed 
an aneuploid DI of 1.5 with QPath analysis and contained an aneuploid sub-
population with DI = 1.5 in the tissue section DNA ploidy analysis. Because of 
the limited size of this lesion, only 141 nuclei could be used for tissue ploidy 
measurement. In spite of this limited number of nuclei, identical results were 
obtained with all three techniques for this case.
Chapter 4
100
Simultaneous assessment of DNA ploidy and biomarker expression in paraffin-embedded tissue sections
101
Figure 3. a, results of Dna ploidy analysis on isolated nuclei of the case shown in Figure 2. an aneuploid 
peak is seen with ploidy index = 1.29. B, Fluorescence microscopic image of double target fluorescence in 
situ hybridization analysis of the same case as in Figure 3a, using centromere probes for chromosomes 1 
(grey) and 7 (white). an imbalance with two copies of chromosome 1 and 3 copies per nucleus of chromo-
some 7 is observed.
ComparIson oF dna pLoIdy anaLysIs In tIssue seCtIons
versus CytospIns
To be able to compare data from tissue ploidy analysis with QPath and FISH 
analysis, for each patient the percentages of cells present in the two regions 
of interest defined above (red and blue regions in Figure 2A) were calculated. 
A classifier was constructed classifying specimens as diploid or non-diploid using 
these two percentages: a specimen is classified as diploid if and only if the 
square	root	of	the	sum	of	the	squares	of	the	two	percentages	is	<0.5;	otherwise	
the specimen is classified as non-diploid. Table 3 shows results of this classifier 
for tissue section ploidy analysis for data from transmitted light microscopy 
and fluorescence microscopy. One case containing CIS was classified as diploid 
on QPath analysis (ploidy histogram in Figure 4A). However, this specific case 
was evidently non-diploid in tissue ploidy analysis for both transmitted light 
(Figure 4B) and fluorescence microscopy (Figure 6A), probably indicating that 
QPath analysis misclassified this case. In transmitted light microscopy, sensitivity 
for detecting non-diploid profiles is 100% with specificity 92%. Based on results 
from tissue section analysis, no distinction could be made between tetraploid 
and aneuploid cases.
Table	3.	Comparison	of	results	from	DNA	ploidy	analysis,	assessed	in	cytospins	of	isolated	nuclei,	and	
tissue	section	ploidy	analysis. 
Tissue	ploidy	analysis
DNA	ploidy	measured	in	isolated	nuclei
diploid tetraploid aneuploid
Transmitted	light	microscopy	(n=22)
diploid 11 0 0
non-diploid 2 4 5
Fluorescence	microscopy	(n=5)
diploid 3 0 0
non-diploid 1 1 0
Figure 4. results of a specimen containing carcinoma in situ, which was found to be diploid by analysis of isolated 
nuclei. a, the results of analysis of isolated nuclei. B, results from tissue section ploidy analysis in transmitted 
light. Letters indicate individual nuclei that are classified as aneuploid and which are shown in the histological 
image in Figure 6.
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reLatIonshIp between hIstoLogy, dna pLoIdy, mIb-1 and
FIsh
Tissue section analysis enables study of the relationship between DNA ploidy 
and MIB-1 immunohistochemistry with histology. In the scatterplot in Figure 
4A,B number of nuclei are indicated by an asterisk, which were all located in 
a single microscopic field of view. The corresponding histological image is 
shown in Figure 5. Individual nuclei are indicated by letters, using red for 
MIB-1+ nuclei and green for MIB-1) nuclei.
Figure 5. Microscopic image of MiB-1-stained tissue section containing most of the aneuploid nuclei from the 
case in Figure 4B (individual nuclei indicated by letters).
Figure 6 shows similar data from the same case, containing CIS, for tissue ploidy 
analysis in fluorescence microscopy. Because of the multiplexing possibilities 
of this imaging modality, simultaneous assessment of DNA ploidy, MIB-1 
and DSB marker γ-H2AX was possible. The scatterplot in Figure 6A contains 
different symbols indicating the level of expression of γ-H2AX. Clearly, both 
proliferating and non-proliferating aneuploid cells are present in the histological 
image in Figure 6B, showing γ-H2AX positivity in the majority of cells.
Figure 6. Data from the case shown in Figures 4 and 5 (containing carcinoma in situ, classified as diploid with 
analysis of isolated nuclei), as measured using fluorescence microscopy. next to information resembling that 
of Figures 4 and 5, expression of Dna double strand break marker γ-H2aX is shown using different symbols 
in the scatterplot in a. in the microscopic image (x400) in B the nuclear Dna stoichiometric DraQ-5 staining 
is shown in dark grey, MiB-1 proliferation marker is shown in white and γ-H2aX in light grey.
Figure 7 shows images from the example case in Figures 2 and 3, containing 
moderate dysplasia. Nuclei from different scatterplot regions are indicated 
by circles. Figure 7A,B shows microscopic images with Feulgen–Schiff staining, 
Figure 7C,D the corresponding MIB-1-stained areas. Evidently, aneuploid 
MIB-1+ nuclei (indicated by red circles, located in the red-coloured region in 
Figure 2A) are located more basally compared with MIB-1) aneuploid nuclei 
(indicated by blue circles, located in the blue-coloured region in Figure 2A). 
Interestingly, the images in Figure 7A,C are from a part of the tissue section 
classified as ‘without abnormalities’ by the pathologist, whereas Figure 7B,D 
was classified as dysplastic. The same phenomenon was observed in the FISH 
analysis.
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Figure 7. Microscopic images (x400) of tissue sections of the patient shown in Figures 2 and 3, stained by the 
Feulgen procedure (a,B) and corresponding images stained by MiB-1 immunohistochemistry (c,D). Displayed 
are images from an area classified as ‘within normal limits (a,c) and of an area classified as dysplastic (B,D). 
Dark grey circles indicate aneuploid MiB-1+ nuclei (located in the white region in Figure 2a) and light grey 
circles indicate aneuploid MiB-1 - nuclei (dark grey-coloured region in Figure 2a).
dIsCussIon
In the present study we set out to assess DNA ploidy in tissue sections at the 
level of the individual cell. In fact, this is an unattainable goal, in the sense 
that the information available from truncated nuclei is insufficient to reach 
reliable results. Therefore, precision of the measurement was increased by 
combining stoichiometric DNA staining with proliferation marker MIB-1.
Comparison of data from tissue section analysis with ploidy assessment in 
isolated nuclei and FISH results showed that ploidy data from tissue sections 
were reliable. Moreover, it was shown that for small aneuploid subpopulations 
the possibility of selective sampling within morphologically defined areas may 
be a definite advantage of DNA ploidy analysis in tissue section analysis over 
analysis of isolated nuclei: one case that was classified as diploid based on 
measurement of isolated nuclei clearly contained an aneuploid subpopulation 
in tissue section ploidy analysis. 
In previous studies similar conclusions have been drawn.15,24 Ploidy analysis in 
tissue sections has appeared useful in a number of studies,15,17,19,21,30,31 but 
contradictory results have also been published.22,24,32,33 Most likely, the extent 
of the aneuploid subpopulation and the relative size of nuclei play an important 
role in this. Small nuclei (in relation to section thickness) suffer less from trun-
cation and larger aneuploid populations will be detected more easily. Also, in 
a number of studies selective sampling was performed to include as much as 
possible nuclei with minor truncation.21,30,31
The present study was aimed at finding (possibly minor) deviations from a 
diploid DNA profile, with a minimum of sampling bias. To correlate ploidy 
data with histology, we also wanted to identify individual aneuploid nuclei. 
Data show that this would not have been possible without combining ploidy 
analysis with MIB-1 assessment. The reduction in sensitivity of tissue section 
analysis compared with analysis of isolated nuclei resulted in the present 
study in an inability to distinguish between tetraploid and aneuploid DNA 
profiles. The same phenomenon has been observed before.19 The diagnostic 
implication of this effect is unclear.
An alternative to DNA ploidy analysis is the use of FISH, which may be 
performed in tissue sections to identify genomic alterations.9 In the present 
study, it was found that deviations from the diploid DNA profile were always 
confirmed by double-target FISH data deviating from the normal 2 versus 2 
pattern. Although less sensitive for detecting alterations in copy numbers of 
specific chromosomes, DNA ploidy analysis is not restricted to analysis of 
alterations in one or two chromosomes, and also may be combined with other 
relevant markers. Nevertheless, by using appropriate combinations of probes, 
FISH has proven to be of value in predicting malignant progression of head 
and neck precursor lesions.9
An example of the applicability of the technique described here is the study 
of so-called fields as precursors of premalignancies.34 The field concept has 
been extensively studied by molecular analysis of microdissected areas in 
tissue sections.35,36 It was shown that normal-appearing resection margins of 
squamous cell carcinoma often contain genetic and phenotypic alterations.36 
This so-called field in which the initial tumour has arisen may have functioned 
as a precursor for the tumour and therefore may give rise to additional 
malignancies. Currently, no techniques exist to identify the extent of the 
field satisfactorily in situ in tissue sections. The possibility of recognizing and 
characterizing genetically and phenotypically altered regions in tissue sections, 
as described in the present study, may prove very beneficial to this type of 
research. As an example, in the present study it was shown that aneuploidy 
was present in a leukoplakia both in the area classified as dysplastic as well as 
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in the surrounding, morphologically normal appearing tissue. This observation 
matches the concept of an expanding, preneoplastic field,34 showing the 
presence of genetic aberrations that are not restricted to the morphologically 
identified dysplastic tissue. In both regions, proliferating nuclei were located 
in the basal compartment of the epithelium, whereas G0 cells were located more 
superficially, showing intactness of the normal stratification of the epithelium in 
this moderate dysplasia. The combination of aneuploidy and normal-appearing 
epithelium with proliferation confined to the basal cell layers shows that ploidy 
alterations may precede the development of dysplasia. This is in agreement 
with the observation that even alterations in multiple malignancy related 
genes do not necessarily result in recognizable cellular features.35 By using 
fluorescence microscopy, simultaneous assessment of other relevant markers 
will increase the power of this analysis. For example, by combining tissue section 
ploidy analysis with FISH it will be possible to detect loss of the CDKN2A 
gene. This gene encodes for tumour suppressor proteins p16INK4a and 
p14ARF, loss of which has been described as an early event in head and neck 
squamous cell carcinoma carcinogenesis.37,38 In the present study, one example 
case containing CIS showed γ-H2AX+ loci in clusters of aneuploid nuclei (both 
proliferating and non-proliferating). This seems indicative for a deregulated 
physiological cellular response to DNA DSBs, which in turn may result in genetic 
instability and carcinogenesis.
The use of fluorescence microscopy for ploidy analysis in tissue sections 
appeared very useful in the present study. First, use of fluorescence microscopy 
was less tedious because no restaining and repositioning of the sections were 
required. Also, for the five cases analysed, distinction between QPath diploid 
and nondiploid cases was improved in fluorescence microscopy compared 
with transmitted light microscopy. Lastly, the possibility of conveniently linking 
expression of biomarker expression to ploidy analysis makes this technique 
highly relevant. At present, we are studying the possibility of increasing the 
number of simultaneous signals that may be measured in a single nucleus. 
The use of quantum dots seems especially promising in this respect.39
Tissue fragments obtained from biopsy specimens (e.g. larynx, breast) 
associated with a premalignant lesion are usually small. Since the majority of 
tissue of these lesions is used for diagnostic purposes, a limited amount 
of tissue is left for additional analysis techniques or research purposes.16 
Therefore, isolation of nuclei for preparation of cytospins, requiring several 
50 μm thick sections, may not be an option. The technique described here, 
requiring only a single 7-μm section, will solve this problem and increase the 
number of biopsy specimens, allowing determination of DNA content. DNA 
ploidy analysis may be useful in gaining knowledge of the cellular alterations 
that accompany the transition from the premalignant stage to carcinoma, which 
is currently limited. As a result, it might be possible to distinguish between 
premalignant lesions that will progress and those that will not, as ploidy changes 
quite often herald this transformation.6,40–42 Most probably, multiparameter 
fluorescence with other relevant markers will open up new avenues in this area.
reFerenCes
1.  Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. The molecular biology of esophageal 
adenocarcinoma.	J.	Surg.	Oncol.	2005;	92;	169–190.
2.		 Rajagopalan	H,	Lengauer	C.	Aneuploidy	and	cancer.	Nature	2004;	432;	338–341.
3.  Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett’s esophagus. Gastrointest. Endosc. Clin. N. 
Am.	2003;	13;	369–397.
4.  Robinson JK, Rademaker AW, Goolsby C, Traczyk TN, Zoladz C. DNA ploidy in nonmelanoma skin 
cancer.	Cancer	1996;	77;	284–291.
5.  Smits T, Olthuis D, Blokx WA et al. Aneuploidy and proliferation in keratinocytic intraepidermal  
neoplasias.	Exp.	Dermatol.	2007;	16;	81–86.
6.  Yu C, Zhang X, Huang Q, Klein M, Goyal RK. High-fidelity DNA histograms in neoplastic progression 
in	Barrett’s	esophagus.	Lab.	Invest.	2007;	87;	466–472.
7.  Levine DS, Rabinovitch PS, Haggitt RC et al. Distribution of aneuploid cell populations in ulcerative 
colitis	with	dysplasia	or	cancer.	Gastroenterology	1991;	101;	1198–1210.
8.  Abou-Elhamd KE, Habib TN. The flow cytometric analysis of premalignant and malignant lesions in 
head	and	neck	squamous	cell	carcinoma.	Oral	Oncol.	2007;	43;	366–372.
9.  Veltman JA, Bot FJ, Huynen FC, Ramaekers FC, Manni JJ, Hopman AH. Chromosome instability as an 
indicator	of	malignant	progression	in	laryngeal	mucosa.	J.	Clin.	Oncol.	2000;	18;	1644–1651.
10.  Kerkhof M, Steyerberg EW, Kusters JG et al. Aneuploidy and high expression of p53 and Ki67 is  
associated	with	neoplastic	progression	in	Barrett	esophagus.	Cancer	Biomark.	2008;	4;	1–10.
11.  Garrity MM, Burgart LJ, Mahoney MR et al. Prognostic value of proliferation, apoptosis, defective 
DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: 
a	North	Central	Cancer	Treatment	Group	Study.	J.	Clin.	Oncol.	2004;	22;	1572–1582.
12.  Haroske G, Baak JP, Danielsen H et al. Fourth updated ESACP consensus report on diagnostic DNA 
image	cytometry.	Anal.	Cell.	Pathol.	2001;	23;	89–95.
13.  Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA 
content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem. 
1983;	31;	1333–1335.
14.  Dodd LG, Kerns BJ, Dodge RK, Layfield LJ. Intratumoral heterogeneity in primary breast carcinoma: 
study	of	concurrent	parameters.	J.	Surg.	Oncol.	1997;	64;	280–287.
15.  Huang Q, Yu C, Zhang X, Goyal RK. Comparison of DNA histograms by standard flow cytometry and 
image	cytometry	on	sections	in	Barrett’s	adenocarcinoma.	BMC	Clin.	Pathol.	2008;	8;	5.
16.  Gauthier ML, Berman HK, Miller C et al. Abrogated response to cellular stress identifies DCIS associated 
with	subsequent	tumor	events	and	defines	basal-like	breast	tumors.	Cancer	Cell	2007;	12;	479–491.
Chapter 4
108
Simultaneous assessment of DNA ploidy and biomarker expression in paraffin-embedded tissue sections
109
17.  Susnik B, Poulin N, Phillips D, LeRiche J, Palcic B. Comparison of DNA measurement performed by flow 
and	image	cytometry	of	embedded	breast	tissue	sections.	Anal.	Quant.	Cytol.	Histol.	1995;	17;	163–171.
18.  Freed JA. Improved correction of quantitative nuclear DNA (ploidy) measurements in tissue sections. 
Anal.	Quant.	Cytol.	Histol.	1999;	21;	103–112.
19.  Forte JD, Croker BP, Hendricks JB. Comparison of histologic and cytologic specimens of urothelial 
carcinoma	with	image	analysis.	Implications	for	grading.	Anal.	Quant.	Cytol.	Histol.	1997;	19;	158–166.
20.  Gschwendtner A, Mairinger T. DNA measurement on histologic slides. Does it work on human tissue?. 
Anal.	Quant.	Cytol.	Histol.	1997;	19;	294–300.
21.  Klapperstuck T, Wohlrab W. DNA image cytometry on sections as compared with image cytometry on 
smears	and	flow	cytometry	in	melanoma.	Cytometry	1996;	25;	82–89.
22.  Sapi Z, Hendricks JB, Pharis PG, Wilkinson EJ. Tissue section image analysis of breast neoplasms.  
Evidence	of	false	aneuploidy.	Am.	J.	Clin.	Pathol.	1993;	99;	714–720.
23.  Huang Q, Yu C, Klein M, Fang J, Goyal RK. DNA index determination with Automated Cellular Imaging 
System	(ACIS)	in	Barrett’s	esophagus:	comparison	with	CAS	200.	BMC	Clin.	Pathol.	2005;	5;	7.
24.  Ottesen GL, Christensen IJ, Larsen JK et al. DNA ploidy analysis in breast carcinoma. Comparison of 
unfixed	and	fixed	tissue	analyzed	by	image	and	flow	cytometry.	Anal.	Quant.	Cytol.	Histol.	1997;	19;	
413–422.
25.  Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 
antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalinfixed paraffin 
sections.	J.	Pathol.	1992;	168;	357–363.
26.  Barnes L, Eveson JW, Reichart P, Sidransky D eds. World Health Organization classification of tumours. 
Pathology	and	genetics.	Head	and	neck	tumours.	Lyon:	IARC	Press,	2005;	177–180.
27.  Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC. Identification of chromosome 
9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma 
in	situ	associated	with	carcinoma.	Am.	J.	Pathol.	2002;	161;	1119–1125.
28.  Bergshoeff V, Hopman A, Zwijnenberg I et al. Chromosome instability in resection margins predicts  
recurrence	of	oral	squamous	cell	carcinoma.	J.	Pathol.	2008;	215;	347–348.
29.  Canny J. A computational approach to edge detection. IEEE Trans. Patern Anal. Mach. Intelligence 
1986;	8;	679–714.
30.  Andrejevic-Blant S, Osterheld MC, Caron L, Ballini JP, Monnier P. Deoxyribonucleic acid content as an 
indicator of progression of squamous cell carcinogenesis in the esophagus: comparative analysis on 
imprint-cytospin	and	tissue	section	preparation.	Cancer	Detect.	Prev.	2006;	30;	276–283.
31.  Williams RA, Baak JP, Meijer GA, Charlton IG. Influence of section thickness, mean nuclear diameter 
and nuclear crowding on DNA ploidy in histologic sections of melanocytic skin lesions. Anal. Quant. 
Cytol.	Histol.	1999;	21;	413–424.
32.  Uyterlinde AM, Smeulders AW, Baak JP. DNA measurement errors with a scanning microdensitometer 
in	cytologic	and	histologic	samples	of	breast	cancers.	Anal.	Quant.	Cytol.	Histol.	1991;	13;	115–122.
33.  Dorman A, Graham D, Curran B, Henry K, Leader M. Ploidy of smooth muscle tumours: retrospective 
image	analysis	study	of	formalin	fixed,	paraffin	wax	embedded	tissue.	J.	Clin.	Pathol.	1990;	43;	465–468.
34.  Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s 
concept	of	field	cancerization:	evidence	and	clinical	implications.	Cancer	Res.	2003;	63;	1727–1730.
35.  Koshiji M, Yonekura Y, Saito T, Sakaida N, Uemura Y, Yoshioka K. Genetic alterations in normal epithelium 
of colorectal cancer patients may be a useful indicator for subsequent metachronous tumor development. 
Ann.	Surg.	Oncol.	2002;	9;	580–586.
36.  Tabor MP, Brakenhoff RH, van Houten VM et al. Persistence of genetically altered fields in head and 
neck	cancer	patients:	biological	and	clinical	implications.	Clin.	Cancer	Res.	2001;	7;	1523–1532.
37.  Kresty LA, Mallery SR, Knobloch TJ et al. Alterations of p16(INK4a) and p14(ARF) in patients with severe 
oral	epithelial	dysplasia.	Cancer	Res.	2002;	62;	5295–5300.
38.  Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the 
head	and	neck.	J.	Clin.	Pathol.	2006;	59;	445–453.
39.		 True	LD,	Gao	X.	Quantum	dots	for	molecular	pathology:	their	time	has	arrived.	J.	Mol.	Diagn.	2007;	9;	
7–11.
40.		 Hunter	KD,	Thurlow	JK,	Fleming	J	et	al.	Divergent	routes	to	oral	cancer.	Cancer	Res.	2006;	66;	7405–7413.
41.  Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular 
biological	characteristics.	Crit.	Rev.	Oral	Biol.	Med.	2003;	14;	47–62.
42.  Maley CC, Galipeau PC, Li X et al. The combination of genetic instability and clonal expansion predicts 
progression	to	esophageal	adenocarcinoma.	Cancer	Res.	2004;	64;	7629–7633.
111
cHaPter 5
Simultaneous assessment of biomarkers 
predicts malignant potential of laryngeal 
mucosal lesions
A.J.H.M. Fleskens
V.E. Bergshoeff
J.A.W.M. van der Laak
I. Otte-Höller
N. Saksens
E.J.M. Speel
B. Kremer
R.P. Takes
P.J. Slootweg
In preparation
Simultaneous assessment of biomarkers predicts malignant potential of laryngeal mucosal lesions
113
abstraCt
IntroduCtIon: The possibility that a laryngeal mucosal premalignant lesion 
(LMPL) will progress to invasive cancer is a common clinical concern. However, 
there are no means to predict which of these lesions will become carcinoma 
and which will not. The aim of this study was to assess the predictive value of 
simultaneously assessing DNA ploidy and biomarker expression at the level 
of the individual cell in LMPLs.
materIaLs and methods: Sections of paraffin-embedded tissue (7 μm) from 
37  LMPLs were included. The specimens represented a range of diagnoses 
varying from hyperkeratosis to moderate dysplasia, according to the WHO 
classification. Progression was defined as development into severe dysplasia/
carcinoma in situ (CIS) or laryngeal squamous cell carcinoma (LSCC) at least 6 
months after the biopsy. Sections were stained by the DNA stoichiometric DRAQ 
procedure in combination with immunohistochemical staining of proliferation 
marker Ki67, p53 and DNA double strand break marker γ-H2AX. Ploidy status 
was also assessed using fluorescence in situ hybridization (FISH) with probes 
against chromosomal centromeres 1 and 7.
resuLts: Seventeen patients showed progression during follow-up. When the 
samples were divided into a low-grade (hyperkeratosis, hyperplasia, inflam-
mation) and high-grade group (mild and moderate dysplasia), an optimal 
correlation was found between the parameter histology and progression-free 
survival	 (Hazard	 Ratio	 (HR)	 of	 2.34;	 Confidence	 Interval	 (ConfInt)	 0.9-6.4;	
p=0.095). For all possible combinations of expression of the four biomarkers, 
the combination of high DNA and low p53 showed the most significant 
correlation	with	progression-free	survival	(HR=3.17;	ConfInt	1.2-8.6;	p=0.023).	
A worse progression-free survival was also observed for patients with chro-
mosomal	instability:	HR	2.37;	ConfInt	0.9-6.4;	p=0.089.			
dIsCussIon: Based on the results of this study, the presence of nuclei with 
high DNA content and low p53 expression  in LMLP  has more predictive value 
then histopathology. Moreover,this finding also indicates that in these cells, an 
abnormal DNA content fails to induce an expected physiological upregulation 
of p53, an event that may play a role in progression to malignancy. 
ConCLusIon: Our data demonstrate that malignant transformation of low-
grade LMPLs correlates with the presence of nuclei with the combination of 
high DNA and low p53. To confirm the utility and prognostic power of this 
feature as a predictive parameter, a well designed, prospective study could 
be considered.
IntroduCtIon
Similar to other epithelial malignancies, the development of laryngeal 
squamous cell carcinoma (LSCC) is considered to be a multistep process driven 
by an accumulation of genetic alterations in the surface epithelium.1-4 Their 
accumulation is reflected in a series of morphologic changes for which terms 
such as laryngeal squamous dysplasia, laryngeal intraepithelial lesion, laryngeal 
intraepithelial neoplasia, or laryngeal epithelial precursor lesion are variably 
used.4 
Laryngeal precancer is reported to affect 2 females and 10 males per 100,000 
of the population in the United States.5,6 The fraction of such lesions that 
transform into malignancy varies widely in the literature, ranging from 0% to 
80%.7 Meta-analysis showed an overall malignant transformation rate of 14% 
(95% Confidence Interval (ConfInt) 8% to 22%) for laryngeal dysplastic lesions 
of any degree.8
Histopathological examination of hematoxylin and eosin-stained (H&E-stained) 
slides is currently the gold standard for assessing the malignant potential of 
laryngeal mucosal premalignant lesions (LMPLs) in clinical practice.9,10 However, 
its value is severely hampered by poor intra- and inter-observer reproducibility 
and by the fact that the presence and degree of dysplasia does not reliably 
predict biological behavior.4,11-15 
As a consequence, there is no consensus on the management of patients with 
these lesions.7,16 Different treatment and follow-up strategies are pursued. 
Apart from dealing with the patients’ complaints, the clinical management of 
LMPLs would ideally be based on their potential to transform into malignancy. 
To that end, novel markers are needed: not only must these be reproducible 
between different laboratories but they must reliably identify which precursor 
lesions are most likely to progress to severe dysplasia/carcinoma in situ (CIS) 
or invasive carcinomas (all diagnoses with an indication for treatment). The 
identification of the molecular alterations associated with the development 
of laryngeal squamous cell carcinoma might provide valuable diagnostic tools 
for assessing the cancer risk of precursor lesions. Ultimately, such tools could 
lead to a more unified classification of laryngeal epithelial precursor lesions 
than those presently available.4,17 This in turn would be conducive to more 
efficient treatment and follow-up protocols for these lesions.
In a previous study we described the simultaneous assessment of DNA ploidy 
and other biomarkers in paraffin-embedded tissue sections.18 The objective 
of the present study is to assess the predictive value of that method for 
malignant progression by simultaneously assessing DNA ploidy, p53, Ki67 and 
γH2AX in LMPLs. These markers were selected because they reflect different 
but presumably interacting cancer-related cellular processes: proliferation, 
stress response, and genome integrity.19
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materIaLs and methods
patIent seLeCtIon and  materIaL
Thirty-seven paraffin-embedded tissue specimens from laryngeal biopsies of 37 
patients (32 male, 5 female) were obtained from the archives of the Department 
of Pathology at the Radboud University Nijmegen Medical Center (Nijmegen, 
The Netherlands). The use of patient material was in accordance with local 
ethical guidelines. All specimens were routinely fixed in 4% formalin and paraffin-
embedded. Standard 4-μm thick hematoxylin and eosin (H&E)-stained sections 
were used for classification of the lesions.
The cases in this study were classified according to the WHO criteria.20 From 
each tissue block one 7 μm section was cut for biomarker analysis (p53, Ki67, 
γH2AX, DRAQ-5) and two 4 μm sections for FISH analysis as described below.
Inclusion criteria were as follows: specimens were obtained by (micro)laryngeal 
surgery between 1985 and 2005 and the histopathological diagnosis fell within 
the spectrum of LMPLs from hyperkeratosis to moderate dysplasia. In 27 cases 
we used the tissue obtained during the first biopsy (also in cases of multiple 
biopsies during follow-up). In 10 cases this was not possible due to insufficient 
quality and/or quantity of laryngeal tissue. In these 10 cases a biopsy as close 
as possible to the first biopsy was used. Clinical data were  obtained from the 
archives of the Department of Otorhinolaryngology and Head & Neck Surgery at 
the Radboud University Nijmegen Medical Center (Nijmegen, The Netherlands).
staInIng oF tIssue seCtIons For bIomarker vIsuaLIzatIon
As mentioned in our previous study, we developed and validated a procedure 
to assess DNA ploidy in paraffin-embedded tissue sections by applying 
sequential analysis of Ki67 proliferation marker and Feulgen-DNA staining in 
a single section.18 We also presented an alternative to the tedious procedure 
of sequential chromogenic staining, using multiplexed immunofluorescence. 
For a limited number of cases, we obtained results similar to those from 
sequential chromogenic staining. In light of these results, in the present study 
we employed immunofluorescence, as it allows assessment of up to four bio-
markers simultaneously at a single-cell level (DRAQ-5,  p53, Ki67 and γH2AX).
Paraffin sections of 7 μm mounted on superfrost glass slides were dried 
overnight at 37ºC. They were deparaffinized in Xylol and rehydrated through 
a graded series of alcohol until water. After rinsing in Tris-buffered saline (TBS) 
the slides were placed in Citrate buffer at pH6 and cooked for 10 min in a 
microwave oven for antigen retrieval. The slides were allowed to cool down 
for 90 min and were then thoroughly washed in TBS for several hours to 
diminish fluorescent background staining. In order to lessen the surface tension 
and allow better penetration into the nucleus, the slides were preincubated 
with TBS containing 1% BSA and 0.2% Triton X100 for 30 min. Incubation of the 
first antibodies, all together diluted in one tube with TBS containing 1% BSA, 
was done overnight at 4ºC. The slides were rinsed in TBS and the secondary 
antibodies were applied for 60 min at room temperature in TBS with 1% BSA. 
Table 1 gives an overview of the primary and secondary antibodies used. Sub-
sequently the slides were incubated for 30 min with DRAQ-5 (Biostatus 
DR50200) 1:100 in TBS and mounted in fluoromount G.
table 1. used antibodies
Ki67 MIB-1 Mouse DAKO M7240 1:100
P53 (FL-393)-G Goat Santa Cruz sc-6243-G 1:200
Phospho-Histone H2A.X (Ser139) Rabbit Cell Signaling #2577 1:200
Alexa F488 anti goat Donkey Invitrogen A11055 1:200
Alexa F350 anti mouse Donkey Invitrogen A10035 1:200
Alexa F568 anti rabbit Donkey Invitrogen A10042 1:200
sImuLtaneous assessment oF dna pLoIdy and bIomarker
expressIon In paraFFIn-embedded tIssue seCtIons
Microscopic fields were selected in scanned H&E-stained slides by an expe-
rienced head and neck pathologist (PJS). Fields were selected containing 
abnormal tissue and also (if available) normal epithelium. Next, the selected 
fields were relocated in the fluorescently labeled sections. Images were acquired 
on a Leica DMI6000B microscope using a 63x objective, a Leica DCF 360FX 
camera, and LAS-AF software (Leica Microsystems, Rijswijk, The Netherlands). 
The setup used in this study resulted in a specimen-level pixel size of 0.144 μm. 
For each manually selected microscopic field of view, images were acquired 
sequentially for the four markers. The images were corrected for unequal illumi-
nation using empty reference images for each excitation/emission wavelength 
combination.
Automated measurement of nuclear signals was performed as described 
previously.18 In brief, individual nuclear profiles in tissue-section images were 
recognized using digital image analysis software, based on DRAQ-5 nuclear 
staining. If required, interactive correction of nuclear profiles was performed using 
a standard computer mouse. Next, within each nuclear profile the integrated 
intensity of DRAQ-5 DNA-staining, p53, Ki67 and γH2AX were determined for 
subsequent data analysis. In this way, the combined expression of the studied 
biomarkers was available for each individual nucleus. A detailed description 
of the biomarker analysis is given in the ‘Statistical analysis’ section below.
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deteCtIon oF Chromosome 1 and 7 aLteratIons by FIsh
FISH was performed on 4-μm thick tissue sections as described previously.21,22 
Briefly, sections were deparaffinized, pretreated with 85% formic acid ⁄ 0.3% 
H2O2, 1 M NaSCN and 4 mg ⁄ml pepsin in 0.01M HCl, post-fixed in 1% formal-
dehyde in phosphate-buffered saline (PBS), dehydrated in an ethanol series 
and hybridized with a mixture of digoxigenin-labeled human centromere 
1-specific and biotin-labeled centromere 7-specific DNA probes [1 ng ⁄ μl 60% 
formamide, 2x sodium-saline citrate (SSC), 10% dextran sulphate and 50x 
excess salmon sperm carrier DNA]. After hybridization the preparations were 
washed stringently in 2x SSC at 42˚C (two times for 5 min) and 0.1x SSC at 
60˚C (two times for 5 min). The probes were detected by application of (i) mouse 
anti-digoxin (Sigma) ⁄ avidin fluorescein (Vector Laboratories, Burlingame, CA, 
USA), (ii) rabbit anti-mouse rhodamin (Dako, Glostrup, Denmark) ⁄ biotinylated 
goat anti-avidin (Vector), and (iii) swine anti-rabbit rhodamin (Dako) ⁄ avidin 
fluorescein. Preparations were mounted in Vectashield (Vector Laboratories) 
containing	4,6-diamidino-2-phenyl	indole	(Sigma;	0.2	μg	⁄	ml).	
Microscope images were recorded with the Metasystems Image Pro System 
(black	and	white	charge	coupled	device	camera;	Metasystems,	Sandhausen,	
Germany) mounted on top of a Leica DM-RE fluorescence microscope (Leica, 
Wetzler, Germany) equipped with fluorescein-, rhodamine-, and DAPI-specific 
filter sets for single-color analysis and a double bandpass filter set (fluorescein, 
rhodamine) for simultaneous dual-color analysis.
ControLs and evaLuatIon oF FIsh resuLts
Hybridizations on tissue sections with proven aneusomies (monosomy, disomy, 
trisomy, and tetrasomy) as well as on normal areas within the tissue sections 
under study were used as controls to exclude hybridization artefacts and 
interpretation problems. Evaluation of the FISH results was carried out by two 
investigators (VEB and EJMS) according to earlier described criteria.22, 23 FISH 
signals were scored per color and nucleus for the presence of aberrant copy 
numbers of chromosomes 1 and 7. The highest copy number per nucleus was 
determined and set if ≥ 20% of the nuclei (with a minimum of 50 nuclei and a 
maximum of 500 nuclei, depending on the size of the lesion) showed this 
number of FISH signals. Based on this evaluation, the lesions were categorized 
as either monosomic, disomic, trisomic, tetrasomic, or polysomic (> 4 signals 
per nucleus) for the respective probe targets. After this evaluation, the lesions 
were divided into two groups. The first consisted of lesions without evidence 
of chromosome alterations (diploid). The lesions in the second group showed 
either altered but balanced chromosome 1/7 copy numbers (trisomy or tetrasomy, 
indicating tri- or tetraploidization) or characteristics of chromosome instability 
(CI), i.e., the lesions contained chromosome copy number imbalances and/or 
chromosome polysomy.
statIstICaL anaLysIs
The predictive value of histopathology, FISH, and DNA ploidy for malignant 
progression was studied using Cox regression. Progression was defined as 
development into severe dysplasia/carcinoma in situ (CIS) or LSCC at least 6 
months after the time that the biopsy that was analyzed, was taken. Therefore, 
cases with progression within 6 months after the biopsy were excluded. Patients 
without progressive lesions were censored at the date of last follow-up or 
date of death.
To study the combined expression of different biomarkers at the cell level, 
the intensity of biomarkers was recorded in discrete categories. First, for each 
marker, quartile values (i.e. biomarker intensity values below which 25, 50, 
and 75% of the feature values of individual cells are) were calculated over all 
cells measured in this entire study. Next, the intensity of each cell for each 
biomarker was put into an intensity category (1–4) on the basis of these values. 
See Figure 1 for an example of p53 expression in 4 categories. At the specimen 
level, the percentage of cells in single and combined categories was determined. 
For example, the combined analysis of p53 and yH2AX expression results in 
4x4 possible combinations. It therefore yields 16 features for the different 
percentages of cells present in these categories (e.g., one feature would be 
the percentage of cells having both p53 in the second quartile and yH2AX in 
the fourth). For the analysis of the combined expression of >2 features, the 
number of possible combinations (and thus the number of features) would 
become very large. Therefore, intensity value subdivision was reduced to two 
categories (above or below the median value, which  encompasses taking 
together categories as defined above 1 + 2 and 3 + 4) for these analyses. In 
the present study, DRAQ-5 staining, which is stoichiometric with DNA, was used 
to be able to calculate the DNA ploidy level of cells. This analysis was hampered 
by suboptimal stoichiometry of DRAQ-5, also evidenced by subsequent 
experiments comparing DRAQ-5 and Feulgen staining (data not shown). 
Also, for a number of cases insufficient diploid reference cells could be 
measured. Therefore, DRAQ-5 staining was treated similar to analysis as for 
the other biomarkers rather than used to calculate DNA ploidy. Table 2 shows 
the features that were analyzed.
A Cox regression analysis (multivariate, stepwise) was conducted to investigate 
which features correlate with progression-free survival. Receiver operating 
characteristic (ROC) analysis was used to derive a threshold value for the opti-
mal combination of biomarkers. All data analysis was performed using SPSS 
software version 20.0 (IBM SPSS Inc., Chicago, IL, USA). 
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Figure 1. intensity categories (1-4) with p53 as example.
table 2. analysed features of biomarkers
Features #combinations
DRAQ-5 (DNA) 4
Ki67 4
p53 4
yH2AX 4
Ki67 / p53 16
Ki67 / yH2AX 16
p53 / yH2AX 16
DRAQ-5 / Ki67 16
DRAQ-5 / p53 16
DRAQ-5 / yH2AX 16
DRAQ-5 / Ki67 / p53 8
DRAQ-5 / Ki67 / yH2AX 8
DRAQ-5 / p53 / yH2AX 8
DRAQ-5 / Ki67 / p53 / yH2AX 16
Total features 152
resuLts
patIent CharaCterIstICs
The 37 cases in this study consisted of 3 specimens showing hyperkeratosis / no 
abnormalities, 3 inflammation, 12 hyperplasia, 7 mild dysplasia, and 12 moderate 
dysplasia. A summary of clinical patient characteristics is shown in Table 3. 
Median age at biopsy was 59 (26-81) years. The median period of follow-up 
was 106 (19-272) months. During follow-up, 17 of the 37 (46%) cases showed 
progression.
table 3. patient characteristics
gender 32 ♂ and 5 ♀ 
Age	at	diagnosis	(median)	 59 (26-81) years
Follow-up	(median) 106 (19-272) months  
Progression	 17 patients 
Histopathology	(WHO)	 Normal / Hyperkeratosis 3
Inflammation 3
Hyperplasia 12
Mild dysplasia 7
Moderate dysplasia 12
Tobacco	smoking Non-smokers (n=4)
Smokers (n=32)
Unknown (n=1)
alcohol No alcohol (n=2)
< 2 units/day (n=15)
2-4 units/day (n=9)
5-8 units/day (n=5)
> 8 units/day (n=2)
Unknown (n=3)
hIstopathoLogy
Progression-free survival analysis based on histopathological diagnosis 
showed no significant difference between the histopathological subgroups 
as defined in the WHO.20 However, when defining a low-grade (hyperkerato-
sis, hyperplasia, inflammation) and high-grade group (mild and moderate 
dysplasia), Cox regression analysis showed a Hazard Ratio (HR) of 2.34 (Con-
fInt	0.9-6.4;	p=0.095)	as	shown	in	Figure	2.	The	presence	of	hyperkeratosis,	
age, gender, smoking, or alcohol use was found not to be a confounder.
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Figure  2. comparison of histology low-grade (hyperkeratosis, hyperplasia, inflammation) vs high-grade (mild 
and moderate dysplasia). Hr 2.34; confint 0.9-6.4; p=0.095.
tIssue pLoIdy anaLysIs
Determination of the DNA ploidy status in tissue sections was only possible 
in a disappointingly low number of cases (n=18), The analysis was hampered by 
suboptimal stoichiometry of DRAQ-5, also evidenced by subsequent experi-
ments comparing DRAQ-5 and Feulgen staining (data not shown). Also, in a 
number of cases the amount of normal epithelium that could be measured 
was insufficient to serve as an internal diploid reference. As described previ-
ously, such a reference is crucial for our method of measuring ploidy in tissue 
sections.18 After analyzing progression-free survival for the 18 available cases, 
no	difference	was	 found	between	diploid	 and	 non-diploid	 cases	 (HR	 1.51;	
ConfInt	0.3-7.5;	p=0.62).
FIsh
Double-target FISH analysis for chromosomes 1 and 7 could be determined 
for 36 cases (the tissue of one case with normal/hyperkeratosis histopathology 
could not be assessed). Twelve patients showed CI: 2 with hyperplasia, 3 with 
mild dysplasia, and 7 with moderate dysplasia. A worse progression-free 
survival	was	observed	for	patients	with	CI:	HR	2.37;	ConfInt	0.9-6.4;	p=0.089	
(Figure 3). Gender, smoking, and alcohol use appeared not to be confounders 
for this relationship. Age, however, was found to be a negative confounder. 
FISH	corrected	for	age	showed	a	HR	of	3.15	(ConfInt	1.0-9.5;	p=0.042).	When	
performing a multivariate Cox regression analysis including both histopathol-
ogy and FISH, a decrease was observed in the regression coefficients (with 
corresponding	decrease	in	HR):	HR	2.10	(ConfInt	0.64-6.9;	p=0.22)	for	histo-
pathology	and	HR	1.66	(ConfInt	0.55-5.1;	p=0.37)	for	FISH.	This	is	indicative	of	
a strong relationship between these two parameters.
Figure 3. FisH. Hr 2.37; confint 0.9-6.4; p=0.089.
CombInatIon oF bIomarkers
On average, 2855 nuclei could be measured in a tissue section. Because of 
overlapping nuclear profiles, only part of the nuclei present in a measurement 
field was available for analysis. All the features described in Table 2 were includ-
ed in a multivariate stepwise Cox regression analysis. The feature describing 
the percentage of cells having a combination of high DNA (category 4) and 
low	p53	(category	1)	was	found	to	be	the	most	significant	(HR=2.31;	ConfInt	
1.0-5.2;	p=0.043).	This	combination	exceeded	the	predictive	value	of	DRAQ-5,	
p53, Ki67, and γH2AX as single markers, which were found not to correlate with 
survival (all p-values >0.05). ROC analysis was used to determine the optimal 
cut-off point in terms of sensitivity and specificity for predicting progression, 
yielding a value of 3% as the cut-off point. Using this cut-off in univariate Cox 
regression	analysis	we	found	HR=3.17	(ConfInt	1.2-8.6;	p=0.023;	Figure	4).	An	
illustration of this parameter in a histopathological context is shown in Figure 5. 
Low-grade
High-grade
no	chromosome	instability
chromosome	instability
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Figure 4. ‘Dna high-p53 low’. Hr=3.17; confint 1.2-8.6; p=0.023.
White arrows: DraQ category 4 and p53 category 1
grey arrows: DraQ category 4 and p53 category 4
Figure 5. Fluorescence microscopy image with cells with ‘Dna high-p53 low’
hIstopathoLogy and bIomarkers
When distinguishing between histologically high grade and low grade lesions, 
the combination of low-grade cases (n=18) in which more than 3% of the nuclei 
had high DNA (category 4) and low p53 (category 1) was found to be significant 
(HR	6.4;	ConfInt	1.2-33.2;	p=0.027),	as	shown	in	Figure	6.	This	was	not	found	
for	the	19	high-grade	cases	(HR	1.48;	ConfInt	0.4-5.6;	p=0.56).	This	means	that	
the additive value of biomarker analysis is especially of relevance for the low 
grade lesions.
Figure 6. the combination of histopathological low-grade cases (n=18) and sections with more than 3% nuclei 
with high Dna and low p53. Hr 6.4; confint 1.2-33.2; p=0.027.
dIsCussIon
Prediction of the malignant potential of LMPLs is a clinically important yet 
challenging task. It was shown that histological examination is hampered by 
considerable inter- and intraobserver variation.4,11-15 Gale et al. reported that 
data in the literature on the risk of malignant transformation are controversial 
because of inconsistent use of morphological criteria in different classifications.24 
In a systematic review by Weller et al. it was concluded that malignant transfor-
mation rate increases with severity of dysplasia grade (10.6% for mild/moderate, 
30.4% for severe/CIS).8 In our study, an optimal correlation with progression was 
found when distinguishing a low-grade (hyperkeratosis, hyperplasia, inflam-
mation) from a high-grade group (mild and moderate dysplasia). Interestingly, 
this different chance for progression in the low- and the high-grade group 
Nuclei	with	DNA	high	and	p53	low	exceeds	3%
dashed line represents cases 
with	nuclei	with	DNA	high	and	
p53	low	exceeds	3%
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supports the relevance of the (simplified) grading system that we previously 
proposed in a study on interobserver variability in another population of 
laryngeal lesions.11 
Candidate biomarkers to aid in the assessment of the malignant potential of 
premalignancies in general are DNA ploidy analysis (e.g. FISH and image 
cytometric DNA content analysis) and analysis of the expression of cancer 
related proteins (e.g. tumor suppressor p53, proliferation marker Ki67). 
However, analysis of single biomarkers has not yet been established as a 
sufficiently valuable tool in LMPLs.4,9,25,26 In view of these problems, we 
analyzed if a simultaneous assessment of several biomarkers at the single cell 
level could have any benefit in distinguishing between LMPLs with risk of 
progression from those with a more benign course. Selected biomarkers were 
DRAQ-5, a dye that binds stoichiometrically to DNA and that was included to 
determine DNA content whereas the other chosen markers p53, Ki67 and 
γH2AX reflect genetic stress, cellular response to stress and proliferation, all 
features that may be involved in the development of malignancy. CI was 
assessed using FISH with probes against chromosomal centromeres 1 and 7.
CI showed a clear trend toward lower progression-free survival although, not 
independent of histology (a multivariate Cox regression analysis is indicative 
of a strong relationship between these two parameters). The ploidy status 
analyzed simultaneously with the expression of biomarkers in our study 
showed no trend at all, possibly due to some serious methodological problems 
as described in the Results section. That is why we used features as high and 
low DNA content instead of ploidy for our multiparameter study.
Among the multiple available studies concerning p53, two previous studies 
demonstrated an association between p53 expression (as a single feature) 
and progression to malignancy.4,27,28 Munck-Wikland et al. reported that 4 out 
of 8 (50%) of the CIS lesions which progressed were p53-positive and 7 out of 
25 (28%) of the non-progressive lesions (p=0.34). In the same study 9 of the 27 
(33%) high-grade DNA aberration lesions progressed to invasive cancer. 
None of the 7 CIS lesions displaying low-degree DNA aberration progressed 
to invasive cancer (p=0.13).27 Uhlman et al. reported that linear basal staining 
for p53 was seen in at least one pre-progression biopsy in 10 out of 18 patients 
who progressed versus 0 of 20 who did not progress (p< 0.01).28 In a systematic 
review Nankivell et al. published an overall pooled relative risk for p53 of 1.42 
(ConfInt 0.20-10.12). None of the pooled relative risks for p53 with sensitivity 
analysis was statistically significant.9 We had the same outcome for p53 as a 
single marker: a predictive value which was found not to correlate with survival 
(p-value >.5). The same was found for DRAQ-5. Therefore, we conclude that 
CI	 (HR	 2.37;	 ConfInt	 0.9-6.4;	 p=0.089)	 had	 a	 better	 predictive	 value	 than	
DRAQ-5 as a single marker. Ki67 showed also no predictive value as a single 
feature in our study. In literature, three studies on Ki67 showed contradictory 
results.29-31 No data in literature are available in order to compare our findings 
concerning γH2AX. 
To summarize, none of our simultaneously assessed biomarkers showed any 
significant predictive value as a single feature. However, when combining 
them, we observed that the presence of nuclei with a high DNA content and 
low p53 expression predicted progression towards malignancy. ROC analysis 
showed an optimal cut-off point to be reached when the percentage of nuclei 
with	high	DNA	content	and	low	p53	expression	exceeds	3%	(HR=3.17;	ConfInt	
1.2-8.6;	p=0.023).	Therefore,	we	conclude	that	the	simultaneous	assessment	
of multiple biomarkers at the single cell level performs better in predicting 
malignant progression than determining them as single features. 
The combination of nuclei with high DNA content and low p53 expression 
showed a better predictive value than the histopathological WHO grading. 
This especially concerns the low-grade lesions (hyperkeratosis, hyperplasia, 
inflammation) and was not found for the high-grade ones(mild and moderate 
dysplasia). Therefore, this combination may be used as an additional tool to 
distinguish between those low-grade lesions that will and those that will not 
show malignant transformation. As a consequence, in clinical practice, it could 
be considered to adjust treatment and follow-up depending on  histopatho-
logical grading and biomarkers, with  low-grade (hyperkeratosis, hyperplasia, 
inflammation) lesions  in combination with less than 3% of nuclei with high 
DNA content and low p53 expression being a more favorable group. 
From a biological point of view the results may be explained as follows: when 
functioning properly, p53 is activated by hypoxia or DNA damage, leading to 
cell-cycle arrest, attempted DNA repair, and, if DNA repair is ineffective, to 
apoptosis.4,32 Our finding that cells with low p53 expression and high DNA 
content may indicate that in these cells, an abnormal DNA content fails to 
induce this expected physiological upregulation of p53.  The absence of this 
p53 response to genetic damage may play a role in the malignant progression 
of these lesions. The biology behind this phenomenon may be diverse, either 
laying in the gene itself, its upstream regulators or downstream effectors. 
Nevertheless, our finding provides additional evidence of the prominent 
position of p53 in head and neck carcinogenesis.  
ConCLusIon
Our data demonstrate that malignant transformation of LMPLs correlates with 
the presence of nuclei having both a high level of DNA and low p53 protein. To 
confirm the utility and prognostic value of this combination as a predictive 
parameter, a well designed, prospective study should be considered.
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In this thesis the current clinical approach of laryngeal mucosal premalignant 
lesions (LMPLs) is investigated and described and possible improvements are 
proposed, in order to optimize the prediction whether a lesion will or will not 
develop into carcinoma. In Chapter 2 we showed that there is no consensus 
regarding the management of these lesions, and in Chapter 3 the limitations 
of the histopathological evaluation are demonstrated. To obtain additional 
tools for a better prediction of malignant progression, we developed a method 
that is described in Chapter 4 for simultaneous assessment of the DNA ploidy 
status and other biomarkers in paraffin-embedded tissue sections at the level 
of the individual cell. Then, we applied this method on laryngeal mucosal 
premalignant lesions retrospectively (Chapter 5). 
termInoLogy
The terminology of LMPLs in clinical and pathological reports has changed 
significantly over the last six decades. Common agreement has been achieved 
on terms that are used only for the clinical appearance but that do not have 
any histopathological and prognostic implications. The most frequently applied 
clinical diagnoses are laryngeal leukoplakia, erythroplakia, erythroleukoplakia, 
pachydermia, and chronic laryngitis.1-6 
From these designations, keratosis is the most ambiguous, since it is often 
wrongly used interchangeably for macroscopic as well as microscopic features. 
Strictly spoken, keratosis should only be used in a histological context denoting 
the appearance of a keratin layer on the surface of the squamous epithelium.1,3,7 
The same semantic confusion may arise from the use of the term leukoplakia.8
Besides the problems arising from using clinical terminology for a histological 
diagnosis or vice versa, ambiguities may be due to disagreements in terminology 
as is used for the histological classification of LMPLs.1 
management
In Chapter 2 it is shown that there are significant differences in the management 
of LMPLs between otorhinolaryngologists at tertiary and secondary referral 
centers, depending on the location and histopathology of the lesions. In 
general, the former tend to excise a leukoplakic lesion more frequently than 
the latter, who tend to be more conservative and more frequently only take a 
biopsy. Concerning the management of the lesions after an initial biopsy, 
the differences in management of mild and moderate dysplasia are the most 
obvious. Otorhinolaryngologists at secondary referral centers chose in 57% 
for watchful observation and in 35% for referral to a tertiary center. In contrast, 
otorhinolaryngologists at tertiary referral centers prefer close observation in 
85% in case of mild and moderate dysplasia. The referral of 35% of these cases 
may be considered unnecessary as this watchful observation does not have to 
be performed in a tertiary setting. However, the differences in approach for 
mild and moderate dysplastic lesions may be influenced by the fact that 
otorhinolaryngologists at secondary referral centers have limited access to 
laser microsurgery. Furthermore, the uncertainty caused by unfamiliarity with 
these lesions, the unpredictability of the behavior of LMPLs and the awareness 
of the possibility of sampling errors may contribute to these referrals. 
To what extent the management (i.e. only biopsy or excision of a lesion) influ-
ences the risk of progression is difficult to assess. It is imaginable that an excision 
may result in a better prognosis (less risk of progression) in comparison with 
only taking a biopsy. However, genetic alterations in the surrounding mucosal 
fields that may lack morphologic tissue changes and hence not recognizable 
by conventional histology, may lead to development of a carcinoma despite 
of a complete excision of the clinically visible leukoplakic lesion.9 Weller et 
al. reported in a review that lesions treated by surgical excision have a lower 
malignant transformation rate than those that have not. This was not statis-
tically significant, however, and therefore, it is not possible to make strong 
recommendations regarding the role of surgery in this condition. However, 
this provides a good basis for further research.10
The management of LMPLs is controversial: on the one hand, the best oppor-
tunity for cure should not be spoiled but on the other hand, treatment should 
not lead to unnecessary morbidity and loss of function.11,12 The over-riding 
reason for the disparity in practice is the lack of high level evidence to guide 
management.13 Also for this reason, the duration and frequency of follow-up 
remains a matter of debate. Mehanna et al. defined high and low risk patients 
and suggested a distinction in follow-up between high (same manner as T1 
laryngeal carcinoma) and low (should be followed up for a minimum of 6 months) 
risk patients.14 Weller et al. concluded in a review of the risk and interval to 
malignant transformation of patients with dysplasia that transformation into 
malignancy can occur late and does not appear to be dependent on histological 
grade. Furthermore, they stated that it is not clear whether a recurrence will 
be manifest by patients exhibiting any new symptoms. In their opinion, there 
is little evidence therefore, to support the early discharge of patients with 
mild/moderate dysplasia.10
In future research, there is a clear need for consensus on and development of 
guidelines concerning the management of laryngeal precursor lesions. They 
could be useful to optimize the diagnosis, treatment, and follow-up of these 
lesions.
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hIstopathoLogICaL gradIng 
systems
One of our aims was to obtain more insight into the problems related with 
histopathological grading systems of LMPLs. In Chapter 3.2 and 3.3 we described 
data regarding intra- and interobserver variability. The variability was significant 
with weighted К-values that were below 0.55 (indicating only moderate agree-
ment). Furthermore, no clear tendency in favor of one particular histopathological 
classification system (WHO, SIN, SIL) was observed in Chapter 3.2. With the 
proposal of a two- and three-grade system (useful for WHO, SIN, SIL) we were 
able to improve these К-values and to correlate histopathology with the daily 
clinical practice of the otorhinolaryngologist  (no periodic observation, periodic 
observation, and treatment ((laser) surgery or radiotherapy). Our opinion is 
that the implementation of a two- or three-grade system as an alternative 
grading system should be considered.
In Chapter 3.2 we also found that simultaneous pathological assessment 
provides added value in comparison with independent assessment because 
in this way a high level of consensus could be obtained. Therefore, assessment 
of LMPLs by more than one pathologist might be advisable. The introduction 
of whole slide imaging (WSI) in surgical pathology slide conferences/panels 
and (real-time) consultation of expert pathologist(s) nation- or worldwide by 
means of a secure internet connection will facilitate such a simultaneous 
assessment by different expert pathologists within a short period of time. 
This so-called ‘virtual microscopy’ is a valid alternative for the diagnostic 
assessment of laryngeal premalignancies, as described in Chapter 3.3. 
In the years to come the usefulness of this web based pathology in clinical 
practice has to be determined. Realizing that this innovation has also lots of 
other advantages (i.e. digital archiving, remote working) it suggests improve-
ment of patient care and cost effectiveness.15-18 
In addition to the advantages that may be obtained by the developments 
allowing simultaneous assessment of LMPLs by several experienced patholo-
gists, the application of biomarkers may open new avenues in this area. Their 
current status was described in an Intermezzo and it is concluded that for the 
time being, they are not suited for application in clinical practice. However, a 
combined assessment at the single cell level may increase their value. This issue 
was pursued in the second part of this Thesis.
method deveLopment
To assess the value of simultaneous assessment of biomarkers in improving the 
predictive value of biopsies from LMPLs we developed a method, described 
in Chapter 4, for determining DNA ploidy status and biomarker expression in 
tissue sections at the level of the individual cell. DNA aneuploidy has been 
suggested as a useful marker for neoplastic progression of premalignant 
lesions,19-27 and the combination of the DNA ploidy status and the expression 
of proteins related with cell cycle progression and DNA damage response 
appeared to be capable to estimate the malignant potential of e.g. Barrett’s 
oesophagus and colonic cancer.28,29 We used paraffin-embedded tissue sections 
of oral premalignancies, of which the ploidy status/chromosomal instability (CI) 
was assessed with the Hedley procedure30 and fluorescence in situ hybridization 
(FISH) on chromosome 1 and 7,31 to validate this method. To assess the DNA 
ploidy status it was necessary to combine the stoichiometric DNA staining 
(Feulgen) with the proliferation marker MIB-1 to allow the differentiation between 
cells in which an increased DNA content is due to a physiologic S-phase and cells 
in which the increased DNA content is not related with progressing through 
the cell cycle. We also described an alternative to the tedious procedure of 
sequential chromogenic staining, using multiplexed immunofluorescence. 
For the five cases analyzed, distinction between diploid and non-diploid cases 
(Hedley procedure) was improved in fluorescence microscopy compared with 
transmitted light microscopy. The possibility of conveniently linking expression 
of biomarker expression to ploidy analysis made it possible to investigate 
multiple biomarkers in LMPLs simultaneously. 
appLICatIon oF the deveLoped
method on LmpLs
In Chapter 5, the practical applicability and value of the method as described in 
Chapter 4 was further analyzed. Markers for DNA (DRAQ5), p53, MIB-1, ploidy, 
p53 and yH2AX were assessed simultaneously at the level of the individual 
cell. These markers were selected because they reflect different but presumably 
interacting cancer-related cellular processes: proliferation, stress response 
and genome integrity. No other published studies analyzed these proteins 
simultaneously at the single cell level in laryngeal lesions. As this approach 
required the use of immunofluorescence, the amount of DNA was assessed 
with DRAQ5 instead of Feulgen. 
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Determination of the DNA ploidy status in tissue sections appeared to be only 
possible in a disappointingly low number of cases (n=18), due to a suboptimal 
stoichiometry of DRAQ-5. Also, in a number of cases the amount of normal 
epithelium that could be measured was insufficient to serve as an internal 
diploid reference. Possibly due to these technical shortcomings, no significant 
difference was found between diploid and non-diploid cases concerning the 
predictive value. Using FISH, we found a worse progression-free survival for 
patients	with	CI	(Hazard	Ratio	(HR)	2.37;	Confidence	Interval	(ConfInt)	0.9-6.4;	
p=0.089). FISH corrected for age (which was found to be a negative confounder) 
showed	a	HR	of	3.15	(ConfInt	1.0-9.5;	p=0.042).	So,	CI	showed	a	clear	trend	
toward lower progression-free survival although, not independent of histology 
(a multivariate Cox regression analysis is indicative of a strong relationship 
between these two parameters).
Regarding our biomarker study, one of the different markers showed any 
significant predictive value as a single feature. However, when combining 
them, we observed that the presence of nuclei with a high DNA content 
and low p53 expression predicted progression towards malignancy with an 
optimal cut-off point when the percentage of nuclei with high DNA content 
and	low	p53	expression	exceeds	3%	(HR=3.17;	ConfInt	1.2-8.6;	p=0.023).	The	
combination of these results and the findings described in the Intermezzo made 
us to conclude that the simultaneous assessment of multiple biomarkers at the 
single cell level has an additional value in predicting malignant progression 
above employing them as single features. 
Our observations also indicate that in the investigated LMPLs described in 
Chapter 5, abnormal DNA content does not lead to the expected upregulation 
and concomitant overexpression of p53. The biology behind this phenomenon 
may be diverse, either laying in the gene itself, its upstream regulators or down-
stream effectors. Nevertheless, our finding provides additional evidence of 
the prominent position of p53 in head and neck carcinogenesis. 
In the population of LMPLs described in Chapter 5, classified according to the 
WHO-system, we found that separating between a low-grade  (hyperkeratosis, 
hyperplasia, inflammation) and high-grade group (mild and moderate dysplasia) 
showed an optimal differentiation between histology and progression-free 
survival. Interestingly this definition of a low- and high-grade group is in accor-
dance with the grading system we proposed in Chapter 3.2 (Table 2). We also 
noted that the combination of nuclei with high DNA content and low p53 
expression showed an improvement in predictive value in comparison with 
the histopathological subgroups as defined in the WHO (current diagnostic 
management) as well as with the histopathological low- (hyperkeratosis, 
hyperplasia, inflammation) and high (mild and moderate dysplasia) grade 
group.
reLevanCe and Future 
deveLopments
In our Introduction, we discussed the shortcomings of the histopathologic 
analysis of LMLPs and subsequently, we showed how this could be improved by 
evaluation of tissue sections by 3 pathologists for which purpose web based 
telepathology may be useful. In view of these considerations, we developed an 
education program in order to improve the diagnostic process (i.e. decrease 
inter- and intraobserver variability) of LMPLs with the tools that are currently 
available. This education program was recently started by Pathology residents. 
Pathologists of secondary and tertiary referral centers will also participate in 
the future. Hopefully, this will lead to an increase in uniformity of assessment.
Another point mainly discussed in the Intermezzo is the potential value of 
biomarkers and we have shown that our approach appears to be helpful in 
identifying patients at risk for progression that have low-grade lesions (hyper-
keratosis, hyperplasia, inflammation). As a consequence, in clinical practice, it 
should be considered to treat or at least follow up the patients with these 
low-grade lesions that show more than 3% of nuclei with high DNA content 
and low p53 expression. This means a change in approach for these patients 
as currently patients with these low-grade lesions usually have no follow-up.  
So, possibly in LMPLs we have to use a risk-stratification biomarker panel 
instead of a single marker.32 It is mandatory, however, to confirm the utility  and 
prognostic power of biomarkers in large, well-designed, prospective studies 
before their implementation in routine clinical practice.33 
ConCLusIon
In this thesis we have analyzed and quantified the current handling of LMPLs by 
the otorhinolaryngologist and the pathologist. We have objectified the variability 
in the management of a laryngeal leukoplakic lesion by an otorhinolaryngologist. 
Regarding the histopathological grading it was found that pathologists showed 
a considerable inter- and intraobserver variability which demonstrates that there 
is a need for additional more objective tools. 
In order to find such additional accurate tools in determining the risk of 
malignant progression of LMPLs and to optimize surveillance and intervention 
we developed a method to analyze different biomarkers simultaneously at 
the single-cell level and we assessed their predictive value. Based on our data, 
nuclei with the combination of high DNA and low p53 are the most significant 
and promising as their  presence showed to be of additional value in predicting 
malignant progression.  
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Hoofdstuk 1 van dit proefschrift betreft een algemene introductie over laryn-
geale mucosale premaligne laesies (LMPLs) en geeft een overzicht van de 
onderwerpen die aan bod komen in het proefschrift. Een LMPL is een afwijking 
van het slijmvlies van de stembandregio (larynx) die kan leiden tot het ontstaan 
van kanker. Echter, of en wanneer dit gebeurt is nog grotendeels onduidelijk. 
Er bestaan tot op heden in de dagelijkse klinische praktijk geen goede diag-
nostische kenmerken die van nut zijn bij het voorspellen van dit risico.
In de klinische praktijk van de KNO-arts presenteren LMPLs zich vaak als witte 
(leukoplakie) of rode (erytroplakie) veranderingen van het slijmvlies. Bij de histo-
logische beoordeling van deze weefsels bepaalt de patholoog gebruikmakend 
van classificatiesystemen de ernst van de afwijking, ook wel aangegeven als 
de mate van dysplasie, waarbij met toenemende ernst van dysplasie er meer 
kans zou zijn op het ontwikkelen van kanker in de toekomst. 
Naast het inventariseren van de behandeling van LMPLs door KNO-artsen en 
de variabiliteit in beoordeling van het verwijderde weefsel door pathologen, 
ligt het zwaartepunt van dit proefschrift op het ontwikkelen en toepassen van 
een methode om met behulp van een combinatie van bepaalde eiwitten 
(markers) beter te kunnen inschatten welke premaligne afwijking wel en welke 
uiteindelijk niet zal ontaarden in kanker.
In hoofdstuk 2 worden de resultaten van een enquête naar de huidige behan-
deling van LMPLs, gehouden onder KNO-artsen werkend in academische en 
perifere ziekenhuizen, beschreven en bediscussieerd. KNO-artsen werkend 
in een academisch ziekenhuis bleken de afwijking significant vaker in eerste 
instantie te verwijderen, terwijl KNO-artsen werkend in een perifeer ziekenhuis 
vaker kozen om in eerste instantie alleen een stukje weefsel (biopt) van de 
afwijking te verwijderen voor histologische diagnostiek. Een verklaring zou 
kunnen zijn dat de KNO-artsen werkend in een perifeer ziekenhuis minder de 
beschikking hebben over een laser om deze afwijkingen te verwijderen. Een ver-
schil in beleid tussen de KNO-artsen werd vooral gezien in het geval van LMPLs 
die door de patholoog werden beoordeeld als lichte en matige dysplasie. In 
57% werd door de KNO-artsen werkend in een perifeer ziekenhuis gekozen 
voor nauwgezette follow-up en in 35% voor verwijzing naar een academisch 
ziekenhuis. Onder de KNO-artsen werkend in een academisch ziekenhuis 
werd in 85% gekozen voor nauwgezette follow-up. Mogelijk dat de onvoor-
spelbaarheid van LMPLs eraan bijdraagt om een patiënt te verwijzen naar 
een academisch ziekenhuis.
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In hoofdstuk 3.1 wordt een overzicht gegeven van de verschillende systemen die 
de patholoog kan gebruiken om premaligne laesies in het hoofd-halsgebied 
(en dus inclusief de stembandregio) te beoordelen. Drie systemen (WHO, SIN en 
Ljubljana (SIL)) worden beoordeeld op reproduceerbaarheid en voorspellende 
waarde. Hoofdstuk 3.2 beschrijft de variabiliteit tussen drie pathologen (inter-
observer variabiliteit) wanneer zij het weefsel van 110 LMPLs apart van elkaar 
beoordeelden. De variabiliteit bleek aanzienlijk met hooguit matige overeen-
komst tussen de pathologen. Daarnaast werd er geen duidelijke tendens gezien 
in het voordeel van een van de classificatiesystemen. Een simultane beoordeling 
door de pathologen bleek te leiden tot een hoge mate van consensus. Een 
vereenvoudiging van de classificatiesystemen (een systeem met 2 of 3 keuzes) 
werd voorgesteld en getest waarmee de interobserver variabiliteit afnam. In 
hoofdstuk 3.3 wordt aangetoond dat er eveneens variabiliteit aanwezig is, als 
dezelfde patholoog op verschillende momenten de LMPLs beoordeelt (intra-
observer variabiliteit). Naast de conventionele methode om weefsel te beoor-
delen, is het tegenwoordig mogelijk om coupes met weefsel in te scannen 
zodat de patholoog tot een diagnose komt door het ingescande beeld te 
beoordelen (virtual microscopy). Virtual microscopy biedt onder andere voor-
delen in het werken op afstand (inclusief consultatie van experts) en digitale 
archivering. Nagegaan wordt of het beoordelen van LMPLs met behulp van 
virtual microscopy dezelfde resultaten geeft  als beoordeling met de conven-
tionele methode wat betreft variabiliteit. Dit bleek het geval.
Geconcludeerd wordt dat de matige reproduceerbaarheid van zowel de 
conventionele als de virtuele microscopische beoordeling van LMPLs een 
belemmering vormt voor de bruikbaarheid bij het bepalen van het klinisch 
beleid. De mogelijke uitbreiding van het microscopisch onderzoek met 
biomarkers, resulterend in een betere inschatting van de kans op maligne 
ontaarding  moet worden onderzocht.
In het intermezzo wordt de potentiële waarde uiteengezet van het bepalen 
van verschillende eiwitten in het weefsel van LMPLs om beter te kunnen voor-
spellen welke laesie wel en welke niet in kanker zal ontaarden. Deze eiwitten 
zijn betrokken bij het ontstaan van kanker en worden ook wel biomarkers 
genoemd. Geconcludeerd wordt dat de over- of onderexpressie van een 
enkele biomarker weinig voorspellende waarde toevoegt aan de standaard 
beoordeling door de patholoog. Daarom worden biomarkers nog nauwelijks 
toegepast in de huidige klinische praktijk. Of de voorspellende waarde van 
biomarkers toeneemt wanneer deze simultaan worden bepaald op het 
niveau van de individuele cel in biopten van LMPLs heeft tot op heden in de 
literatuur geen aandacht gekregen.  
In hoofdstuk 4 wordt de ontwikkeling en validatie van een methode beschreven 
om simultaan de DNA ploïdie-status (het aantal sets van chromosomen in een 
cel) en expressie van enkele relevante eiwitten te bepalen in weefselcoupes 
op het niveau van de individuele cel. Doel hiervan is de hypothese te toetsen 
dat simultane bepaling van meerdere biomarkers een meerwaarde heeft bij het 
inschatten van de kans op maligne ontaarding van een LMPL. Larynxbiopten 
bevatten te weinig materiaal om volgens de standaardtechniek (Hedley methode) 
de DNA ploïdie-status te bepalen. Bepalen van de ploïdie-status in weefsel-
coupes was tot nog toe niet goed mogelijk vanwege aansnijding van celkernen. 
Van in paraffine ingebed weefsel werden in deze studie weefselcoupes gesne-
den welke achtereenvolgens werden gekleurd voor proliferatiemarker Ki67 en 
DNA (Feulgen kleuring). Door alleen te kijken naar de hoeveelheid DNA van 
niet delende cellen kon er onderscheid worden gemaakt tussen aangesneden 
aneuploïde cellen en euploïde cellen. De werkelijke ploïdie-status werd bepaald 
door het analyseren van uit dikke paraffinecoupes opgewerkte kernen en tevens 
door fluorescentie in situ hybridization (FISH) van chromosoom 1 en 7. We 
bleken met deze methode goed in staat om de ploïdie-status op weefselcoupes 
te bepalen. Om tegelijkertijd expressie van een aantal relevante eiwitten te 
kunnen bestuderen werd gebruik gemaakt van fluorescentie microscopie, 
waarbij DRAQ-5 DNA kleuring werd gecombineerd met Ki67 en yH2AX (marker 
voor genetische schade respons). Met deze methode bleek het mogelijk om 
zowel de ploïdie-status betrouwbaar te bepalen alsook de biomarkers Ki67 
en yH2AX simultaan te analyseren op het niveau van de individuele cel.
In hoofdstuk 5 wordt de in hoofdstuk 4 ontwikkelde methode toegepast op 
het weefsel van 37 geselecteerde LMPLs. In dit onderzoek werd de analyse 
gedaan met DRAQ-5 gecombineerd met p53, Ki67 en yH2AX op het niveau 
van de individuele cel. Tevens werd de ploïdie-status bepaald met behulp 
van FISH van chromosoom 1 en 7. Van alle mogelijke biomarker combinaties 
bleek de combinatie van een hoog DNA gehalte en lage expressie van p53 de 
sterkste relatie met een progressie vrije overleving te hebben. Geconcludeerd 
werd dat om het nut en de prognostische waarde van de gevonden combinatie 
te bevestigen als voorspellende parameter een goed ontworpen prospectieve 
studie moet worden uitgevoerd.
Hoofdstuk 6 is het afsluitende hoofdstuk en bevat zowel een overzicht van 
discussies naar aanleiding van de eerdere hoofdstukken als een samenvatting 
hiervan. Eerdere bevindingen worden kritisch geëvalueerd waarbij conclusies, 
relevantie en toekomstige ontwikkelingen gepresenteerd worden. 
Nederlandse Samenvatting
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Alle mensen en instanties die op enige wijze hebben bijgedragen aan de 
totstandkoming van dit proefschrift wil ik zeer hartelijk danken voor hun inzet. 
Een aantal mensen wil ik graag in het bijzonder bedanken.
Beste professor Slootweg, beste Piet. Terugkijkend kan ik me werkelijk geen 
betere promotor voorstellen. Daarmee doel ik onder andere op de eigenschap 
om telkens weer het overzicht te houden met de combinatie van inhoud en 
effectiviteit steeds hoog in het vaandel. Zonder uitzondering altijd snelle en 
duidelijke reacties, zelfs als er grote bestanden met veel MB’s aan de voet 
van de Kilimanjaro moesten worden beoordeeld. Bijzonder prettig om u als 
promotor te mogen hebben. 
Beste dr. Takes, beste Robert. Vanaf het begin heb ik zeer veel vertrouwen 
gevoeld en veel verantwoording gekregen, waardoor ik steeds het gevoel 
heb gehad dat ik in dit promotietraject mezelf kon en mocht ontwikkelen. Je 
bent ook echt de brandstof voor dit proefschrift geweest. De keren dat we 
buiten de normale werktijden om bij jullie thuis afspraken heb ik als zeer prettig 
ervaren, waarbij het een keer niet veel had gescheeld of ik was ingesneeuwd. 
Je kritische en snelle blik met onvermoeibare drive zijn inspirerend. Het is 
voor mij een enorme eer om je eerste promovendus te zijn.
Beste dr. Van der Laak, beste Jeroen. Jouw specifieke expertise heeft er voor 
gezorgd dat we onze hypothesen ook echt konden toetsen. Daarbij heeft ook 
je kritische blik voor een grote meerwaarde gezorgd. Dit in combinatie met je 
bereidheid om tussen allerlei andere bezigheden door ook in een kerstvakantie 
samen statistiek te bedrijven is voor mij essentieel geweest. Het is dan ook een 
eer om eveneens jouw eerste promovendus te mogen zijn.
Beste professor Marres, beste Henri. Ik prijs me gelukkig dat ik onder zo’n 
afdelingshoofd en opleider mijn opleiding tot KNO-arts hebben mogen 
doorlopen. Ondanks je zeer drukke agenda heb ik altijd het gevoel gehad dat 
ik op momenten van voor mij belangrijke beslissingen op meerdere gebieden 
makkelijk met je hierover kon nadenken. Zonder dat dit uren filosoferen 
hoefde te betekenen. Zeer veel dank hiervoor. Mooi dat ook ik in de lijst van 
Marres-promovendi kom te staan.  
Beste Irene, zonder jouw constante inzet en betrokkenheid bij de werkzaam-
heden in het laboratorium had ik waarschijnlijk nog lang moeten wachten om 
je hiervoor te kunnen bedanken. Bij deze.
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Beste co-auteurs, zeker ook Ewa, veel dank voor jullie medewerking en het 
delen van jullie data en kennis.
Waarde leden van de manuscriptcommissie, professor Kaanders, professor 
Merkx, professor Van Diest, veel dank voor het beoordelen van dit proefschrift.
Collegae (oud) AIOS, de bijzonder mooie tijd met jullie heeft er zeker toe 
bij gedragen om dit proefschrift af te kunnen ronden. Niels, Brechtje, Ronald, 
Anne, Liselotte, Stijn, Myrthe, Rutger, Olivier, Bart, Godelieve, Sylvia, Robert-Jan, 
Ferdinand, Ilse, Jan-Willem, Anne-Martine, Veronique, Louise, Hans, Jimmie, 
George, Maarten, Arthur, Hubert, Erik, Joost, Annemarie, Caroline, Henrieke, 
Jasmijn, Ingrid, Eline, Rik, Anne, Saskia, Josephine en Ruud. Oprechte dank 
voor de geweldige samenwerking!
Beste professor Graamans en dr. Van den Hoogen, beste Frank, ik herinner me 
onze eerste kennismaking nog goed. Buitengewoon dat daarna de mogelijk-
heid geboden is om de opleiding te volgen. En er zelfs een promotie uit 
voortkomt. Zeer erkentelijk ben ik jullie hiervoor. Waarbij ik je, Frank, als echte 
mentor heb ervaren. Wie weet blijft dat wel in zekere zin. Daarnaast gaat veel 
dank uit naar mijn andere opleiders, professor Cremers, dr. Theunissen en dr. 
Bouman. Waarbij ik de ‘terugkom-dagen’ in Arnhem als zeer nuttig heb ervaren. 
Henk, extra dank voor deze mogelijkheid. Waarbij ik natuurlijk ook de rest van 
de staf in het UMC St Radboud, VieCuri Medisch Centrum en het Rijnstate 
Ziekenhuis niet mag en wil vergeten te noemen. 
Aanstaande collegae, beste Bert, Noortje en Stijn. Werkelijk geweldig dat ik 
jullie op deze plek al kan noemen. Ik zet in op een zeer goede en prettige 
toekomst.
Bobby, ik vind het gaaf dat ik je ook op deze plek kan bedanken voor je 
optreden als paranimf. Heel mooi dat we dit soort dingen samen kunnen 
meemaken. Ik hoop dat we er over vele jaren nog eens samen, onder het 
genot van een alcoholische versnapering, op terug kunnen kijken.
Robert en Vivianne, ondanks dat we door allerlei praktische redenen de laatste 
jaren de deur niet bij elkaar platliepen is er altijd een sterke verbondenheid 
geweest. Des te leuker dat we elkaar vanaf nu veel meer zullen zien. Wij zijn 
heel trots op jullie. 
Lieve Jan en Annie, vanaf het begin heb ik me altijd volledig thuis gevoeld bij 
jullie. Heel veel dank voor de onvoorwaardelijke steun en betrokkenheid bij 
alles wat we doen. Men zegt dat je je schoonouders niet voor het uitzoeken 
hebt, ik had het echter niet beter kunnen treffen. En dan spreek ik ook namens 
Cathelijne voor wat betreft opa en oma. 
Fieke, zoals vroeger weleens gekscherend gezegd, voel ik toch een zekere 
verantwoordelijkheid voor je als grote broer. Des te mooier om vanaf de zijlijn 
te zien wat je allemaal doet en bereikt. Heel fijn dat je mijn paranimf bent. 
Yves, ik heb heel veel respect voor je.
Bregje en Jasper, tijdens het bedenken van deze woorden weten Ilona en ik dat 
Cathelijne een kleine neef krijgt. Hopelijk weten we rondom deze promotie dat 
alles goed is gegaan. Wij verheugen ons zeer op de aankomende momenten 
met z’n zessen.  
Lieve Oop, heel jammer dat je het einde van dit promotietraject niet meer 
mee hebt kunnen maken. Zoals je weet ben ik heel blij dat ik je zo lang heb 
mogen kennen.
Lieve pap en mam, enorm veel dank voor de onvoorwaardelijke liefde en steun 
die jullie me geven. Heel mooi om jullie in een nieuwe fase als opa en oma te 
zien, waardoor ik me alleen maar gelukkiger met jullie prijs. 
Lieve Cathelijne, hopelijk heb je de eerste weken van je leven niet te veel 
meegekregen van een vader die alleen maar achter de computer zat om deze 
promotie tot een goed einde te brengen. Je lach en vrolijkheid doen mij 
smelten. Je hoort bij ons.
Lieve Ilona, het voelt heel fijn om de laatste woorden van dit proefschrift aan 
jou te mogen richten. Samen hebben we ook dit traject doorlopen, waarbij ik 
altijd op je begrip en steun kon rekenen. Prijzenswaardig. Dat we elkaar na 
tien jaar nog steeds zo leuk vinden moeten we koesteren. Ik houd ontzettend 
veel van je en ben er heel trots op dat we samen de ouders zijn van Cathelijne. 
Ik heb heel veel zin in onze toekomst samen. 
General Discussion and Concluding Remarks
151
aPPenDiX iii 
List of Publications
List of Publications
s.a.J.H.M. Fleskens, V.e. Bergshoeff, a.c. Voogd, M-L.F. van Velthuysen, 
F.J. Bot, e.J.M. speel, B. Kremer, r. takes, P. slootweg. 
Interobserver variability of laryngeal mucosal premalignant lesions: 
a histopathological evaluation. 
Mod Pathol. 2011; 24(7): 892-8
s.J.H.M. Fleskens, r.P. takes, i. otte-Höller, L. van Doesburg, a. smeets, 
e.J.M. speel, P.J. slootweg, J.a.W.M. van der Laak. 
Simultaneous assessment of  DNA ploidy and biomarker expression in 
paraffin-embedded tissue sections. 
Histopathology. 2010; 57(1): 14-26 
s.a.J.H.M. Fleskens, J.a.W.M. van der Laak, P.J. slootweg, r.P. takes. 
Management of laryngeal premalignant lesions in the Netherlands. 
Laryngoscope. 2010; 120(7): 1326-35
M.M. Hengeveld, a.J.H.M. Fleskens, P.J. slootweg, H.a.M. Marres. 
[Angiolymphoid hyperplasia with eosinophilia]. Dutch title: Angiolymphoïde 
hyperplasie met eosinofilie. 
Ned Tijdschrift KNO. 2010; 16(4): 183-186
a.J.H.M. Fleskens, r.i. Lalisang, g.M.J. Bos, L.F.r. span, M. van gelder, 
r.L.H. Jansen, H.c. schouten. 
HLA-matched allo-SCT after reduced intensity conditioning with Fludarabine/
CY in patients with metastatic breast cancer. 
Bone Marrow Transplant. 2010; 45(3): 464-7
s. Fleskens, P. slootweg. 
Grading systems in head and neck dysplasia: their prognostic value, 
weaknesses and utility. 
Head Neck Oncol. 2009; 1(11); 1-8
r. speyer, H.c.a. Bogaardt, V.L Passos, n.P.H.D. roodenburg, a. Zumach, 
M.a.M. Heijnen, L.W.J. Baijens, s.J.H.M. Fleskens, J.W. Brunings. 
Maximum phonation time: Variability and Reliability. 
J Voice. 2010; 24(3): 281-4
155
s. Fleskens, M.r. scheltinga. 
An infected midline epidermal inclusion cyst. Otolaryngol
Head Neck Surg. 2007; 137(2): 346-7
a.J.H.M. Fleskens, M.r.M. scheltinga, P.V. van eerten, L.H.M. Verhoef, 
H.L.M. Pasmans, g. Vreugdenhil. 
Sore throat and a swollen neck: Lemierre’s syndrome until proven otherwise. 
Ned Tijdschr Geneeskd. 2006; 150(45): 2461-6
suBMitteD
B. sturm, a.J.H.M. Fleskens, F.J. Bot, M-L.F. van Velthuysen, e.J.M. speel, 
P.J. slootweg, J.a.W.M. van der Laak. 
Virtual microscopy is a valid alternative for the diagnostic assessment of 
laryngeal premalignancies.
aPPenDiX iV 
Curriculum Vitae
154
Appendix III 
curriculum Vitae
Stijn Fleskens werd geboren op 4 november 1982 te Veldhoven. In 2001 behaalde 
hij zijn VWO diploma aan het Sondervick College te Veldhoven. Hierna kon 
worden gestart met de studie Geneeskunde aan de Universiteit Maastricht. 
Tijdens de coschappen werd zijn voorkeur voor KNO-Heelkunde steeds duide-
lijker. Na het behalen van het artsexamen op 27 augustus 2007 startte hij in 
september met het promotietraject binnen de afdeling KNO-Heelkunde van 
het UMC St Radboud. Waarmee in samenwerking met de afdeling Pathologie 
de eerste schreden met betrekking tot dit proefschrift werden gezet. In augus-
tus 2008 begon hij met de opleiding tot KNO-arts in het UMC St Radboud 
met prof. dr. K. Graamans, prof. dr. C.W.R.J. Cremers, prof. dr. H.A.M. Marres 
en dr. F.J.A. van den Hoogen als opleiders. De perifere stages van de opleiding 
tot KNO-arts werden doorlopen in het VieCuri Medisch Centrum te Venlo en 
Venray onder leiding van dr. E.J.J.M. Theunissen en in het Rijnstate te Arnhem 
onder leiding van dr. H. Bouman. De opleiding werd op 1 augustus 2013 voltooid. 
Sindsdien is hij werkzaam in het Máxima Medisch Centrum te Veldhoven en 
Eindhoven als KNO-arts. Stijn woont samen met Ilona Kraayvanger en sinds 
januari 2013 zijn zij de gelukkige ouders van Cathelijne.


